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CHAPTER I 
INTRODUCTION 
1.1 BONE MARROW TRANSPLANTATION 
Peripheral blood cells have vital and well known functions. Their relatively 
short lifespan leads to a high production rate of approximately 1 Qll new blood 
cells daily in man. This process is called haemopoiesis and the main site for the 
production of blood cells is the bone marrow. Bone marrow is located inside all 
bones, particularly in the pelvis, the vertebrae, ribs and bones of the extremities. 
The common ancestor cell for all haemopoietic differentiation pathways is the 
pluripotent haemopoietic stem cell. This cell maintains the whole process of 
haemopoiesis by its virtue of self-replication and differentiation. In the differ-
entiation pathway, stem cells differentiate to committed progenitor cells, which 
are restricted for their development to a specific cell lineage, such as the 
myeloid, lymphoid, erythroid, thrombocytic and macrophage differentiation 
series. Committed cells will gradually loose their proliferative capacity and 
mature into functional end cells, such as leukocytes, erythrocytes, thrombocytes 
and macrophages. These mature cells leave the bone marrow to circulate 
through blood vessels and to exert their specific functions, e.g. 02 and C02 
transport (erythrocytes), clotting of blood (platelets), and defense against infec-
tions (B-andT lymphocytes, granulocytes and macrophages) in various tissues. 
Most of the current knowledge of haemopoietic stem cells has been 
obtained from observations on radiation chimaeras (Van Bekkum & de 
Vries, 1967). After total body irradiation, haemopoiesis is arrested as well as 
the ability to mount an immunological attack against foreign antigens. 
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BONE MARROW TRANSPLANTATION 
11. Bone marrow collection ~ 
- collection of 
pluripotent stem cells 
2. Total Body Irradiation I 
- immunosuppression 
- destruction of haemopoiesis 
3. Bone marrow infusion I 
4. Posttransplantation complications 
-Graft-versus-Host Disease: 
- skin --> desquamation 
- liver -->jaundice 
- gut --> diarrhea 
- Host-versus-Graft reaction 
- Infections 
- Pneumonitis 
Figure Ll Bone marrow transplantation 
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The subsequent intravenous administration of a relative small number of bone 
marrow cells restores all haematological functions. The term 'radiation chi-
maera' was introduced when it was detected in a recipient of a bone marrow 
graft that all haemopoietic cells of such a bone marrow recipient were of donor 
origin (Ford et al., 1956; Vos et al., 1956; Nowell et al., 1956). 
These early observations have led to clinical bone marrow transplantation 
(BMT) as a treatment modality for damaged or insufficiently functioning 
haemopoiesis. A bone marrow transplantation (Figure 1.1) starts with prepara-
tion of a recipient for grafting. An unprepared recipient, which is not immu-
nodeficient, will oppose engraftment of allogeneic bone marrow cells by im-
munological reactions. For immunosuppression and elimination of the reci-
pient's own haemopoiesis, total body irradiation and/or high dose chemotherapy 
is applied. After such a conditioning, a bone marrow graft is injected to provide 
the recipient with a new, permanently functioning haemopoietic system. For the 
restoration of the haemopoietic system haemopoietic stem cells are indispensable 
since these are the only cells which have the ability of self-replication. Depen-
dent on the relationship between donor and recipient a bone marrow graft is 
designated as: autologous, when the marrow is taken from the same individual; 
syngeneic, when host and donor are genetically identical, which means that the 
marrow is derived either from an identical twin ( outbred species) or from an 
animal of the same inbred strain; allogeneic, when host and donor are geneti-
cally different but still belong to the same species; and xenogeneic, when host 
and donor belong to different species. 
After transplantation, donor cells may mount an immunological reaction 
against host tissues dependent on the genetic disparity between host and donor. 
The result of this graft-versus-Host (GvH) reaction is a disease with high mor-
bidity and mortality. Despite these complications, BMT is an appropriate treat-
ment for a variety of diseases. The updated results of many bone marrow trans-
plantation centers, as reported by the European and International Bone Marrow 
Transplantation Registry, are presented in Table 1.1. The probability of survival 
in patients with acute myeloid leukemia in first remission is 50%. Transplants 
for patients with chronic granulocytic leukemia yielded the best results when 
undertaken in chronic phase with a long term survival of approximately 60%, 
while transplants in blast crisis resulted in a 20% survival rate. BMT for 
nonmalignant disease, such as severe combined immunodeficiencies, aplastic 
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anemia and thalassemia major, gave encouraging results of 50 - 80% long-term 
survival rates. In the next paragraphs, the current state of research for 
haemopoietic stem cells, engraftment and GvH disease is discussed in more 
detail. 
Table 1.1 
Current status of survival and relapse after allogeneic bone marrow 
transplantation. 
Type and stage 
of disease 
ALL, 1st remission 
ALL, ~ 2 remission 
ANL, 1st remission 
ANL, > 2 remission 
CGL, chronic phase 
CGL, ace. phase 
non malignant diseases: 
SCID 
Aplastic anemia 
Thalassemia major 
PROBABILITY 
Survival 
40-55% 
20-35% 
50% 
25-35% 
50-60% 
20-30% 
60-70% 
70-80% 
80% 
OF 
Relapse 
20-30% 
50-60% 
20-25% 
50-70% 
10-20% 
55-80% 
30% 
Reference 
a 
a 
b 
b 
c 
c 
d 
e 
f 
ALL= Acute Lymphoblastic Leukemia; ANL= Acute Nonlymphoblastic Leukemia; CGL= 
Chronic Granolocytic Leukemia; SCID= Severe Combined Immunodeficiencies 
a: (Ringden for EBMT, 1987; Gratwohl for EBMT, 1988; Champlin for IBMTR, 1987), 
b: (Ringden for EBMT, 1987, ; Gratwohl for EBMT, 1988; Champlin for IBMTR, 1987; 
Weisdorf et al., 1988), c: (Ringden for EBMT, 1987; Gratwohl for EBMT, 1988; Storb et al., 
1987), d: (O'Reilly et al., 1987; Fisher et al., 1986), e: (Bacigalupo for EBMT, 1988; Storb et 
al., 1987), f: (Lucarelli et al., 1985) 
1.2 PLURIPOTENT HAEMOPOIETIC STEM CELLS 
Haemopoiesis is a complex process, since it encompasses both the multiplication 
of all types of precursor cells as well as the differentiation from haemopoietic 
stem cells to functional peripheral blood cells. The complexity is due to the wide 
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range of functions, which are exerted by peripheral blood cells, such as clotting, 
transport of 02, phagocytosis and defense against infections. If this whole inge-
nious process has been tom down by irradiation or cytotoxic drugs, trans-
plantation of a relatively small number of stem cells will result in repopulation 
of the whole haemopoietic system. The transplanted bone marrow cells give 
progeny to a great variety of functional end cells, which include not only blood 
cells but also macrophages in tissue such as lung, liver, peritoneal cavity, 
epidermis, spleen and thymus (reviewed by Wagemaker, 1985; Figure 1.2). 
Mast cells (Kitamura, 1977) and osteoclasts (Scheven et al., 1986) are also 
descendents of haemopoietic stem cells and, under special circumstances, 
macrophages in the brain are of donor origin (Hoogerbrugge et al., 1988). 
In search of a cell which is responsible for the maintenance of 
haemopoiesis, mice appeared to be very valuable. 
PROLIFERATION AND DIFFERENTIATION OF HAEMOPOIETIC STEM CELLS 
self renewing stem cells 
• (j)-~ <~
@)-®<· 
(1-@ 
committed progenitor cells 
Q'fllli:IG 
----
•• 
----·· 
• • 
Macrophages $ 
4J 
mature blood cells 
Figure 1.2 Differentiation of haemopoietic stem cells. 
T ·lymphocytes 
B-lymphocytes 
Granulocytes 
Monocytes 
Erythrocytes 
Platelets 
Mast cells 
Osteoclasts 
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Starting about seven days after transplantation macroscopically visible nodules, 
which contain haemopoietic cells, become visible on the spleen of lethally 
irradiated recipients. The number of spleen colonies appeared to be linearly 
related to the number of transplanted cells (Till and McCulloch, 1961). Trans-
plantation experiments with bone marrow cells with unique chromosome 
markers demonstrated that cells present in an individual spleen colony carried 
the same unique marker, suggesting that spleen colonies were derived from one 
single cell (Becker et al., 1963; Wu et al., 1967). The properties of extensive 
self-replication and pluripotentiality were demonstrated by the development of a 
complete haemopoietic system after transplantation of a single spleen nodule 
into a lethally irradiated recipient (Trentin and Fahlberg, 1963). Because of 
these observation, murine pluripotent stem cells can be assayed by their ability 
to form colonies in a spleen of a lethally irradiated recipient mouse and are 
referred to as colony-forming unit/spleen (CFU-S). Although recent observa-
tions suggest that not every spleen colony forming cell represents a pluripotent 
haemopoietic stem cell (Magli et al., 1982; Baines et al., 1983; Harris et al., 
1984; Visser et al., 1984), this assay is still of considerable value for experi-
mental haematology. 
An equivalent of the spleen colony assay for stem cells is not available in 
outbred species such as humans and rhesus monkeys for obvious reasons. The 
development of clonal cultures of haemopoietic cells in semisolid culture 
medium enabled the investigation of haemopoietic differentiation. In those cul-
tures, individual progenitor cells of a particular haemopoietic lineage are able to 
proliferate and generate a clone of maturating progeny cells that remain in 
physical proximity to each other and are identifiable as a colony. For the main 
haemopoietic lineages such assays have been developed (Metcalf, 1984). Most of 
these in vitro assays represent committed progenitor cells. The assay for multi-
lineage progenitor cells (CFU-GEMM) has some characteristics of haemopoietic 
stem cells including differentiation along multiple cell lineages (Fauser and 
Messner, 1979), the capacity for self-renewal (Ash et al., 1981) and originating 
from a single progenitor (Powell et al., 1984). In humans, autologous bone 
marrow transplantation after in vitro purging with 4-hydroperoxy-cyclophos-
phamide has demonstrated that this colony assay failed to predict the marrow 
reconstituting ability. In spite of a drastic reduction in colony counts by this 
drug (Rowley et al., 1985; Kaizer et al., 1985), the in vitro treated marrow was 
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still capable to repopulate autologous recipients conditioned with lethal 
chemo/radiotherapy (Yeager et al., 1986). 
Another approach for the study of haemopoietic cell differentiation is iden-
tification of the pluripotent haemopoietic stem cell by surface markers. Espe-
cially in mice, several investigators have been successful in the purification of 
CFU-S on the basis of their physical and surface properties. Rat (Castagnola et 
al., 1981; Goldschneider et al., 1980) and mouse (Visser et al., 1984, 1988; 
Spooncer et al., 1985; Bauman et al., 1986; Spangrude, 1988; de Vries, 1988) 
haemopoietic stem cells have been purified to almost complete purity. Although 
the haemopoietic stem cells of rats, mice, rhesus monkeys, and man can be 
distinguished from other cells on the basis of ultrastructural characteristics (Van 
Bekkum et al., 1971; Moore et al., 1972; Dicke et al., 1973; Van Bekkum et al., 
1979), stem cell specific surface antigens have not been identified yet. Class I 
and/or class II antigens of the major histocompatibility complex are present on 
the cell surface of stem cells in mice (Visser et al., 1984; Van den Engh et al., 
1978), dogs (Szer et al., 1985) and of very primitive progenitor cells (CFU-
GEMM) in rhesus monkeys (Winton et al., 1985) and humans (Fitchen et al., 
1982). Studies on the purification of human stem cells are hampered by the lack 
of a reliable assay for haemopoietic stem cells. 
1.3 ENGRAFTMENT 
The successful engraftment of a bone marrow graft requires proper preparation 
of a recipient by myeloablative total body irradiation and/or chemotherapy. The 
objectives of conditioning of an allogeneic recipient are a) the creation of space 
in bone marrow to allow homing and proliferation of stem cells , b) the sup-
pression of immunological reactions of the recipient directed against histocom-
patibility antigens present on donor haemopoietic cells in case of allogeneic 
transplants, and c) in case of malignancies, eradication of tumor cells 
(Vriesendorp, 1985). 
After transplantation of bone marrow cells into untreated, syngeneic mice 
only a very small proportion (2-16 %) of the cells are of donor origin (Micklem 
et al., 1968; Takada et al., 1971; Saxe et al., 1984). The concept that a lack of 
space was responsible for these observations, was supported by the observation 
that transplantation of normal, syngeneic bone marrow into alpha-thallassemic 
mice resulted in a sustained conversion to normal red cell phenotype when 
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recipients were prepared by a sublethal dose of total body irradiation of 2-3 Gy 
(Barker et al., 1986; Wagemaker, 1986). 
The immunological reaction of the host upon the injection of foreign bone 
marrow cells is dependent on several variables (see Table 1.2). The role of these 
variables has been extensively described by Vriesendorp (1985) and will be dis-
cussed briefly here. 
The differences in major and minor histocompatibility antigens between 
donor and recipient are important factors determining whether a bone marrow 
graft will be accepted by the host. The influence of genetic disparity between 
donor and recipient on engraftment is well illustrated by the numbers of cells 
required in various donor-recipient combinations. Extensive studies in mice 
have demonstrated that 20-30 times more cells are required for 50% radio-
protection (LD50) after supralethal TBI in allogeneic marrow transplantations 
in comparison to syngeneic transplantations (van Bekkum and de Vries, 1967). 
For rhesus monkeys 107 autologous bone marrow cells/kg body weight are 
sufficient to protect lethally irradiated recipients, while 3-4 x 108 bone marrow 
cells/kg body weight from an unrelated, mismatched donor are required for 
100% radioprotection (Vriesendorp, 1985; personal observations). A similar 
difference between cell dose required after either autologous or mismatched 
bone marrow transplantation has been reported for dogs (Vriesendorp, 1985). 
Another indication for the role of MHC-barriers on engraftment is the fre-
quency of engraftment in different genetic donor-recipient combinations using 
identical conditioning regimens and cell numbers. 
Table 1.2 
Factors which determine the severity of a Host-versus-Graft Reaction. 
Histoincompatibility between donor and recipient 
Conditioning of the recipient 
Route of administration 
Cellular composition of a bone marrow graft (stem cells/lymphocytes) 
Prior sensitization of recipient 
Decontamination of the gastrointestinal tract of the recipient 
Sex of the donor 
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Experiments in outbred species such as dogs (Vriesendorp et al., 1982; Deeg et 
al.,1982), monkeys (Wagemaker et al., 1981) and humans (Powles et al., 1983; 
Hansen et al., 1986; Anasetti et al., 1989) have shown that transplantation across 
MHC-barriers are associated with a higher frequency of engraftment failures. 
A host-versus-graft reaction normally prevents the engraftment of foreign 
bone marrow, unless the recipient's competence for an immunological attack is 
abrogated by an intensive immunosuppressive treatment prior to the transplan-
tation. Total body irradiation, busulphan and cyclophospamide are mostly 
applied for this purpose. As a single agent, total body irradiation is superior to 
busulphan or cyclophosphamide in rhesus monkeys as well as in dogs. This 
effect was observed in matched and mismatched donor-recipient combinations. 
(van Bekkum et al., 1970; Vriesendorp, 1985). 
The cellular composition of a bone marrow graft has a major influence on 
the outcome of a bone marrow transplantation. The number of pluripotent 
haemopoietic stem cells determines the repopulating ability of a bone marrow 
graft. Experiments with highly purified stem cells (Visser et al., 1984; Bauman 
et al., 1986; Spangrude et al., 1988; de Vries, 1988) have shown that pluripotent 
stem cells are primarily responsible for sustained engraftment. Donor lympho-
cytes induce an acute GvH reaction in case of allogeneic bone marrow trans-
plantations. Since the recipient's immunocompetent cells are among the targets 
of the GvH reaction, donor lymphocytes can abrogate residual immunological 
resistance against donor cells. 
Pluripotent stem cells are not only present in bone marrow, but can also be 
found in tissues such as fetal liver, spleen and peripheral blood. In mouse, the 
highest concentration of stem cells is found in bone marrow which is matched 
only by the fetal liver. In comparison to bone marrow' the proportion of stem 
cells is 100 times less in peripheral blood and 20 times less in spleen 
(Wagemaker, 1985). 
The presence of pluripotent stem cells in the peripheral blood (Calvo et al., 
1976; Storb et al., 1977; Reiffers et al., 1986) indicate that they, apparently, can 
leave the bone marrow, enter the circulatory system and remigrate to the bone 
marrow. This migration pattern permits bone marrow transplantation by 
administration of haemopoietic cells intravenously. This route of administration 
was proven to be superior to a subcutaneous, intraperitoneal and intra-arterial 
route (reviewed by Vriesendorp, 1985). 
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Blood transfusions given prior to bone marrow transplantation can induce 
sensitization of recipients and can interfere with engraftment as was first 
demonstrated in rhesus monkeys (van Putten et al., 1967). Subsequent studies in 
dogs have revealed that donor blood has a more pronounced influence on 
engraftment than third-party blood transfusions. Whole blood transfusions and 
donor skin epithelial cells strongly sensitized recipients resulting in engraftment 
failures in all cases. Sensitization and subsequent engraftment failure could be 
prevented by using leukocyte-poor platelet and leukocyte-poor red blood cell 
transfusions (Storb et al., 1979). The problem of sensitization is especially 
encountered in patients with severe aplastic anemia, who have received multiple 
blood transfusions. In these patients either multiple platelet or red blood cell 
transfusions before transplantation were associated with a higher incidence of 
engraftment failures (Storb et al., 1983). Exposure of blood transfusions to 
ultraviolet irradiation abolished their ability to sensitize recipients and engraft-
ment failures were no longer observed in dogs (Deeg et aL,1985). 
Decontamination of the gastrointestinal tract is employed to decrease the 
incidence and severity of GvHD (see section 1.5.1), but it also hampers engraft-
ment. This has been clearly demonstrated in dogs. In haplomismatched donor-
recipient combinations, a conditioning regimen of 2 x 6.0 Gy resulted in suc-
cessful engraftment in 5/5 recipients not subjected to gastrointestinal decon-
tamination. When the gastrointestinal tract of the recipients was selectively 
decontaminated, an identical conditioning regimen and the same number of bone 
marrow cells resulted in sustained engraftment in only 1/4 of the recipients 
(Vriesendorp et aL, 1981). In rhesus monkeys complete decontamination of the 
gastrointestinal tract was accompanied by a delayed regeneration of leukocytes. 
Take failures occurred in a total of 4 out of 25 recipients. This is not statistically 
significant different from the 23% take failures which were observed in a 
comparable group of conventional recipients (Heidt, 1989). 
1. 4 GRAFT- VERSUS-HOST DISEASE 
Until recently the most serious complication after transplantation of allogeneic 
bone marrow was GvHD and its associated infections. Two forms of GvHD have 
been identified: acute and chronic. 
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Acute GvHD is a process that develops early after transplantation and it 
manifests itself by lesions in skin, liver, gut and lymph nodes resulting in a vari-
ety of symptoms such as a generalized maculopapular rash, hepatitis, diarrhea, 
and a delayed reconstitution of haemopoietic and lymphoid function (Thomas, 
1975: Zurcher 1985). In the period of early investigations into the nature of 
GvHD, discussions were held whether the severe atrophy of lymphatic tissue in 
animals suffering from "secondary disease" was due to a host-versus-graft 
immunological reaction (Makinodan, 1957) or to a graft-versus-host reaction. 
Circumstantial evidence for.a graft-versus-host reaction was that the transfer of 
allogeneic lymphoid cells into an immunological nonresistent recipient caused a 
syndrome very similar to the secondary disease observed after allogeneic bone 
marrow (Billingham and Brent 1957; van Bekkum et al., 1957; Santos et al., 
1958; Nowell et al., 1959; Vos et al., 1959; Trentin, 1959). These observations 
led to several experiments in which lymph node cells were added to bone 
marrow cells and grafted in lethally irradiated recipients. These bone marrow 
grafts caused severe disease and mortality in the recipients. The classical 
experiment, demonstrating the nature of the graft-versus-host reaction, is that 
transplantation of a fixed number of bone marrow and a graded number of 
lymph node cells resulted in a linear-log relationship between mortality and the 
number of lymphoid cells grafted (van Bekkum, 1964). Subsequent experiments 
have revealed the factors which influence the induction of acute GvHD: 
- the cellular composition of the haemopoietic graft, especially the 
proportion T lymphocytes and stem cells 
- the number of cells transplanted 
-the immunogenetic disparity between donor and recipient 
- the composition of the microflora of the recipient 
For a detailed discussion of the influence of these individual factors, the reader 
is referred to a recent review (Van Bekkum, 1985). 
After the classical experiments in mice which demonstrated that the number 
of lymphocytes added to a bone marrow graft is related to the severity of an 
acute GvH reaction, the causative role of lymphocytes in the induction of graft-
versus-host disease was established and confirmed in other animal models. In 
dogs, transplantation of bone marrow from DLA-identical siblings will produce 
signs of acute Gv HD in a minority of the recipients, since in this species bone 
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marrow contains a low proportion of lymphocytes. When donor lymph node 
cells are added to the DLA-matched bone marrow graft, the severity and inci-
dence of GvHD accordingly increases. According to the observation that the 
incidence and severity of acute GvHD is dependent on the number of lympho-
cytes present in a bone marrow graft, a high incidence of early mortality due to 
severe acute GvHD is observed after allogeneic bone marrow transplantations in 
rhesus monkeys. In this species bone marrow contains approximately 20% T 
lymphocytes and induces severe acute GvHD in the majority of the recipients 
(7/8) of related, RhLA-identical donors (Wagemaker et al., 1982). Similar to the 
bone marrow of rhesus monkeys that of humans contains a high proportion of 
lymphocytes and subsequently the incidence of acute GvHD is approximately 
50% in patients who receive a bone marrow graft of an HLA-identical sibling 
and of whom half will die (Thomas, 1975). Although the proportion of lympho-
cytes is almost identical in humans and rhesus monkeys, the reported incidence 
of acute GvHD is not identical. This is attributed to the fact that the rhesus 
monkeys received no additional treatment for the prevention of GvHD while 
human patients in general receive prophylactic agents such as methotrexate. 
Differences in loci of the major histocompatibility complex (MHC) as well 
as in loci outside MHC also play an important role in the induction of GvHD. 
The influence of loci outside the MHC is illustrated by the well known occur-
rence of Gv HD in of 50% of the patients grafted with bone marrow from an 
MHC-identical sibling. The incidence of severe GvHD is related to the degree of 
immunogenetic disparity between donor and recipient as was shown in several 
outbred species such as rhesus monkeys (Wagemaker et al., 1982), dogs (Storb et 
al., 1985) and humans (Hansen et al., 1986). The risk of severe acute GvHD 
(grade II to IV) appeared to be 40% for recipients of HLA-identical bone 
marrow graft, while the risk of acute GvHD was 68%, 75% and 92% when 
donor and recipient were incompatible for one, two or three loci of the MHC 
respectively (Hansen, 1986). The role of the different loci of the major histo-
compatibility complex on the induction of acute GvHD will be further discussed 
in section 1.7 (mismatched bone marrow transplantation). 
The influence of the composition of the microflora of the recipient has been 
extensively studied in murine models for bone marrow transplantation. Infusion 
of 107 bone marrow cells from H-2 incompatible donors into lethally irradiated 
mice results in a late onset type GvHD. In this delayed type of GvHD, symptoms 
of the disease become manifest three weeks after transplantation and a majority 
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of the recipients will die (van Bekkum and de Vries, 1967). Mortality due to 
delayed GvHD can successfully be prevented when the recipients are germfree 
mice (Jones et al., 1971; van Bekkum et al., 1974; Truitt, 1978) or when the 
gastrointestinal tract of conventional mice has been decontaminated by means of 
nonabsorbable antibiotics prior to transplantation (Heit et al., 1973; Truitt, 1978; 
van Bekkum et al., 1974). An acute type of GvHD can be induced in mice by 
supplementing bone marrow cells with 107 spleen cells resulting in the deaths of 
the recipients within three weeks. Decontamination of the gastrointestinal tract 
delayed the onset of acute GvHD and mortality but did not prevent it (van 
Bekkum et al., 1974). The significance of gastrointestinal decontamination for 
outbred species will be discussed in detail in the next paragraph dealing with 
methods to prevent acute GvHD. 
Because of the overriding influence of acute GvHD on the outcome of an 
allogeneic BMT, much research effort was put into the treatment of GvHD. In 
view of the immunologic etiology of GvHD, attempts to prevent it were focused 
either on the elimination of the immunocompetent donor T lymphocytes from 
bone marrow grafts or on the administration of immunosuppressive agents 
started before acute GvHD becomes apparent. 
1.5 PREVENTION OF ACUTE GRAFT VERSUS HOST 
DISEASE 
1.5.1 IMMUNOSUPPRESSION AFTER 
TRANSPLANTATION 
Based on results obtained in experiments with mice (Uphoff, 1958) and espe-
cially with dogs (Thomas, 1962; Storb et al., 1970; Storb et al., 1970a), 
methotrexate (MTX) has been widely employed as prophylaxis for acute GvHD 
in patients (Thomas, 1975). Despite the use of HLA-matched siblings as donors 
and MTX for GvHD prophylaxis, the incidence of acute GvHD was still30-70% 
and it was fatal in approximately one-half of the patients with GvHD (Thomas, 
1975; Bortin et al., 1981; Storb et al., 1983; Weiden et al., 1979). The value of 
MTX as GvHD prophylaxis has been challenged recently. One group reported 
that four courses of MTX were as effective as seventeen standard courses of 
MTX for prophylaxis of acute and chronic GvHD (Smith et al., 1985). More 
intriguing is a report that no difference in the incidence of acute GvHD was 
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found between patients receiving standard MTX prophylaxis and patients who 
received no prophylaxis at all (Lazarus et al., 1984). Marrow toxicity of MTX 
resulted in a delayed engraftment in comparison to a control group. A 
controlled trial will be necessary to resolve this controversy. 
The administration of antithymocyte globulin was quite effective in mon-
keys (Van Bekkum et al., 1972) and dogs (Storb et al., 1973). In contrast to 
these preclinical experiments, two randomized trials in human patients did not 
demonstrate any influence of antithymocyte globulin on the incidence of GvHD 
(Weiden et al., 1979a; Doney et al. 1981). However, when antithymocyte 
globulin was given in addition to MTX and prednisone, the incidence of GvHD 
was 21% in comparison to 48% in the group who received MTX alone (Ramsay 
et al., 1982). 
Recently, a new and powerful immunosuppressive agent, cyclosporine A 
(Borel et al., 1977; Tutschka et al., 1979), has been introduced into clinical 
studies for the prevention of GvHD. Several pilot studies have been carried out 
showing that it is effective in preventing acute GvHD in humans (Powles et al., 
1980; Speck et al., 1981; Hows et al., 1982). Controlled studies in dogs have 
shown that it is as effective as MTX in preventing GvHD in different genetic 
combinations (Deeg et al., 1982). The combined use of a short course of MTX 
and cyclosporine A till day 100 had superior results in DLA-mismatched litter-
mates in comparison to historical controls treated with MTX alone (Deeg et al., 
1984). These results in dogs encouraged the Seattle Bone Marrow Team to start 
several prospective trials (Table 1.3). An early report on the effect of either 
cyclosporine A or MTX on the incidence of Gv HD in patients transplanted for 
leukemia in relapse, mentioned a superior result obtained when cyclosporine A 
was administered (Irle et al., 1985). In a recent report on the same patient group 
no difference between these drugs with regard to their potency to prevent acute 
GvHD was found (Storb et al., 1988). These results were confirmed in a 
randomized trial performed in Sweden (Ringden et al., 1986). In patients trans-
planted for acute nonlymphoblastic leukemia a 33% incidence of acute GvHD 
was found in the group receiving cyclosporine A, while 56% of the patients, 
who were given MTX, developed GvHD (Storb et al., 1986). No difference in 
the incidence of GvHD was observed in patients transplanted for chronic myelo-
cytic leukemia (Storb et al., 1985). In none of the studies a significant difference 
in survival was observed. The combination of MTX and cyclosporine was very 
successful in dogs and a recent clinical studies have confirmed the superiority of 
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the combination over cyclosporine alone (Storb et al., 1987a) or methotrexate 
alone (Storb et al., 1987a). In these studies a reduction of the incidence of acute 
GvHD by the combination of MTX and cyclosporine A was associated with a 
reduction in the incidence of fatal infections and with an increased survival. 
Table 1.3 
Efficacy of Cyclosporine A alone or in combination with methotrexate to 
prevent acute GvHD. 
probability of 
disease N treatment acuteGvHD reference 
lellicernia, relapse 30 MTX 71% 
26 CyA 45% p=0.11 Irle, 1985 
ANL 36 MTX 56% 
39 CyA 33% p=0.07 Deeg, 1985 
CML 23 MTX 42% 
25 CyA 46% p=0.70 Storb,1985 
Aplastic anemia 24 MTX 53% 
22 MTX+CyA 18% p=0.012 Storb,1986 
ANLorAML 50 CyA 54% 
43 MTX+CyA 33% p=0.014 Storb,1986 
ANL= acute nonlyrnphoblastic lellicernia; CML= chronic myeloid lellicernia; 
MTX= methotrexate; CyA= Cyclosporine A. 
Antibiotic decontamination of the intestinal tract did significantly reduce 
mortality due to delayed GvHD (Jones et al., 1971; van Bekkum et al., 1974; 
Heit, 1973; Truitt, 1978) and mitigated the severity of acute GvHD in mice (van 
Bekkum et al., 1974). Heidt (1989) investigated the influence of faecal flora of 
the donor on the induction of lethal GvHD. Lethal GvHD was only observed in a 
group of "conventional" recipients which received bone marrow cells from SPF 
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(specified pathogen free) donors. No GvHD was seen when there is identity 
between the microflora of recipient and donor or when SPF recipients were 
given bone marrow cells from "conventional" donors. Clinical studies regarding 
the influence of GID on the incidence and severity of GvHD are contradictory 
(Heidt et al., 1985; Heidt, 1989; Storb et al., 1983; Buckner et al., 1983; 
Buckner et al., 1985; Deeg et al., 1985; Skinh!Zij, 1987). Heidt (1989) reported a 
beneficial effect of complete GID in children with none of the 11 patients with 
successful GID developing severe GvHD. This in contrast to 7 out 29 patients in 
whom complete GID was not achieved. The difference in results could be due to 
either incomplete GID or to a too short period of decontamination, since in mice 
an effect of GID on GvHD is only observed when GID is successfully maintained 
from 10 days before (Truitt, 1979) until 40 days after bone marrow trans-
plantation (van Bekkum et al., 1977). 
1.5.2. T LYMPHOCYTE DEPLETION OF BONE MARROW 
GRAFTS 
The most effective method for prevention of acute GvHD is elimination of 
immunocompetent T lymphocytes from a bone marrow graft. Two decades ago, 
experiments with mice have already proven that T lymphocyte depletion is an 
effective method to prevent acute GvHD (Dicke et al., 1968; Rodt et al., 1974). 
These results were confirmed in outbred species such as dogs (Kolb et al., 1979) 
and rhesus monkeys (Dicke et al., 1970; Wagemaker et al., 1982). The elimina-
tion of T lymphocytes from human bone marrow transplants required the 
development of methods, which were applicable for treatment of large volumes 
of human bone marrow. Meanwhile, several methods have been developed and 
applied for human transplant purposes such as albumin gradient (Dicke, 1970), a 
combination of density gradient and E-rosette sedimentation (Lowenberg et al., 
1986), differential agglutination of mature blood elements with soybean agglu-
tinin and subsequent removal ofT lymphocytes from the unagglutinated bone 
marrow fraction byE-rosette sedimentation with sheep red blood cells (Reisner 
et al., 1980; Reisner et al., 1981; O'Reilly et al., 1986), complement mediated 
lysis ofT lymphocytes using monoclonal antibodies (Martinet al., 1985; Sandel 
et al., 1985; Prentice et al., 1986; Racadot et al., 1986; Mitsuyasu et al., 1986; 
Hale et al., 1986, Herve et al., 1987), anti-T lymphocyte monoclonal antibodies 
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coupled to the toxin ricin (Vallera et al., 1983; Kersey et al., 1986) and coun-
terflow centrifugation-elutriation (De Witte et al., 1983; De Witte et al., 1984). 
Table 1.4 
Prevention of acute Graft-versus-Host Disease by T lymphocyte depletion from 
bone marrow grafts of HLA-identical siblings. 
BMT number of take 
Center patients methods failure 
New York 57 soy b. 4 
Seattle 20 mea 6 
Minneapolis 17 mea-ricin 4 
Wisconsin 7 mea 0 
London 21 mea 1 
France 57 mea 11 
Los Angeles 20 mea 5 
Campath-1* 264 mea 34 
Nijmegen 14 elutr. 0 
Utrecht 7 soy b. 0 
Rotterdam 8 albumin 1 
Rotterdam 17 alb.+E-r 0 
Paris 21 mea 0 
530 66 (12.5%) 
mea= monoclonal antibody and complement; 
soy b. = soybean agglutination and E-rosette sedimentation; 
elutr. = e1utriation centrifugation; 
albumin = discontinuous albumin density gradient; 
GvHD 
>=grade II reference 
3/53 O'Reilly,1986 
3/14 Martin,1985 
4/13 Kersey,1986 
on Bozdech, 1985 
1/20 Prentice, 1986 
4/52 Racadot,1986 
3/20 Mitsuyasu,1985 
34/230 Hale,1986 
2/14 De Witte,1984 
2fi De Gast,l986 
2fi Lowenberg, 1986 
0/17 Hagenbeek, 1987 
3/21 Gluckman, 1987 
61/464 (13.1 %) 
alb+E-r =disc. albumin density grad. + E-rosette sedimentation. 
*:review of results in BMT centers which use the monoclonal antibody CAMPATH-1 forT 
lymphocyte depletion. 
So far reports are very encouraging with respect to the incidence of severe, 
acute GvHD (13%: see Table 1.4). This score surpasses the best results obtained 
17 
by immunosuppressive treatment of recipients after transplantation as prophy-
laxis for GvHD. 
Difference between the various methods used for T lymphocyte depletion 
are not being observed. All methods deplete 1-2 logs T lymphocytes, which is 
sufficient to prevent acute GvHD in this donor-recipient combination according 
to our retrospective analysis of the results of transplantations of T lymphocyte 
depleted bone marrow grafts in different donor-recipient combinations in rhesus 
monkeys ( Wagemaker, 1986a). The frequency of severe GvHD does not seem to 
be affected by the use of additional immunosuppressive treatment of recipients 
after transplantation. Only the BMT center in Nijmegen using elutriation 
centrifugation forT lymphocyte depletion observed severe GvHD when addi-
tional immunosuppresion was not administered after transplantation. 
The question of how many T lymphocytes are permitted in a bone marrow 
graft has yet to be answered. In patients, who received a bone marrow graft 
depleted from T lymphocytes by CAMP A TH-1 and autologous complement, the 
incidence of acute GvHD was significantly correlated with the presence of more 
than 4 x 106 T lymphocytes/kg body weight after purging (Hale et al., 1988). In 
24 patients the measured number ofT lymphocytes was more than 4 x 106 T 
lymphocytes/kg body weight and 14 (58%) of them suffered from some degree 
of GvHD compared to 48 (23%) of 211 patients who's bone marrow graft 
contained less than 4 x 106 T lymphocytes/kg body weight. Quantification of 
clonable T lymphocytes have demonstrated that 1 x 105 clonable T lympho-
cytes/kg body weight correlated with no acute GvHD (Kernan et al.,1986). 
Atkinson et al (1987) has also found a direct relation between the number ofT 
lymphocytes in a bone marrow graft and the frequency of acute GvHD. On basis 
of a retrospective analysis of the relationship between the number ofT lympho-
cytes in a bone marrow graft and the incidence of lethal GvHD in different 
genetic combinations, the maximum number of T lymphocytes allowable in a 
bone marrow graft without causing lethal GvHD were calculated. For RhLA-
identical sibling monkeys the maximum number of T lymphocytes/kg body 
weight was found to be 2 x 106 T lymphocytes. In a bone marrow graft from an 
unrelated, A!B matched donor 6 x 105 T lymphocytes/kg body weight are 
permitted and in unrelated, totally mismatched donor-recipient combinations 
only 105 T lymphocytes/kg body weight are allowed (Wagemaker, 1986a). 
The encouraging results with T lymphocyte depleted bone marrow grafts in 
HLA-identical siblings were followed by attempts to apply T lymphocyte deple-
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tion for mismatched transplantations. The preliminary results of these trials are 
discussed in section 1.7. 
1.5.2.1 ENGRAFTMENT OFT LYMPHOCYTE DEPLETED 
BONE MARROW GRAFTS 
An undesirable consequence of the utilization of T lymphocyte depletion is the 
increased frequency of take failures if the conditioning of the patients is not 
adapted. It was clearly and timely demonstrated in canine (Vriesendorp et al., 
1981a), rhesus monkeys (Wagemaker et al., 1982) and murine (Soderling et al., 
1985) models of mismatched BMT that a take of T lymphocyte depleted allo-
geneic marrow requires more intense conditioning than T lymphocyte 
containing grafts. Results with patients confirmed these findings, especially when 
partially mismatched, related donors were used (Bozdech et al., 1985; O'Reilly 
et al., 1985). Nonspecific loss of haemopoietic progenitor cells during the T 
lymphocyte depletion could partially contribute to this effect as was measured by 
granulocyte/macrophage colony formation (GM-CFU) (Patterson et al., 1986; 
Blazar et al., 1985; Martin et al., 1985; Herve et al., 1985). However, the 
reduced incidence of engraftment was still observed after transplantation of a 
non limiting number of stem cells in animal experiments (Vriesendorp et al., 
1981; Wagemaker et al., 1982; Soderling et al., 1985) and no correlation has 
been found between the number of GM-CFU infused and failure of engraftment 
after T lymphocyte depletion (Martin et al., 1985; O'Reilly et al., 1985). A 
more likely explanation is that T lymphocyte depletion of the graft reduces 
immunosuppression of the recipient by abrogation of the anti-host immunologi-
cal reactivity of the graft. This concept of reciprocal interference (Nakic, 
1966; Vriesendorp et al., 1981b) between GvHD and engraftment is endorsed by 
the fact that additional immunosuppression of recipients promotes engraftment 
of T lymphocyte depleted grafts in experimental animals (Vriesendorp et al., 
1981a; Wagemaker et al., 1982; Soderling et al., 1985) and humans (O'Reilly et 
al., 1986; Martinet al., 1985; Sondel et al., 1985) . 
An alternative explanation for the increased frequency of engraftment fail-
ures ofT lymphocyte depleted bone marrow graft is that T lymphocytes have an 
essential function during the engraftment. This hypothesis is based on the 
knowledge that T lymphocytes can produce several haemopoietic growth factors 
(Metcalf, 1986). Hence, depletion ofT lymphocytes would deprive the graft of 
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the growth factors essential for proliferation of haemopoietic cells (Sieff et al., 
1985; Soderling et al., 1985). 
1.5.2.2 T LYMPHOCYTE DEPLETION AND LEUKEMIA 
RELAPSE 
When leukemic cells are among the targets of a GvH reaction, it is expected that 
a mitigation of the GvH reaction would have consequences for the graft-versus-
leukemia (GvL) reaction. This hypothesis is supported by the observation that 
the incidence of leukemia relapses in patients with acute nonlymphoblastic 
leukemia is much higher in recipients of identical twin bone marrow grafts 
(50%) than in recipients of HLA-matched siblings (reviewed by O'Reilly, 1983). 
Several studies in humans have reported a decreased risk of leukemia recurrence 
in patients who develop acute or chronic GvHD following transplantation from 
HLA-identical siblings (Weiden et al., 1979a; Weiden et al., 1981; Bacigalupo et 
al., 1985). On the basis of these reports one could predict that a reduction in the 
incidence of GvH will be correlated with an increase in leukemia relapses. Anal-
ysis of the results of patients, who received an allogeneic bone marrow trans-
plantation for chronic myeloid leukemia in chronic phase, has indeed demon-
strated that T lymphocyte depletion decreases the incidence and severity of acute 
and chronic GvHD, but this effect was counterbalanced by a significant increase 
in leukemia relapses (Apperley et al., 1986, 1988; Goldman et al., 1988). The 
actuarial survival of patients of T lymphocyte depleted or unmodified bone 
marrow grafts did not differ significantly. For acute leukemia firm conclusions 
can not be drawn regarding a relationship between T lymphocyte depletion and 
leukemia relapse. Mitsuyasu et al. (1986) reported a higher number of relapses 
in the group of patients which received a T lymphocyte depleted bone marrow 
graft in comparison to controls but the difference was not significant. In other 
early reports, the incidence of leukemia relapses in good risk patients, who 
received a T lymphocyte depleted graft, was not significantly different from the 
incidence of relapse in comparable good risk patients transplanted with con-
ventional grafts (O'Reilly et al.,1986; Prentice et al.,1986). 
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1.6 CHRONIC GVHD 
Chronic GvHD is a separate clinical syndrome affecting between 15 to 40% of 
the transplanted patients who survive more than 6 month's. Two thirds of the 
patients with chronic GvHD have preceding acute GvHD but in one-third it 
develops without preceding clinical signs of acute GvHD. It results in localized 
or widespread sclerodermatous changes of the skin, skin and joint contractures, 
xerostomia, xerophthalmia, biliary cirrhosis, malabsorption, and failure to 
thrive (Shulman et al., 1980; Sullivan et al., 1981). The disease resembles the 
systemic collagen vascular diseases, especially systemic lupus erythematosus and 
progressive systemic sclerosis. Predisposing factors for the development of 
chronic GvHD are moderate to severe acute GvHD, increasing age of the patient 
and the use of viable donor buffy coat cells in addition to the marrow in case of 
aplastic ahemia (Storb et al., 1983; Ringden et al., 1985). Donor buffy coat cells 
were added to bone marrow to prevent engraftment failures. The beneficial 
effect can be attributed to more GvHD in comparison to bone marrow alone. 
Subsequently more chronic GvHD was seen. Treatment with immunosuppressive 
drugs, either prednisone alone or in combination with azathioprine, cyclophos-
phamide, or procarbazine, has been shown to be effective in abrogating the 
adverse natural course of extensive chronic graft-versus-host disease (Sullivan et 
al., 1981). 
1. 7 MISMATCHED BONE MARROW TRANSPLANTATIONS 
HLA compatibility between donor and recipient is generally felt to play a criti-
cal role in clinical bone marrow transplantation. The incidence of GvHD is still 
high (50%) when related donors are used who are totally matched for the MHC 
antigens and methotrexate is applied for GvH prophylaxis. For this reason it is 
widely held that the probability of achieving a successful transplant is diminished 
by HLA incompatibility. However, the majority of patients who are candidates 
for bone marrow transplantation do not have HLA-identical siblings. Therefore, 
several studies were started to explore the use of related, mismatched donors and 
unrelated donors. 
In rhesus monkeys the effect of donor selection on acute GvHD has been 
studied extensively. Transplantation of stem cell enriched, T lymphocyte 
depleted bone marrow grafts in related donor-recipient combinations has 
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revealed that the incidence of lethal GvHD is low (1/8: median survival > 2 
years) in RhLA-identical siblings, and high (4/5: median survival 25 days) when 
donor and recipient were mismatched for the D/DR loci (and identical for the 
AlB loci). Experiments with unrelated donors demonstrated that matching for 
the A and B loci (and mismatching for the D/DR loci) reduced the incidence and 
severity of GvHD (5/9: median survival 50 days), but the effect of matching 
became apparent only when stem cell enriched, T lymphocyte depleted bone 
marrow grafts were employed (Wagemaker et al., 1982, 1986a). The results of 
matching for the A and B loci became more impressive when the gastrointestinal 
tract was completely decontaminated. In this situation no lethal GvHD occurred 
in 4 monkeys (Heidt, 1989). 
In the past decade, cautious exploration of the use of family-member donors 
other than HLA-identical siblings has been started in clinical centres. As 
mentioned earlier in this chapter, the probability of severe (grade ~ 2), acute 
GvHD increases when the immunogenetic disparity between donor and recipient 
increases. In the study of the Seattle Bone Marrow Transplantation Team 
(Hansen et al., 1986) the risk of acute GvHD was 40% at day 75 after trans-
plantation when donor and recipient were HLA phenotypically identical and 
reactive in the MLC. The risk of severe, acute GvHD was 68% in case of HLA 
one locus incompatibility, 75% when donor and recipient were incompatible at 
two loci and 92% when three HLA loci differed. Incompatibility for class I anti-
gens appeared to have the same effect on GvHD as incompatibility for class II. In 
this study of the Seattle Bone Marrow Transplantation Team, it appeared that 
HLA incompatibility can impede the rate of engraftment, increase the risk of 
rejection and substantially increase the incidence of acute GvHD. An analysis of 
the survival of 25 patients transplanted in remission with marrow from a donor 
who was incompatible for one HLA locus, showed no significant difference with 
a series of recipients with genotypically identical donors (Hansen et al., 1986). 
Powles et al (1983) described the clinical course of 35 patients, who received a 
marrow graft from mismatched family donors. Eleven patients (31%) survived 
the transplantation. A remarkable finding was that 12 patients died from a 
capillary leakage syndrome, which was associated with pulmonary oedema, 
convulsions, intravascular haemolysis and renal failure. 
The encouraging results on the prevention of acute GvHD by T lymphocyte 
depletion prompted several centers to investigate whether this approach could 
reduce the risk of mismatched transplantations (Table 1.5). The longest expe-
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rience with mismatched bone marrow transplantation has been gained with the 
treatment of young patients with severe combined immunodeficiency (SCID). 
The published results indicate that engraftment failures is a major obstacle. 
However, the incidence of severe, acute GvHD is low and the probability of 
survival (60%) does not differ significantly in those patients, who received HLA 
mismatched, T lymphocyte depleted bone marrow grafts, and patients who's 
donors were HLA-identical siblings (Fisher et al., 1986a; O'Reilly et al., 1987). 
Transplantation of HLA-mismatched, not T lymphocyte depleted marrow grafts 
was associated with a poor survival prognosis of 18% (Fisher et al., 1986a). 
Table 1.5 
Transplantations of T lymphocyte depleted bone marrow grafts from related, 
mismatched donors. 
Disease Conditioning N Engraftment GvHD2:2 Reference 
(number) (number) 
Leukemia 1320cGy+Cy 5 0 Bozdech,1985 
1320 cGy+Cy+ARA-C 4 4 3 Bozdech,1985 
1320 cGy+Cy+ARA-C+ 
Csa 10 10 2 Bozdech,1985 
Leukemia 1200 cGy+ARA-C 15 14 2 Cahn, 1988 
Melphalan+ATG 
Leukemia 1320-1440 cGy+ARA-C 48 32 3 O'Reilly, 1987 
or+Cy 
Leukemia 1200 cGy+ARA-C+Cy 8 0 Henslee,1987 
1400 cGy+ARA-C+Cy 24 23 9a Henslee,1987 
cGy =Total body irradiation dose in centiGray; ARA-C =cytosine arabinoside; 
Cy = Cyclophosphamide; Csa = Cyclosporine A 
a: acute GvHD more than grade 2 
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The early reports on patients with leukemia, who received HLA-mis-
matched, T lymphocyte depleted bone marrow grafts, indicate that the obstacles 
are the same as in recipients ofT lymphocyte depleted, HLA-identical marrow 
grafts, namely an increased frequency of engraftment failures. Several clinical 
centers have searched for adequate conditioning regimens which permit 
sustained engraftment. In New York 34 recipients of HLA-mismatched marrow 
were conditioned for grafting by hyperfractionated TBI followed by cyclophos-
phamide or ARA-C and additional pretransplant immunosuppressive drugs (Anti 
Thymocyte Globulin (ATG) +procarbazine or ARA-C) and 15 rejected their 
graft. Of these 34 patients, 22 patients received immunosuppressive drugs 
(cyclosporine A or steroids) for promotion of engraftment, but 8 of these 22 
patients still rejected the bone marrow graft. The most successful treatment was 
the administration of A TG in the early posttransplant period, which resulted in 
17 out of 18 durable engraftments (O'Reilly et al., 1987). The other trans-
plantation centers (Wisconsin and Lexington) also found that the problem of en-
graftment failures could be overcome by additional immunosuppression 
(Bozdech et al., 1985; Henslee et al., 1987). The incidence of severe acute GvHD 
ranged from 10% (O'Reilly et al., 1987) to 40% (Henslee et al., 1987). In 
contrast to SCID patients, survival of leukemia patients with HLA-mismatched 
donors was inferior to survival of recipients of HLA-identical bone marrow 
grafts. O'Reilly (1987) reported that the inferior survival was mainly due to 
more lethal infections in comparison to HLA-matched bone marrow transplan-
tations. 
The possibility of using unrelated donors who are phenotypically HLA-
identical with the patient is attracting more attention. A few successful trans-
plantations have been reported (Hansen et al., 1980; Hows et al., 1987; 
Duquesnoy et al., 1983; Liu Yin et al., 1984; McGlave et al., 1987), but it is to 
early to draw any conclusions. The same holds for the use of unrelated, 
partially, mismatched donors (Gingrich et al., 1985; McGlave et al., 1987). 
1.8 RHESUS MONKEY; AN ANIMAL MODEL FOR 
EXPERIMENTAL BMT 
For more than 25 years Rhesus monkeys (Macaca Mulatta) and Cynomolgous 
monkeys (Macaca Iris) have been employed for experimental bone marrow 
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transplantations. The Radiobiological Institute TNO has a long experience of 
approximately 30 years with bone marrow transplantation in rhesus monkeys 
(Crouch et al.,1961). 
1.8.1 IRRADIATION AND ENGRAFTMENT IN RHESUS 
MONKEYS 
The radiosensitivity of rhesus monkeys has been determined for 300 kV X-rays 
as well as for fission neutrons (Broerse et al., 1978). Over a range from 450 to 
700 cGy (X-ray), there appeared to exist a steep dose-survival curve with 100% 
30 day survival after a dose of 450 cGy and no animal surviving a dose of 600 
cGy (hvl 2.0 mm Cu; dose rate 25-30 cGy). The LDso of rhesus monkeys has 
been estimated to be approximately 5.25 Gy. Autologous bone marrow protects 
up to a dose of 900 cGy. After a total body irradiation of 1000 cGy and more all 
the animals died due to gastrointestinal toxicity within 17 days. The dose 
survival curve was even more steeper for neutron irradiation since after 200 
cGy all animals survived and none survived a dose of 300 cGy.For neutrons the 
LD50 was estimated to be 250 Gy. For animals treated with autologous bone 
marrow grafts the 50% survival point was reached after 475 cGy (Broerse et 
al., 1978). 
The number of fresh autologous bone marrow cells required for engraft-
ment is approximately 1 x 107 /kg body weight (van Putten et al., 1962), while 
engraftment of allogeneic marrow grafts 2.5-3 x 108/kg body weight (van 
Putten et al., 1962) is required. Transplantation experiments with fetal monkey 
liver and spleen of 3-month gestation demonstrated that the number of cells ob-
tained from one single donor (2-3 x 1Q8Jkg body weight ) was insufficient for 
successful engraftment (van Putten et al., 1962). 
1.8.2 BONE MARROW COMPOSITION IN RHESUS 
MONKEYS 
With respect to the potency to induce an acute GvH reaction, rhesus monkey 
bone marrow is identical to human bone marrow. Aspiration marrow contains 
approximately 23 ± 2 % T lymphocytes (Wagemaker et al, 1982). In RhLA-
identical siblings 2-4 x 1 os bone marrow cells/kg body weight induced severe, 
fatal GvHD in 90 % of the recipients with a median survival of 22 days 
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(Wagemaker et al., 1982). When unrelated donors were used, the median 
survival time was 12 days, deaths being uniformly due to severe GvHD 
(Wagemaker et al., 1982). 
In search of methods which could be applied to mitigate the incidence and 
severity of acute GvHD, density gradients were used to separate stem cells from 
lymphocytes (Dicke, 1970; Moore et al., 1972). Early progenitor cells, which 
are able to form colonies in the GM-CFU assay, can be recovered from the light 
density fractions of a discontinuous albumin density gradient. Among these early 
progenitor cells, haemopoietic stem cells are present as has been proven by the 
experiments in which transplantation of 2 x 106 autologous, low density cells/kg 
body weight protected a lethally irradiated monkey (Dicke, 1970; Dicke et al., 
1973). The phylogenetic relation between man and rhesus monkeys has always 
been an advantage. Recently, many monoclonal antibodies directed against 
human lymphocytes (Letvin et al., 1983; Jonker et al., 1983) and myeloid cells 
(Letvin et al., 1983; Pesando et al., 1985) appeared to crossreact with rhesus 
monkey cells. So, for a variety of reasons, rhesus monkeys are well suited to test 
the feasibility of using monoclonal antibodies. 
1.8.3 GRAFT VERSUS-HOST DISEASE IN RHESUS 
MONKEYS 
The morbidity and mortality pattern in rhesus monkeys is identical to humans. 
The clinical symptoms comprise diarrhea and anorexia and may start as early as 
the end of the first week, and death ensues between day 8 and 17 after trans-
plantation of marrow from unrelated donors. The median survival of rhesus 
monkeys is 25 days after transplantation of bone marrow from a RhLA-identical 
sibling. The use of other genetic donor-recipient combinations, i.e. unrelated 
matched donors and family donors mismatched for 1 haplotype, resulted in a 
shorter median survival time (Wagemaker et al., 1982). The pathological fea-
tures of the lesions induced by acute GvHD have been object of intensive study 
in the Radiobiological Institute TNO and have been described in detail (de Vries 
et al., 1961; de Vries, 1967; Zurcher, 1985). Similar to humans, the graft 
versus host reaction damages particularly the epithelium of the gut, the skin and 
the liver, resulting in clinical symptoms such as diarrhea, anorexia, jaundice, 
erythaema, and a rapid loss of weight (wasting). 
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After establishing the pattern of morbidity and mortality due to GvHD, 
several methods have been tried to mitigate the incidence of acute GvHD in rhe-
sus monkeys (Table 1.6 ). The early experiments included preirradiation of bone 
marrow. Experiments in mice had demonstrated that pre irradiation might have a 
favorable influence on the incidence of secondary disease (the early description 
for GvHD) (Cudkowicz, 1961). A fourfold increase in cell number was given to 
compensate for nonspecific cell loss after irradiation. Survival and severity of 
Gv HD was not influenced by preirradiation of a bone marrow graft with 250 
cGy X-rays. A similar experiment with a fourfold increase in cell number and 
400 cGy of X-rays resulted in a longer survival with evidence of temporary and 
incomplete regeneration of bone marrow (van Putten et al., 1962). 
Table 1.6 
Mitigation of Acute GvHD in unrelated rhesus monkeys 
Method to prevent number of mean 
acuteGvHD animals survival range reference 
(days) (days) 
controls 25 14 5-25 van Putten,1962 
pre-irradiation graft 
250 cGy 1 8 
400 cGy 1 >40a van Putten,1962 
storage at 40 C 
0 hours 2 11 9-13 
48-96 hours 4 13 7-16 
120 hours 1 no regenemtion van Putten,1962 
Amethopterin 4 19 11-27 Muller-Berat,1966 
cyclophosphamide 7 39 23-65 Muller-Berat,1966 
Anti-lymphocyte-serum 
horse 15 27 13-41 van Bekkum, 1972 
a: endogenous regeneration 
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A simple method of storage of bone marrow cells at + 40 C had been proved to 
be much more successful in mice (van Bekkum, 1964). This method mitigated 
the severity of GvHD and did not diminish the radiation protection potency. In 
unrelated monkeys, this method appeared not successful (see Table 1.6; van 
Putten et al., 1962). This was the first experiment in which it was concomitantly 
demonstrated that methods which are effective in decreasing the secondary 
disease in rodents are not necessarily effective in monkeys due to the difference 
in the proportion of immunocompetent lymphocytes present in bone marrow. 
Accordingly it was recommended to carry out preclinical experiments in 
monkeys before applying methods, developed in mice, in clinical practice. 
Amethopterin (Methotrexate) is one of the earliest drugs applied for the 
treatment of GvHD. Uphoff (1958) was the first to report a beneficial effect of 
amethopterin in mice. Thomas described a pronounced beneficial effect of post-
transplantation administration of this drug in dogs. Fifty percent of a series of 
20 dogs survived more than 150 days after allogeneic bone marrow transplanta-
tion. Graft rejection occurred in 5 dogs (Thomas et al., 1962). The bone mar-
row transplantation group in Rijswijk has tried to reproduce these results in 
rhesus monkeys. Mortality due to acute GvHD was prevented in 3 out of four 4 
monkeys, but long time survivors were not observed (Muller-Berat et al., 1966). 
Cyclophosphamide mitigated more successfully the incidence and severity of 
GvHD and markedly prolonged survival when it was administered after trans-
plantation (Muller-Berat et al., 1966). 
Going along with the ideas that secondary disease was caused by donor 
lymphocytes, treatment protocols were designed to eliminate lymphocytes. In the 
earliest experiments anti-lymphocyte sera (ALS) were prepared by immunizing 
rabbits or horses with thymocytes. Van Bekkum et al (1972) injected monkeys 
24 hours before BMT subcutaneously with ALS and investigated the effect on 
the incidence and severity of GvHD. The ALS produced in rabbits appeared to 
be toxic not only to lymphocytes but also to other bone marrow cells since only 
3 out of 11 monkeys showed engraftment. Pretreatment of the recipient with 
horse ALS resulted in engraftment in 15 out of 16 animals. Survival ranged 
from 7-41 days. Severe to very severe signs of GvHD were seen at autopsy in 5 
out of 15 monkeys. Mild GvHD was observed in the other 10 monkeys, but none 
of the animals escaped death from GvHD at a latter stage. Again these results did 
not confirm the results in mice, where a single administration of ALS before 
administration fully prevented GvHD (Van Bekkum et al., 1970). 
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At the same time it was attempted to eliminate donor lymphocytes from a 
bone marrow graft by density centrifugation using a discontinuous albumin 
gradient (Dicke, 1970). In the low density fractions the proportion of 
haemopoietic stem cells is greater than in normal bone marrow. The propor-
tion of lymphocytes in the low density fraction is similar to normal bone 
marrow. However, the enrichment of stem cells enabled transplantation of 
approximately 10 times less cells, which means that the absolute number of 
lymphocytes is accordingly 10 times lower than in an unseparated bone 
marrow graft. An one log lymphocyte depletion was sufficient to lower the 
incidence and severity in RhLA-identical siblings and long term survivors were 
seen. These results were confirmed in human studies, which demonstrated that 
this method did reduce the incidence and severity of GvHD in HLA-identical 
siblings (Lowenberg et al., 1986). For a complete prevention of acute GvHD 1-
2 log T lymphocytes had to be removed for rhesus monkey bone marrow 
(Wagemaker et al., 1982) as well as for human bone marrow (Lowenberg et al, 
1986; Hagenbeek, 1987). 
1.9 OUTLINE OF THIS THESIS 
The major complication after allogeneic bone marrow transplantation is the 
occurrence of acute GvHD. This complication can be successfully prevented 
when T lymphocytes are depleted from a bone marrow graft. The beneficial 
effect of prevention of acute GvHD is counterbalanced by an increased fre-
quency of engraftment failures. In view of this problem several experiments 
were planned to unravel whether the engraftment failures after T lymphocyte 
depletion were attributable to the loss of the trophic function of T lymphocytes 
or were attributable to the loss of the immunosuppressive action of donor T-
lymphocytes. When the latter option is valid, more immunosuppression of the 
recipient would result in sustained engraftment ofT lymphocyte depleted bone 
marrow grafts. 
With regard to T lymphocyte depletion, it was attempted to positively select 
for stem cells and concomitantly negatively select for T lymphocytes. Stem cells 
are the essential cells in a bone marrow graft since they are responsible for sus-
tained engraftment. A positive selection of these cells would yield an uniform 
method for preparation of a bone marrow graft rich in stem cells and fully 
depleted of T lymphocytes. A second approach was to investigate whether deple-
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tion of a subpopulation of T lymphocytes (helper/inducer or suppres-
sor/cytotoxic T lymphocytes) was sufficient to prevent acute GvHD. 
A general introduction to bone marrow transplantation is described in 
chapter I. Materials and methods are described chapter II. 
To assess the influence T lymphocyte depletion on the repopulating ability 
of stem cells, an in vivo assay had to be developed, since in outbred species a 
reliable assay to predict the repopulating ability of a bone marrow graft was not 
available. The dev~lopment of the assay was based on the assumption that the 
regeneration rate of peripheral blood cells after autologous bone marrow trans-
plantation is a function of the number of stem cells present in marrow graft. The 
relationship between regeneration patterns of peripheral blood cells and graded 
numbers of autologous bone marrow is described in chapter 3. After estab-
lishing this in vivo assay, T lymphocyte depleted autologous bone marrow grafts 
were transplanted. As a control on the predictive value of the assay, Dr-positive 
cells were depleted from autologous grafts assuming that this would drastically 
reduce the repopulating ability of a bone marrow graft. This assumption was 
based on the fact that the Dr antigen is present on stem cells in several species. 
In chapter 4, an attempt is made to purify the hemopoietic stem cell of the 
rhesus monkey. A positive selection of stem cells of rhesus monkeys was made 
using a discontinuous albumin density gradient and a positive selection of Dr-
positive cells by flow cytometry. Ultimately the capacity of purified cells to 
repopulate an irradiated recipient was investigated. 
In chapter 5, the promotion of engraftment of T lymphocyte depleted, 
allogeneic bone marrow grafts has been studied. It was attempted to quantify the 
additional immunosuppression required to obtain engraftment of T lymphocyte 
depleted grafts. 
In chapter 6, the efficacy of monoclonal antibodies, directed against either 
subpopulations of T lymphocytes or against all lymphocytes, to prevent acute 
GvHD was studied. 
A general discussion on these different investigations is given in chapter 7. 
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CHAPTER II 
MATERIALS AND METHODS 
2.1 ANIMALS 
Young male or female rhesus monkeys (Macaca Mulatta), bred at the Primate 
Center TNO, were used. The monkeys weighed 2.5 to 4 kilogram and were 3 to 
4 years of age at the time of transplantation. 
2.2 ANIMAL CARE 
2. 2.1 ISOLATION PROCEDURE 
Before transplantation, the physical condition of the animals was inspected and 
blood samples were taken for hematological and biochemical examination. The 
faecal flora was investigated on the presence of flagellates. One week before 
transplantation, animals were transferred to either isolations rooms or laminar 
air flow units. Transfer of infections was prevented by caging the monkeys 
separately. To prevent contamination from external sources, barrier nursing and 
disinfection of materials, introduced into the room, was carried out routinely. 
The animals were placed in a restraint chair for physical examination and han-
dling such as administration of medicines at least once per day. The animals 
were not anesthetized for this procedure. Daily blood samples were taken to 
measure repopulation of the haemopoietic system and two to three times a week 
for biochemical tests. The sensitivity pattern of faecal flora was determined 
twice weekly. On the basis of the antibiograms of the faecal flora nonabsorbable 
antibiotics were given. 
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2.2.2 FOOD AND DRINKING 
Monkeys were fed fresh fruits, vegetables and cooked rice. When an animal did 
not eat spontaneously, it was fed by stomach tube. A catheter was passed through 
the nostrils into the stomach. Through the stomach tube the monkeys were 
administered daily + 240 ml of a mixture consisting of 120 ml Nutrison 
(Nutricia, Holland), 80 ml glucose 10% and 40 ml Carvan Cevitam ( a baby fruit 
syrup; Zwaardemaker, Holland). This liquid diet was composed on basis of an 
estimated energy need of 80-90 kcal/kg body weight. Drinking water was acidi-
fied to pH 3 to limit microbial growth. 
2.2.3 ANTIBIOTICS 
For the prevention of infections caused by Pseudomonas aeruginosa, the nonab-
sorbable antibiotic Polymyxine B® (10 mg/kg/day; Pfizer) was given to the ani-
mals from four days prior to transplantation until hematological recovery. Nys-
tatine® (2 x 200.000 IE/day; Sanofi Labaz) was given together with Polymyxine 
B to prevent fungal infections. For the elimination of intestinal flagellates, the 
animals received metronidazole (250 mg/day per os: Flagyl®, Specia/May & 
Baker) for four days prior to transplantation. When after transplantation the 
leukocyte counts dropped below 1 x 109/1, the antibiotic regimen was extended 
with the systemic antibiotics tobramycine (Obracin®, Lilly): 3-5 mg/kg/ day 
intramuscular (i.m.) and cephamandol (Mandol®, Lilly): 100 mg/kg/ day i.m.). 
Changes in the antibiotic regimen occurred on the basis of the sensitivity pattern 
of faecal flora and cultures of blood samples. Other antibiotics, which were 
given regularly, were; ticarcilline (100 mg/ kg/day i.m.: Ticarpen®, Beecham), 
amukacinesulphate (5 mg/kg/day i.m.:Amukin®, Bristol), rifamycine (15-20 
mg/kg per os: Rifadin®, Gist-brocades) and Vancomycin® (20-25 mg/kg intra-
venous, Lilly). 
2.2.4 SUPPORTIVE CARE 
Irradiated whole blood or red blood cell concentrates were given when the 
hematocrit dropped below 20%. Irradiated platelet transfusion were ad-
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ministered when thrombocyte counts fell below 40 x 101211 or when throm-
bopenic purpura were observed. Balanced fluids (1:1 glucose 5% and Ringer's 
lactate) were given intravenously or subcutaneously when signs of dehydration 
were observed. 
2. 3. PREPARATION OF CELL SUSPENSIONS 
2.3.1 BONE MARROW CELL SUSPENSION 
Bone marrow cells were obtained either by aspiration from femoral and/or 
humoral shafts as was described previously (Van Bekkum, 1967) or the donor 
was sacrificed and bones of the vertebral column, sacroiliac bones, femora, 
humeri, sternum, ribs and scapula were pressed in a tissue press. Cells were col-
lected in phosphate buffered salt (PBS) or in Hank's balanced salt solution 
(HBSS) which contained 100 IE heparin/ml (Tromboliquine®; Organon Teknika, 
Holland) and deoxyribonuclease I (DNAse; Behring Diagnostics, La Jolla, CA). 
A mononuclear cell suspension was prepared by centrifugation through a ficoll-
hypaque solution(LSM®, density of 1.077 g/ml; Bionetics, Kensington, UK) for 
30 min at 1600 rpm (TJ-6 Beckman centrifuge; Beckman-RIIC, Scotland). After 
centrifugation, the mononuclear cells were recovered from the interface. There-
after, the cell suspension was filtered through a nylon gauze to obtain a mono-
cellular cell suspension. 
2.3.2 DISCONTINUOUS ALBUMIN DENSITY CENTRIFU-
GATION 
A discontinuous albumin density gradient, designed by Dicke and van Bekkum 
(1970), was employed to obtain cell suspensions enriched for stem cells. Albu-
min powder (fraction V: Sigma Chemical Co., StLouis, MO) was dissolved in 
Tris buffer (pH 7.2, 230 mOsm/1) to a concentration of 35% (w/w) . The opti-
mal osmolarity of the albumin solution was tested in pilot experiments in which 
the distribution of GM-CFU's was measured over a gradient. After establishing 
the optimal osmolarity, a 35% stock solution was prepared. This 35% solution 
was diluted with different volumes of sodium chloride-sodium phosphate buffer 
(NaCl-Phosphate buffer; 0.154 M NaCl; 0.01 M Na phosphate buffer; pH 7.2; 
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299-300 mOsm/1) for the preparation of the desired albumin solutions, namely 
17%, 19%, 20%, 21%, 23% and 25%. The final albumin concentration was 
checked by an Abbe refractometer (Zeiss), as previously described by Dicke 
(1970). 
Mononuclear cells were suspended in 17% BSA and layered on top of a 
gradient consisting of layers with different density (17% -25%). The tube was 
centrifuged for 30 min at 100 C at 2200 rpm (Beckman centrifuge). After cen-
trifugation, distinct layers were visible at the density interfaces in the gradient. 
Cells were collected from the interfaces and washed with PBS. 
2.3.3 CELL COUNTING 
Nucleated cells were counted either in a haemocytometer in Turk solution 
(0.01% crystal violet and 1% acetic acid in saline) or by an automated cell 
counter (ELZONE; Particle Data Inc, Elmhurst or BAKER; Baker Instruments, 
Bethlehem, NY). Both automated cell counters were calibrated for counting cells 
of rhesus monkeys by values obtained in haemocytometers. The number of 
erythrocytes and leukocytes in the peripheral blood of the monkeys were counted 
by either a particle analyzer of ELZONE (Particle Data Inc) or of BAKER 
(Baker Instruments). The leukocyte counts were corrected for erythroblasts. 
Thrombocytes were counted by a thrombocyte counter from BAKER. Reticulo-
cytes were counted after staining slides with brilliant cresylblue (3.3% (v/v) in 
ethanol). Thereafter the percentage of reticulocytes were determined after 
counting at least 1000 erythrocytes. 
2.4 MONOCLONAL ANTIBODIES 
For incubation with monoclonal antibodies (MCA), cells were pelleted and 
MCA's were added to the pellet. The cells were mixed with antibody solution 
and incubated for 30 min at 40 C. After washing with PBS, either goat-anti-
mouse(GAM), conjugated to fluorescein isothiocyanate (FITC) (Nordic, Holland) 
(diluted 1:80 with PBS containing 20% monkey serum) or goat- anti-rat, conju-
gated to FITC, (GARA/FITC: diluted 1 :30; Nordic, Holland) was added to the 
cells labelled with MCA. The incubation time was again 30 min at 40 C. 
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2.4.1 ANTI T LYMPHOCYTE ANTIBODIES 
The OKT antibodies were purchased from Ortho Diagnostics (Raritan,NJ). 
Per 1 o6 pelleted cells 0.02 ml MCA was added. From the Leu antibodies 
(Becton Dickinson, Sunnyvale, CA) 0.01 ml was added to 106 pelleted cells. 
From B9-pool (CD8; 0.05 mg/ml : provided by Dr G. Mawas, Marseille) 0.02 
ml was added to 106 cells. WT 1 (CD7; 0.005 mg/rnl; Tax et al., 1984 ) was 
a gift from Dr W. Tax (St Radboud Hospital, Nijmegen, Holland;) and used 
in concentration of 0.02 ml for 106 cells. 
Table 2.1 
Anti T lymphocyte antibodies and their reactivity pattern with human lymphocytes. 
CD 
CDl 
CD2 
CD4 
CD8 
CD7 
MCA 
Leu1 
Leu5 
OKT4 
OKT4a 
Leu3a 
OKT8 
Leu2 
B9-pool 
WT1 
CAMPATH-1 
reactivity pattern 
T lymphocytes 
E-rosette receptor 
helper/inducer 
T lymphocytes 
cytotoxic/suppressor 
T lymphocytes 
T lymphocytes 
T and B-lymphocyte 
references 
Hansen, 1984 
Hansen, 1984 
Hansen, 1984 
Hansen, 1984 
Tax, 1984 
Hale,1983 
CD= cluster defined nomenclature as proposed by the international work-shop on leukocyte 
antigens (Bernard, 1984). MCA= monoclonal antibody. 
CAMPATH-1 (Hale et al, 1983) was provided by Dr G. Hale and Dr H. 
Waldmann (University of Cambridge, Cambridge, UK) and 0.1 ml CAMPATH-
1 (0.1 mg/ml) was added to 106 cells. These antibodies were selected on the basis 
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of their reactivity pattern with human lymphocytes (Table 2.1) and their cross-
reactivity with rhesus monkey lymphocytes. 
2.4.2 ANTIBODIES DIRECTED AGAINST MYELOID 
CELLS 
For detection of DR-positive cells, bone marrow cells were incubated with either 
the anti-DR antibody 0Kia1 (Ortho Diagnostics), or GMll (supernatant: Jonker 
et al. (1984)), or anti HLA-DR (Becton Dickinson), or YCL 6.8 (0.05 mg/ml), 
or YAML 555.6 (0.01 mg/ml: both provided by Dr G. Hale and Dr H. 
Waldmann). These antibodies recognize an antigen with a molecular weight of 
28-34 kdalton and were used in a concentration of 1 ml for 5 x 107 cells. 
For the staining of progenitor cells the MCA's OKTlO (Ortho Diagnostics: 
Reinherz et al., 1980) or GM 1 (production by Jonker M and Van Meurs G) 
were applied. OKT 10 reacts with human thymocytes and early progenitor cells 
(Crawford et al., 1980, Sieff et al., 1982). GM 1 reacts with human and rhesus 
monkey granulocytes, lymphocytes and early progenitor cells (Jonker, personal 
communication). The antibodies MY 4 and Mol (gift from Coulter Im-
munology) react in humans with mature and immature cells from the granulo-
cyte/monocyte lineage, but not with cells which give progeny to GM-CFU 
(Griffin et al., 1983) and it cross-reacts with rhesus monkey bone marrow cells 
(Letvin et al., 1983). 
2.4.3 COMPLEMENT LYSIS 
After incubation with the MCAs, at the concentrations described above, comple-
ment was added without further washing. For CAMP ATH-1 sera of two mon-
keys were pooled and added at a final concentration of 20% (v/v). For the other 
MCAs rabbit serum (Stichting Bloedonderzoek, Wageningen, the Netherlands) 
was used as a source of complement. The final complement concentrations for 
WT 1, OKT4+4a, B9-pool and the cocktail of anti DR antibodies were respec-
tively 30%, 30%, 50% and 50% (v/v). The cells were incubated with comple-
ment for 1 hour at 370 C. DNAse (Behring Diagnostics) was added to prevent 
clumping. 
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2.5 E-ROSETTE SEDIMENTATION 
Sheep red blood cells (SRBC) less than 2 weeks old were treated with a 140 mM 
2-aminoethylisothiouronium bromide (AET: Sigma, St. Louis, MO) solution (pH 
9.0) at 370 C for 15 min and washed 4-5 times in isotonic saline (Madsen et al., 
1980). A 10% solution of AET SRBC in PBS with 40% heat inactivated (560 C, 
30 min) foetal calf serum (FCS) was prepared. An equal volume of cold 10% 
AET SRBC was added to a cell suspension of 30 x 106/ml. This mixture was 
spun down slowly (800 rpm, TJ-6 Beckman centrifuge; Beckamn-RIIC, 
Scotland) for 5 minutes to purchase optimal rosette formation of sheep erythro-
cytes and T lymphocytes ( E-rosette forming cells: E-RFC). After gently resus-
pending the mixture, it was layered on a ficoll-hypaque gradient and centrifuged 
for 20 min at a speed of 2000 rpm (TJ-6 Beckman centrifuge). E-rosette form-
ing T lymphocytes are spun down the gradient and recovered from the bottom. 
The E-RF cells at the bottom of the gradient are T lymphocytes. A pure T 
lymphocyte population could be obtained when the sheep red blood cells were 
lysed with a hypotonic shock. 
2.6 COLONY FORMATION IN VITRO (GM-CFU) 
Bone marrow progenitor cells can give rise to clusters of cells consisting of 
different cell lineages depending on the stimulating factors present in the 
medium. For our experiments the granulocyte/macrophage colony assay (GM-
CFU) according to Pike and Robinson (1970) was applied. Bone marrow cells 
were cultured using the double layer agar technique with human peripheral 
blood leukocytes as feeder layer and an overlayer consisting of haemopoietic 
cells. Feeder layers were prepared by suspending 106 peripheral blood leuco-
cytes in 1 ml of a medium consisting of 30% (v/v) Dulbecco's medium (800 
mOsm), 20% (v/v) FCS and 50% (v/v) of 1% agar at 370 C. For each experi-
ments two sets of feeder layers were prepared with leukocytes from two indi-
viduals. The haemopoietic cells for the overlayer were resuspended in 1 ml 
medium in which agar is substituted for distilled water and 1 ml medium as 
described above. From this mixture 0.2 ml was placed on a feeder layer. 
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Colonies, defined as cell aggregates of more than 50 cells, were counted at a 25 
fold magnification using an inverted microscope(Zeiss ). Colonies were scored 7-
14 days after initiation of the cultures. 
2. 7 PROLIFERATION OF T LYMPHOCYTES IN VITRO 
Peripheral blood lymphocytes were separated by density centrifugation using 
ficoll-hypaque (LSM®, density 1.077 g/1; Bionetics, Keningston, UK). Lympho-
cytes at a concentration of 2 x 106 cells/ml were cultured in RPMI 1640 medium 
containing 20% (v/v) heat inactivated monkey serum, 2 mM L-glutamine and 
100 )lg/ml streptomycin in microculture plates at 370 C in 5% C02 for 3-4 days. 
Stimulation was performed with phytohaemagglutinin (PHA, 1 mg/ml; 
Borroughs-Wellcome). All cells were cultured in triplicate. In all experiments 
controls were included where PHA was omitted as stimulator. Twelve hours 
before the end of the culture period, 1 )lCi of [14C]-thymidine was added to each 
well. At the end of the culture period, the cells were harvested with a multiple 
automatic sample harvester and the uptake of [14C]-thymidine was measured in a 
liquid scintillation counter. 
2.8 BONE MARROW TRANSPLANTATION PROCEDURE 
2.8.1 TOTAL BODY IRRADIATION 
Recipients were prepared for grafting by total body irradiation (TBI) delivered 
by a single or two opposing beams from a Philips-MiHler X-ray machine. The 
monkeys were placed in a cylindric polycarbonate cage which rotated slowly (3 
times per minute) around its vertical axis during irradiation. The animals were 
not anesthetized during irradiation. The one or two X-ray tubes operated at a 
tube voltage of 300 kV and a current of 10 rnA. The half-value layer thickness 
was 3 mrnCu. The focus-skin distance 80 em and the average dose rate over the 
animal was 20-22 cGy/min (Broerse et al., 1978). 
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Figure 2.1. Irradiation arrangement for exposing the cylindric water phantoms to 
300 kV X-rays. 
On basis of dosimetry measurements in dogs phantoms (Zoetelief, 1984) it was 
decided to change the irradiation protocol from radiation with one beam to two 
opposing beams. Dose measurements were made with an ionization chamber at 
different positions inside cylindrical monkey phantoms (Figure 2.1). 
Measurements, done by Dr Zoetelief from the Radiobiological Institute TNO, 
showed that a more homogeneous dose distribution is obtained by bilateral 
irradiation (see figure 2.2). 
During evaluation of the experimental data it was found that several 
monkeys which were irradiated with two opposing beams died due to irradiation 
pneumonitis, while this complication was hardly ever observed in the period 
when one radiation beam was used. Recent evaluation of the irradiation protocols 
from 1961-1986 for total body irradiation have demonstrated that replacement 
of irradiation filters, different assessment of correction factors for weight of the 
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animal and different assessment of the diameter of an animal and different 
phantoms were the main cause of errors in the calculated irradiation dose in 
lungs. Recent simulation of the different irradiation protocols over the last ten 
years have demonstrated that the actual dose with one single beam was 6-9% 
lower than the reported dose. The actual dose delivered by two opposing beams 
appeared to be 10-14% higher than reported. Lung tissue was simulated by dose 
measurements in cork. The absorbed dose in lungs was 9-13% higher for 
unilateral irradiation and 22-25% higher for bilateral irradiation in comparison 
to the reported doses earlier (data obtained by Dr Zoetelief). The dosimetry 
measurements had their consequences for the experiments performed. For that 
reason the planned dose of irradiation and the actual dose (according to the new 
dosimetry measurements) are shown in Table 2.2 for each monkey used for 
experiments described in this thesis. 
Relative dose distribution of uni- and bilateral irradiation 
+-- __. +-
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Figure 2.2 Relative dose distributions for uni- and bilateral irradiation with 300 
kV X-rays of a cylindric monkey phantom with its center at 90 em from the focus 
or foci. Given are the values in the central circular plane (data obtained by Dr. J. 
Zoetelief). 
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Table 2.2 
Total body irradiation of rhesus monkeys. 
UMN BONE MARROW GRAFT RADIATION DOSE 
number of cells treatment planned actual actual lung dose 
X 106 (Gy) (Gy) (Gy) 
AUTOLOGOUS 
1ST 100 8.5 9.65 10.55 
lHH 30 8.5 9.85 10.60 
3425 10 8.0 7.50 8.20 
3745 10 8.0 7.50 8.20 
3282 10 8.0 7.50 8.20 
lHM 3 8.5 9.80 10.60 
lHW 1 8.5 9.85 10.60 
lHK 8.5 9.80 10.60 
1 JB 8.5 9.60 10.55 
1GB 100 CAMPATH-1 8.5 9.20 10.40 
lDX 100 CAMPATH-1 8.5 9.80 10.60 
1 SN 10 OKT4 8.5 9.80 10.60 
lMY 10 WT-1 8.5 9.65 10.55 
lGA 100 B9-pool 8.5 9.35 10.45 
lFO 10 B9-pool 8.5 9.20 10.40 
lLZ 100 anti-DR 8.5 9.60 10.55 
1 ss 100 anti-DR 8.5 9.85 10.40 
1 NN 100 Y AML + GARA!FITC 8.5 9.50 10.50 
1 LP 3 gradient 8.5 9.40 10.45 
ILL 1.5 gradient + FLS 8.5 9.30 10.45 
lLG 3 gradient+ CAMP A TH-1 8.5 9.45 10.50 
1 RP 0.5 stem cells 8.5 9.70 10.65 
1 TO 0.7 stem cells 8.5 9.55 10.55 
lOT 0.5 stem cells 8.5 9.50 10.50 
lOW 0.6 DR-negative 8.5 9.40 10.45 
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1 HJ 50 unmodified 2 X 6.0 2 X 5.7 2 X 6.2 
1 FB 50 unmodified 2 X 6.0 2x 5.6 2 X 6.4 
lAT 9 gradient+ E-rosette sed 2 X 6.0 2x 5.6 2 X 6.0 
2AW 9 gradient+ E-rosette sed 2 X 6.0 2x 5.6 2 X 6.1 
ALLOGENEIC 
lEA 2.5 gradient+ E-rosette sed 2 x4.5 2x 4.2 2x 4.6 
lDV 2.5 gradient + E-rosette sed 2 X 5.0 2 X 4.2 2 X 5.3 
1 CK 2.5 gradient+ E-rosette sed 2 x5.0 2 X 4.7 2 X 5.2 
lBA 2.5 gradient+ E-rosette sed 2 X 5.5 2x 5.2 2 X 5.8 
1 FE 2.5 gradient + E-rosette sed 2 X 5.5 2 X 5.2 2 X 5.6 
1 EP 2.5 gradient + E-rosette sed 2 X 6.0 2 X 5.6 2 X 6.1 
1 cc 2.5 gradient + E-rosette sed 2 X 6.5 2 X 6.1 2 X 6.8 
lEG 2.5 gradient+ E-rosette sed 2 X 6.5 2 X 6.1 2 X 6.8 
1 EC 400 CAMPATH-1 2 X 6.0 2x 6.5 2 X 7.3 
lJR 400 CAMPATH-1 2 X 6.0 2x 6.9 2x 7.5 
1 CI 400 CAMPATH-1 2 X 6.0 2x 6.7 2x7.4 
1 FN 400 CAMPATH-1 2 X 6.0 2 X 6.7 2x7.4 
lLJ 400 CAMPATH-1 2 X 6.0 2x 6.9 2 X 7.5 
1 HC 400 CAMPATH-1 2 X 6.0 2x 6.6 2x7.4 
lSK 400 OKT-4+4a 2 X 6.0 2 X 6.7 2x7.4 
lLU 400 OKT-4+4a 2 X 6.0 2x 6.7 2x7.4 
1 BX 400 B9-pool 2 X 6.0 2x 6.5 2x7.4 
1 GF 400 B9-pool 2 X 6.0 2 X 6.8 2x7.4 
1 SP 400 WT-1 2 X 6.0 2x 6.8 2x7.4 
lLB 400 WT-1 2 X 6.0 2 X 6.9 2x 7.5 
UMN: unique monkey number, FLS: Forward light scatter 
2.8.2 AUTOLOGOUS BONE MARROW TRANSPLANTATION 
The monkeys were anesthetized with ketalar (5-10 mg!kg body weight: Vetalar®, 
Parke-Davis) and Vetranquil® (0.3 ml/10 kg body weight). Under general 
anesthesia bone marrow was aspirated from the femora. After aspiration a 
mononuclear cell suspension was prepared by density centrifugation using ficoll-
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hypaque (see section 2.3.1). Thereafter, either bone marrow cells were 
cryopreserved as described by Schaefer et al. (1972) or the graft was manipu-
lated in vitro and reinfused in a peripheral vein of the recipient afterwards. The 
recipients were prepared for transplantation by 9.2-9.7 Gy TBI, two opposing 
beams (Figure 2.3). 
BONE MARROW COLLECTION 
TOTAL BODY IRRADIATION 
BONE MARROW INFUSION 
Figure 2.3 Autologous bone marrow transplantation 
Ficoii-Hypaque 
separation 
107 or 108 cells per 
kg body weight 
incubation 
with 
monoclonal 
antibody 
complement 
added: 
60 min 37 °C 
) 
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2.8.3 ALLOGENEIC BONE MARROW TRANSPLANTATION 
Recipients of allogeneic bone marrow transplants were prepared by fractionated 
TBI. The irradiation was given in two doses with 24 hours interval. The bone 
marrow graft was administered intravenously 24 hours after irradiation. 
2.9 FLOW CYTOMETRY 
A flow cytometer is a machine that measures parameters of cells which are made 
to flow in suspension through an intense light source. When cells pases through a 
laser beam, optical signals are generated which contain biochemical or morpho-
logical information about the cells. These optical signals are detected and trans-
lated in electric signals by photomultipliers. Light scatter, generated when a cell 
flow through the laser beam, is detected in oo and 900 direction and gives infor-
mation about the size (00 scatter= forward light scatter (FLS)) and shape (900 
scatter = perpendicular light scatter (PLS)). Using laser light with a defined 
wave length enables the detection of fluorescence particles present on a cell. The 
signals from the photomutipliers are either linearly or logarithmic amplified. 
Except for analysis, flow cytometers are extremely useful because of the 
opportunity to sort cells according to defined parameters. For sorting, the liquid 
jet is vibrated with the help of a piezo-electric crystal at a frequency such that 
droplets break from the flow stream containing individual cells. With "windows" 
the upper and lower limits for the optical parameters are set. A sort logic 
circuitry compares the signals of each cell with the preset "windows". By giving 
droplets different electric charges, the droplets can be deflected when they pass 
through a constant transverse electric field. The deflected droplets are sorted 
into glass tubes. 
2.9.1 FLOW CYTOMETERS 
Two flow cytometers were used for immunofluorescence analysis and cell sort-
ing; a modified F ACS II (Fluorescence Activated Cell Sorter; Becton Dickinson) 
(figure 2.4) or a home build dual laser flow cytometer (RELACS; design: G. van 
den Engh and W. Stokdijk) (figure 2.5). With the modified FACS it was possible 
to measure three parameters. The principles of the RELACS have been described 
previously (Trask, 1985). 
44 
~r=== Fluorescence activated cell sorter ========::::1 
fiHers 
FORWARD LIGHT SCATTER 
Dichroic mirror 
w 
Cells labelled with 
CAMPATH-1 
~ • i~?~~:f~&~~ 
1 ilr~~; :.~1!~~~~ --
CJ . 
FORWARD LIGHT SCATTER 
Figure 2.4 Fluorescence activated cell sorter and dot plots 
Briefly, it is a dual laser flow cytometer with the equipment for multiple param-
eter signal processing. The amplified signals from the photomultipliers are pro-
cessed by a "Peak sense and hold" circuitry which determines the the peak of the 
resultant pulse signals and hold this value temporarily. The peak values are digi-
tized in an analog-to-digital converter. The digital signals are processed for pre-
sentation on a two-dimensional oscilloscope, which enables the characterization 
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of cells by two optical signals, and the parameters can stored in a computer. The 
novelty of the machine is the speed of signal processing with a very short "dead" 
time (5 J.LS) between the detection of the optical signals of a cell and the complete 
storage of the signals in list data acquisition mode in a Hewlett- Packard 200 
computer. The list mode enables analysis afterwards with a software package, 
which included data display in histograms, 2 or 3 dimensional display and 
window setting, and was developed in our institution by Drs R.R. Jonker. 
RIJSWIJK EXPERIMENTAL LIGHT ACTIVATED CELL SORTER 
Laser beam ' / 
-----------·-----/ ' 
Figure 2.4 Rijswijk experimental light activated cell sorter 
2.9.2 FLUORESCENT SIGNALS 
Besides the forward light scatter (FLS) signals as a measure for the size of the 
particles, and the perpendicular light scatter (PLS), which is indicative for the 
shape of a particle, fluorescent signals were used for the characterization of 
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cells. The fluorescent signals could be generated by excitation of fluorochromes 
with light of a specific wavelength. The fluorochromes were directly or indi-
rectly coupled to MCA's, which reacted with cells. The fluorochromes fluores-
cein isothiocyanate (FITC) and phycoerythrin (PE) were excitated with a laser at 
488 nm (0.4-0.5 W). The emitted FITC fluorescence was measured through a 
combination of a broad band multicavity interference filter (520-550 nm: Pom-
fret Research Optics Inc, Stanford, CT) and a 530 nm cut-off filter (Ditric 
Optics, Hudson, MA) by an S-11 type photomultiplier (Thorn EMI, Middlesex, 
U.K.) and PE through a 577 nm cut-off filter (Corion) by a S-20 type photo-
multiplier (Thorn EMI) or a Hamamatsu multiplier R1477 (Hamamatsu, Japan). 
Since there is a overlap in the emission spectra of PE and FITC a comparison 
network (Loken et al., 1977) was used to subtract the FITC emission from the 
PE emission in the region where the PE fluorescence was measured. After the 
comparison network the signals were logarithmic amplified. Propidium iodide 
was used to stain dead cells and measured through a 620 nm cut-off filter 
(Ditric Optics) by an S-20 type photomultiplier. 
2.10 NECROPSY AND HISTOPATHOLOGICAL 
EXAMINATION 
Necropsies and histopathological examinations were routinely done to determine 
the cause of death and in case of allogeneic transplantations to grade the severity 
of GvHD according to the criteria of the International Bone Marrow Transplant 
Registry (1975). Tissue samples were fixed in 4% buffered formaldehyde, 
trimmed, embedded in paraffin and stained with hematoxylin-phloxine-saffran. 
2.11 ENGRAFTMENT 
Between day 21 and day 28 after transplantation peripheral blood cells were 
collected and lymphocytes separated for tissue typing using serologically defined 
determinants as described previously by Bainer et al. (1981). 
2.12 STATISTICS 
Mean, standard deviation and standard error of mean was calculated according to 
the standard formula (Colton, 1974). For statistical analysis of the relationship 
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between regeneration rate of peripheral blood cells and the number of bone mar-
row cells grafted/kg body weight (see chapter III), a linear regression analysis was 
used. The regression line was fitted according to the formula y=a+blog(x). The 
Student's T test was used for the calculation of the 95% confidence limits of the 
line and for the calculation the significance of the hypothesis that the line did dif-
fer from 0. Since single monkeys were used to measure an effect of in vitro ma-
nipulation of autologous bone marrow grafts, the 95% confidence limits were cal-
culated on a predicted individual y value. 
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CHAPTER III 
ASSAY FOR THE REPOPULATING CAPACITY 
OF AUTOLOGOUS BONE MARROW GRAFTS 
IN RHESUS MONKEYS 
3.1 INTRODUCTION 
Pluripotent haemopoietic stem cells are characterized by their virtue of self-
replication and differentiation into all blood cell lineages. Because of these 
properties transplanted stem cells are capable to protect a lethally irradiated 
recipient. A prerequisite for any in vitro manipulation of a bone marrow graft is 
that it does not adversely affect pluripotent haemopoietic stem cells. 
One of the objectives of this study was to eliminate subpopulations of T 
lymphocytes from bone marrow grafts by complement fixing monoclonal anti-
bodies in order to prevent Gv HD. The toxicity for repopulating stem cells of 
such a pretreatment had to be investigated. Bone marrow cultures, such as the 
GM-CFU assay, were thought to provide a good indication for toxicity to stem 
cells, since any toxicity for pluripotent stem cells will affect the number of 
descendents. However, a discrepancy has been observed between the results 
obtained in bone marrow cultures and the repopulating capacity of bone marrow 
cells when bone marrow cells were incubated with 4-hydroperoxycyclophos-
phamide. Although severe toxicity was detected in vitro, the bone marrow cells 
remained their potential to protect a recipient from death due to a lethal dose of 
chemo- and radiotherapy (Rowley et al., 1985; Kaizer et al., 1985; Yeager et al., 
1986). Therefore, it was decided not to rely solely on results of bone marrow 
cultures but to develop an in vivo assay for reconstitution capacity of bone 
marrow grafts. The in vivo assay developed was based on the assumption that the 
rate of recovery of certain peripheral blood cells after an autologous bone 
marrow transplantation is a function of the number of haemopoietic stem cells 
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grafted. Therefore, graded numbers of autologous bone marrow cells were 
transplanted into monkeys, which had received a high dose of whole body 
irradiation. Peripheral blood cells were counted daily until the values had 
normalized or until 35 days after grafting. Although after autologous bone 
marrow transplantation, direct parameters such as MHC-antigens are not 
available to identify graft derived cells, autologous bone marrow trans-
plantations were preferred to allogeneic transplantations because interfering 
processes such as GvHD and host-versus-graft reaction are avoided. 
The validity of the assay was tested by grafting autologous bone marrow 
cells from which pluripotent haemopoietic stem cells were eliminated by incu-
bations with anti-DR antibodies. It has been established that the DR-antigen is 
present on early, pluripotent haemopoietic stem cells of humans (Fitchen et al., 
1982) and non-human primates (Winton et al., 1985).In dogs the DR-antigen is 
present on haemopoietic stem cells (Szer et al., 1985) and the homologue I-E 
antigen is also present on murine stem cells (Fitchen et al., 1981 ). 
After establishing the validity of the assay, the regeneration pattern of 
autologous bone marrow grafts following complement mediated lysis of T 
lymphocyte subpopulations was compared to the regeneration pattern of 
unmodified bone marrow grafts. 
3.2 AUTOLOGOUS REPOPULATION ASSAY 
To assess the relation between regeneration rate of peripheral blood cells and 
cell numbers grafted, irradiated (7.5-9.8 Gy total body irradiation; X-rays) 
monkeys were given graded numbers of cryopreserved, autologous bone 
marrow cells over a range of 106 to 108 cells/kg body weight. For each data 
point one monkey was used, except for three monkeys at the dose of 107 /kg body 
weight. Peripheral blood cell counts were determined daily after transplantation; 
the day of transplantation was designated as day 0. The reconstitution of the 
peripheral blood cells is illustrated in the figures 3.1 and 3.2. The leukocyte 
counts dropped rapidly after total body irradiation and, depending on graft size, 
the counts remained low for at least two weeks. After the administration of 1 os 
cells/kg body weight, leukocyte counts reached the value of 109/l after 15 days 
and subsequently leukocyte counts normalized within a few days. The 
regeneration rates of leukocytes were slightly slower after the cell doses of 3 and 
1 x 107 cells/kg body weight. 
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Figure 3.1. Regeneration of leukocytes after transplantation of graded doses of 
autologous bone marrow cells. 
After a cell dose of either 1 or 3 x 106 cells/kg body weight, leukocyte counts 
reached the value of 109!1 after 23 and 20 days respectively and the subsequent rise 
of leukocytes toward normal values was slower in comparison to higher cell doses. 
The regeneration pattern of reticulocytes showed a similar pattern as for the 
leukocytes with early regeneration after high cell doses and a slower regeneration 
pattern after the cell doses of 1 and 3 x 106 cells/kg body weight. The regeneration 
rate of the autologous grafts was expressed as the time at which the leukocyte 
counts or reticulocytes definitely exceeded a certain value. For both leukocytes and 
reticulocytes regression lines were calculated between the graded cell doses and 
regeneration time. A semilogarithmic relationship between cell dose and rege-
neration time appeared to exist for different points at the regeneration curves of 
leukocytes and reticulocytes (Table 3.1). 
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Figure 3.2 Regeneration of reticulocytes after transplantation of graded doses of 
autologous bone marrow cells. 
Two variables determine the usefulness of a regression line for calibration 
purposes; whether the slope of the line significantly differs from zero and 
whether the distribution of the points around the line is small. The distribution 
of the points is expressed in the standard-deviation and the 95% confidence 
limits. If the regression line is to be employed either to deduce the number of 
bone marrow stem cells in a graft of unknown composition or to detect toxicity, 
narrow confidence limits are required. This requirement was met for the 
regression lines when reticulocyte counts exceed 1% or 2%. For the assessment 
of toxicity and enrichment of haemopoietic stem cells the regression line based 
on reticulocyte counts ;:::_ 1% was applied. Leukocyte counts did not meet the 
requirements stated above, since the variance of the data points is large. Figure 
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3.3a + b shows the regression line of reticulocytes and leukocytes with the 95% 
confidence limits. The differential leukocyte counts gave comparable results for 
each of the subtypes of white blood cells but this did not improve the limits of 
the relationship, probably because of inaccuracy of the counting method. 
Thrombocyte counts could not be used due to the platelet transfusion policy. 
Platelet transfusions were administered when platelet couuts dropped below 40 x 
1 09 cells/1. 
Table 3.1 
Characterization of regression lines calculated on the basis of cell dose grafted 
and regeneration time of peripheral blood cells. 
ya= rb P-valuec st. dev.d 
leukocytes ~ 1 x 109/1 26 - 4 x log(x) .819 .02 1.976 
leukocyteS ~ 2 X 109/1 41 - 9 x log(x) .915 .004 2.808 
leukocytes ~ 3 x 109/1 45 - 10 x log(x) .906 .005 3.32 
reticulocytes ~ 0.5 % 35 - 9 x log(x) .963 .0005 1.83 
reticulocytes ~ 1.0 % 39 - 9 x log(x) .988 .0001 1.05 
reticulocytes ~ 2.0 % 45 - 11 x log(x) .993 .0001 1.02 
a: The regression line is characterized by the formula Y=a +b log(x), where a represents the 
intercept, b the slope of the line and x the cell number x 106/k:g body weight. 
b: correlationcoefficient 
c: significance of slope in comparison to zero 
d. standard deviation of points about the fitted line = standard deviation of regression 
To test the validity of the obtained relationship between cell dose grafted and 
regeneration rate, several experiments were performed, which included 
determination of regeneration rate without transplantation of autologous cells 
and the regeneration rate of grafts that were depleted of DR-positive cells. 
The first experiment involved 2 monkeys that did not receive bone marrow 
following 9.8 Gy total body irradiation (see Table 2.2). These monkeys showed 
endogenous regeneration with leukocyte counts reaching levels greater than 109/1 
after 23 and 27 days, while reticulocyte counts were above 1% at day 28 and 31, 
respectively (Figure 3.4). This is caused by stem cells surviving total body ir-
53 
radiation. When the regression line of reticulocytes is used, the regeneration rate 
of peripheral blood cells in these two monkeys corresponds with a residual 
number of stem cells equivalent to an autologous graft of 0.3 - 1 x 106 bone 
marrow cells/kg body weight. 
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Figure 3.3 The relationship between bone marrow cell numbers grafted and time of 
regeneration of leukocytes and reticulocytes. 
3.3 DEPLETION OF DR-POSITIVE CELLS 
The experiment designed to determine the regeneration time with stem cell 
depleted bone marrow grafts involved two monkeys which receiveg autologous 
bone marrow grafts treated with anti-DR monoclonal antibodies. For the deple-
tion of DR-positive cells several MCA's were selected on basis of their reactivity 
pattern with rhesus monkey bone marrow cells. Staining bone marrow cells with 
anti-HLA-DR/PE and either GM-11, YCL 6.8 or OKial, which were indirectly 
labeled with GAM/FITC or GARA/FITC, resulted uniformly in double-stained 
populations, indicating that the antibodies react with the same cells. 
Complement- mediated lysis of DR-positive cells was done by the simultaneous 
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use of four monoclonal antibodies, since only combinations of these antibodies 
yielded efficient kill of GM-CFU (Table 3.2). 
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Figure 3.4 Regeneration of reticulocytes when recipients were given 9.8 Gy TBI 
and no bone marrow graft. 
The cell dose before antibody treatment was 108 viable cells/kg body weight. 
After the in vitro treatment 20-27% viable cells, 1-2% DR positive cells and 2% 
GM-CFUs were recovered. The cells left after in vitro treatment were reinfused 
into the monkey without correction for cell loss. As shown in Table 3.2 the 
regeneration rate was severely delayed compared to values obtained with 108 
unmodified cells/kg body weight, with one monkey dying after 22 days without 
any signs of regeneration. In this monkey histological signs of bone marrow 
regeneration were not observed. The hematological recovery of the other 
monkey, which died after 21 days with early signs of regeneration, was 
estimated to be equivalent to an bone marrow graft of approximately 5 x 106 
cells/kg body weight, demonstrating that depletion of DR positive cells 
eliminates at least 95% of the repopulating cells. 
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Table 3.2 
Depletion of Granulocyte Macrophage-CFU (GM-CFU) after treatment with anti-
DR antibodies plus complement (N=3). 
GM-CFU/105 nucleated cells± s.da. 
Monoclonal 
antibody without complement with complement 
medium 87 ± 10 86±8 
GM11 86± 10 40±5 
YCL6.8 90± 10 36±5 
HLA-DR 91 ± 14 46±6 
OKia1 74±8 13±2 
all four MCA's n.d. 5±3 
a : values represent mean± SD of individual determinations. 
b : surviving fraction of GM-CFU after complement lysis 
Table 3.3 
surviving 
fractionb 
(% ± s.d.) 
100±9 
46±6 
41 ±6 
53±7 
15±2 
6±3 
Toxicity to repopulating capacity of 108 autologous bone marrow cells/kg body 
weight by a preincubation with anti-DR monoclonal antibodiesa and complement. 
REGENERATION RATE 
incubated unmcxlified 
bone marrow bone marrow 
(95% conf. limits) 
Reticulocytes > 1% (day) 21, > 22b 8-13 
Leukocytes> 10911 (day) 21, > 22b 10- 18 
a: mixture of four anti-DR MCA's GM11, YCL 6.8, anti-HLA-DR, OKia1 
b : died at day 22 after transplantation without evidence of regeneration 
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P -value 
of 
difference 
< 0.005 
< 0.01 
3.4 DEPLETION OFT LYMPHOCYTES 
CAMPATH-1 plus monkey complement efficiently lysed all T lymphocytes, since 
no CAMPATH-1 positive cells or T lymphocytes stained with Leu2a and Leu3a 
could be detected by indirect immunofluorescence analysis after the incubation 
(see also chapter V). The elimination of the T lymphocyte subpopulations by 
complement with either OKT4+4a (CD4) or B9-pool (CDS) or WT 1 was also 
confirmed by immunofluorescence analysis. For the in vivo experiments, the 
preincubation cell dose was either 108 or 107 cells/kg body weight . After com-
plement lysis of the T lymphocytes, the remaining cells were reinfused into the 
monkey. 
Table 3.4 
Regeneration time of reticulocytes following incubation of autologous rhesus 
monkey grafts with monoclonal antibodies and complement. 
reticulocytes > 1 % 
monoclonal cell dose observed expected significance 
antibody per kg (95% conf. limits) of difference 
CAMPATH-1 107 19 18- 21 n.s. 
108 10 8- 13 n.s. 
B9 107 20 18- 21 n.s. 
108 10 8-13 n.s. 
OKT4+4a 107 19 18-21 n.s. 
WT-1 107 22 18-21 p < 0.05 
n.s.: not significant 
Depletion of CAMP ATH -1 or B9-pool positive cells did not influence the 
regeneration of the peripheral blood reticulocytes in 2 monkeys transplanted 
with either 108 cells/kg or 107 /kg body weight (Tables 3.4). Next, the influence 
of depleting OKT4+4a or WT 1 positive cells was investigated each in one 
monkey, each at the same cell dose, i.e. 107 /kg body weight (Table 3.4). 
Depletion of OKT4+4a (helper/inducer T lymphocytes) positive cells failed to 
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exert an influence on the repopulating capacity of the residual bone marrow cells 
(Tables 3.4). After elimination of WT 1 positive cells the leukocyte regeneration 
time was within the 95% confidence limits. The reticulocyte regeneration was 
just outside the 95% confidence limits, but within the 99% confidence limits (the 
latter are not shown) and, therefore, this difference is probably not of any 
biological significance. 
3.5 DISCUSSION 
In the rhesus monkey model the repopulating capacity of a bone marrow graft as 
measured by the regeneration rate of peripheral blood cells was directly related 
to the logarithm of the cell number present in an autologous bone marrow graft. 
The validity of this assay is demonstrated by the highly significant regression 
obtained and the substantial delay in regeneration time after grafting of bone 
marrow cells depleted of stem cells by anti-DR antibodies plus complement. 
Several investigators (Spitzer et al., 1980; Harada et al., 1983; Meloni et al., 
1985) have searched for a relationship between regeneration of peripheral blood 
cells and size of bone marrow grafts in human patients, but failed to demonstrate 
such a relationship. The explanation for the discrepancy between rhesus monkey 
and human results is most likely the small range in cell dose given in the human 
situation (0.5 - 2 x 108 cells/kg body weight) in comparison to the range of 
autologous bone marrow cells given in this study (1 06-108 cells/kg body weight. 
Besides, all patients have been heavily treated with myelosuppressive drugs prior 
to bone marrow collection, which could have an detrimental effect on the 
repopulating capacity of the marrow cells. 
The survival of the 9,8 Gy irradiated, nongrafted monkeys is undoubtedly 
attributable to the profound antimicrobial therapy and the liberal platelet 
transfusions, which also holds true for the monkeys that received low numbers 
of bone marrow cells. Without such supportive care, these monkeys would have 
died prior to haemopoietic regeneration (Van Bekkum, 1967). The delayed 
reconstitution of the nongrafted monkeys is in accordance with the radiosensi-
tivity of the haemopoietic stem cells. It is estimated that a rhesus monkey has 
approximately 8.4 x 1010 bone marrow cells (Pegg, 1966). The surviving 
number of stem cells was calculated to be equal to a bone marrow graft con-
sisting of 0.3-1 x 106 cells/kg body weight. On the basis of these figures a Do of 
the rhesus monkey stem cells can be calculated using the formula; S=n x e-D/Do, 
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S: surviving fraction of bone marrow cells, n: a factor two is used because of the 
shoulder in the cell surviving curve at low doses of TBI, D: irradiation dose. 
According to this formula a Do of 0,8 - 0,9 Gy has been found. 
The prolonged delay in regeneration time after depletion of DR positive 
cells, showed that toxicity to repopulating stem cells could be determined with 
this indirect assay. The repopulating capacity of the residual cells indicated that 
approximately a 2 log reduction haemopoietic stem cell number was caused by 
the anti-Dr antibody treatment. Complement toxicity could not attribute to this 
result because the same complement concentration was used for depletion of B9 
positive cells, which did not cause a detectable significant delay of autologous 
reconstitution. Apparently, DR-antigens are present on rhesus monkey stem 
cells, similar as in of other mammalian species (Szer et al.,1985; Fitchen et al., 
1981). The antigen is present on early, multipotent haemopoietic cells of humans 
(Fitchen et al., 1982) and non-human primates (Winton et al., 1985), grown in 
culture. Results of experiments with long term bone marrow cultures were in 
contrast with these findings in that colony growth was still observed after 
depletion of DR positive cells (Moore et al., 1980; Keating et al., 1984). 
However, this study and two other studies (Greenberger et al., 1985; Falkenburg 
et al., 1984, 1985) have revealed that the findings of Moore and Keating can be 
explained by inefficient complement mediated lysis of DR positive cells. 
The delayed regeneration observed in our experiments does not conclusively 
prove that the DR antigen is present on the haemopoietic stem cell of rhesus 
monkeys, because the possibility remains that accessory cells, essential for 
repopulating stem cells, were removed. However, Visser et al. (1984) and 
Spangrude et al. (1988) have demonstrated that highly purified stem cells are 
able to repopulate a lethally irradiated, syngeneic recipient. The latter results do 
support the hypothesis that repopulating stem cells can repopulate a recipient 
without the help of other cells. In chapter IV of this thesis it is demonstrated that 
highly enriched stem cells are capable to repopulate the haemopoietic system of a 
recipient. 
T lymphocyte depletion from autologous bone marrow grafts with a 
number of carefully selected monoclonal antibodies did not influence the 
repopulating capacity of the graft as measured by the reappearance of peripheral 
blood cells. Most convincing are the results with depletion of CAMP A TH -1 
positive cells from the bone marrow graft, since allogeneic bone marrow 
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transplantation experiments (chapter V) have clearly demonstrated the efficient 
elimination ofT lymphocytes by this technique. 
The results with T lymphocyte depletion exclude the possibility that either 
T lymphocytes and stem cells share the antigens detected by the antibodies used 
in this study, since elimination of T lymphocytes by complement mediated lysis 
did not reduce the number of stem cells. 
The hypothesis that T lymphocytes have a significant trophic function for 
repopulating stem cells, as proposed by Sieff et al. (1985) and Soderling et al. 
(1985), is excluded by our observations. The increased frequency of take 
failures observed after T lymphocyte depletion of allogeneic bone marrow grafts 
has therefore to be attributed to the diminution of the immunosuppressive action 
of the GvH reaction exercised by donor T lymphocytes. This conclusion is in 
complete accordance with the concept of reciprocal interference between GvHD 
and engraftrnent (Nakic, 1966; Vriesendorp, 1981). In dogs was demonstrated 
that transfusion of donor leukocytes or thoracic duct lymphocytes increased the 
engraftment of histoincompatible bone marrow, but also the incidence and 
severity of GvHD (Deeg et al., 1979). 
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CHAPTER IV 
ENRICHMENT OF HAEMOPOIETIC STEM 
CELLS BY SELECTION OF DR POSITIVE 
CELLS FROM BONE MARROW 
4.1 INTRODUCTION 
The ablation of the capacity of an autologous bone marrow graft to repopulate 
an irradiated recipient by depletion of DR-positive cells; as reported in the pre-
vious chapter, in principle opens the possibility to sort stem cells by positive 
selection. From experiments with human bone marrow cells it is known that 
several cells types have a DR-antigen on their cell surface. Among human bone 
marrow cells which carry a DR-antigen on their cell membrane are B-lympho-
cytes, activated T lymphocytes, macrophages, monocytes and myeloid progenitor 
cells. The DR-antigen has been demonstrated on multipotential progenitor cells 
that produce colonies consisting of several celllmeages (CFU-GEMM; Fitchen et 
al., 1982; Ohe et al., 1982) as well as on progenitor cells committed to differ-
entiation along either granulocyte-monocyte, or erythroid, or megakaryocytic-
platelet pathway (Kaplan et al., 1978; Wmchester et al., 1978; Falkenburg et al., 
1985; Linch et al., 1984). 
The experiments iii this chapter deal with the repopulatiilg capacity of puri-
fied stem cells. At the time of these experiments a monoclonal antibody, which 
exclusively reacts with pluripotent haemopoietic stem cells, was not discovered 
in any species. Purification of pluripotent stem cells of mice has been achieved 
with an anti-H2k monoclonal antibody and sorting in combinations with a variety 
of other means (Visser et al., 1984). 
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62 
Using a series of steps analogous to those applied for the purification of murine 
stem cells, it was attempted to purify pluripotent haemopoietic stem cells of 
rhesus monkeys using a DR-antibody and a cell sorter. Since it is known that 
pluripotent haemopoietic stem cells constitute only a small proportion of cells in 
a bone marrow graft, other purification steps, involving density centrifugation 
and depletion ofT lymphocytes, preceded the isolation of DR-positive cells by 
the cell sorter. 
Before carrying out in vivo experiments to assess the repopulating ability of 
the purified cells, an in vitro colony assay (GM -CFU) was used to monitor the 
purification steps. After a reproducible method was developed which yielded 
highly purified stem cells, such stem cell concentrates were grafted into irradi-
ated, autologous monkey recipient. Using the peripheral blood regeneration 
assay described in chapter III, a quantitative assessment of enrichment of 
pluripotent haemopoietic stem cells was made. 
4.2 IN VITRO EXPERIMENTS 
Figure 4.1 shows the purification procedure, which started with the aspiration of 
bone marrow from the femoral shafts of the monkeys. Subsequently, a mononu-
clear cell suspension was prepared by density centrifugation followed by a dis-
continuous albumin density gradient. After enrichment of pluripotent stem cells, 
lymphocytes were removed by the antibody CAMPATH-1 plus complement. The 
last step was sorting DR-positive cells, using a cell sorter. The GM-CFU assay 
was applied to assess enrichment of pluripotent stem cells. 
4.2.1 DENSITY CENTRIFUGATION AND DEPLETION OF 
LYMPHOCYTES 
All experiments were performed with aspiration bone marrow. A ficoll-hypaque 
(LSM; density 1.077 gil) density gradient was run to prepare a mononuclear cell 
suspension and to remove erythrocytes. This was advantageous since an abundant 
number of erythrocytes disturb a discontinuous albumin density gradient as well 
as GM-CFU cultures (Dicke 1970). After the ficoll density centrifugation was 
run, cells were collected from the interface. 
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Table 4.1 
Distribution of nucleated cells and granulocyte/macrophage colonies (GM-CFU) 
in discontinuous albumin density gradients (N=4). 
material 
CFU 
Ficoll 
recovery of 
nucleated 
cells(%) 
100 
albumin gradient 
fraction 19-21% 7 ±3* 
fraction 21-22% 16±5 
fraction 22-23% 18 ±8 
fraction 23-25% 26±2 
bottom 30± 10 
recovery 98±8 
recovery of 
colonies 
GM-CFU (%) 
100 
101 ±46* 
28± 13 
5±2 
6±6 
1 ±0,2 
140 ± 40 
*: mean recovery and standard deviation of mean 
normalized 
recovery 
GM-CFU (%) 
100 
72±33 
20± 10 
3±1 
4±4 
1±0 
100 ± 29 
enrichment 
factor 
GM-
1 
14,1 ± 4,9 
1,7 ± 0,5 
0,3 ± 0,2 
0,2± 0,3 
0,1 ± 0,02 
In comparison to aspiration bone marrow 41.7 ± 8.7% of the nucleated cells and 
all GM-CFU's were recovered from the interface of a ficoll gradient (N=24). 
Since in this chapter recovery and enrichment is expressed in reference to the 
cell suspension, obtained after ficoll gradient, All enrichment factors should be 
factors should be multiplied by 2.4 when one wishes to express the enrichment -
related to the aspiration bone marrow, i.e. the starting material. 
A discontinuous albumin gradient consists of five layers with different 
density. The distribution of nucleated cells and GM-CFU's over the several 
layers after density centrifugation are shown in Table 4.1. The highest concen-
tration of progenitor cells is found in the lightest density fraction of a discon-
tinuous albumin gradient. This fraction contains 70% of all GM-CFU's. Since a 
proportion of all progenitor cells is recovered from this fraction, it was decided 
to avoid selection in this stage of the purification procedure and to collect all 
cells from the two top fractions. Eighteen percent of all nucleated cells are 
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recovered from these two light density fraction and approximately 90% of the 
GM-CFU's. 
Mter collection of cells form the two light density fractions a cell suspen-
sion is obtained in which GM-CFU's are approximately 7 times enriched in 
comparison to the cell suspension harvested from the ficoll gradient. 
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4.2.2 FORWARD AND PERPENDICULAR LIGHT 
SCATTER PROPERTIES 
Forward light scatter of a laser beam is a function of cell size while perpendic-
ular light scatter is a function of the shape of a cell. Van den Engh et al. (1978) 
and others (Visser et al., 1984; Bauman et al., 1986) have shown that pluripotent 
haemopoietic stem cells gave a high forward light scatter signal. Transplantation 
of cell suspensions obtained by counterflow centrifugation-elutriation has 
demonstrated that those bone marrow cells, which are capable to repopulate a 
lethally irradiated recipient, were recovered from the large cell fraction in 
humans (De Witte et al., 1983) as well as in rhesus monkeys (Monroy et al., 
1986). 
Cells from the combined two top fractions of a albumin gradient were 
analyzed for their forward and perpendicular light scatter characteristics. Dis-
tribution of cells and GM-CFU according to forward and perpendicular light 
scatter is depicted in Figure 4.2. In the fraction with a high forward light scatter 
signal a minority of the nucleated cells was found, but this fraction contained 
80% of all the GM-CFU's. GM-CFU's were equally distributed over the 
different fractions of perpendicular light scatter, indicating that this parameter 
can not be used for purification. 
4.2.3 SURFACE MARKERS OF GM-CFU 
With the fluorescence activated cell sorter (FACS) it is possible to isolate cells 
on the basis of the parameters scatter and fluorescence. For optimal use of the 
latter parameter several MCA's directed against human myeloid cells were 
analyzed for their reactivity pattern with GM-CFU's of rhesus monkeys. The 
antibodies GM1 (Jonker, Primate Center TNO) and OKT10 (Crawford et al., 
1981; Sieff et al., 1982) react with the majority of cells which give progeny to 
colonies consisting of granulocytes and macrophages in humans as well as in 
rhesus monkeys (see Table 4.2). This means that these antibodies react with 
either haemopoietic stem cells or with committed precursor cells or with both. 
Sorting of cells, positive for one of these antibodies, did not result in a marked 
enrichment of GM-CFU's. 
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enrichment of GM-CFU. Similar results were obtained with other monoclonal 
antibodies directed against the DR antigen, such as the antibodies YCL 6.8, 
YAML 555.6 and HLA-DR. 
My4 (Griffin, 1983) and Mol (Griffin, 1983: a gift from Coulter Im-
munology) did not react with myeloid progenitor cells (Table 4.2). 
Table 4.2 
Surface antigens on progenitor cells in rhesus monkeys. 
monoclonal 
antibody 
none 
GM-1 
GM-11 
Mol 
My4 
OKTlO 
positive 
cells 
50% 
32% 
12% 
18% 
67% 
GM-CFU/105 
negative 
fraction 
positive 
fraction 
170±25 
32± 15 (14%) 195 ± 45 (84%) 
28 ± 8 (11%) 495 ± 101 (89%) 
122 ± 31 (95%) 50±36 (5%) 
180 ± 29 (93%) 60±29 (7%) 
32± 10 (7%) 228 ± 61 (93%) 
The antibodies RFB-1 (a gift form Dr Bodger, New Zealand; Bodger, 
1983) and MylO (Strauss, 1987) react with the CD34 antigen present on early 
progenitor cells in human bone marrow but according to our own determination 
they react not with rhesus monkey bone marrow cells. 
None of the antibodies reacted exclusively with cells which give progeny to GM-
CFU's. Therefore, it was decided to purify pluripotent stem cells on the analogy 
of the purification procedure for mouse stem cells. Mouse stem cells were puri-
fied by using a density gradient, a preselection with wheatgerm agglutinin and a 
final selection on basis of the expression of a class I antigen (H2k). The purifica-
tion procedure for rhesus monkey stem cells was slightly modified. 
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After preparation of a stem cell enriched cell suspension using the 
discontinuous albumin density gradient, lymphocytes were eliminated by a 
treatment with the antibody CAMPATH-1 plus complement. Subsequently, bone 
marrow cells were sorted on the expression of the DR-antigen using the antibody 
Y AML 555.6 (Swirsky et al., 1983). 
The complement lysis of lymphocytes resulted in a recovery of 11.1% of 
nucleated cells, 76 ± 9% recovery of GM-CFU's and 12.5-fold enrichment of 
these progenitor cells in comparison to the suspension harvested from ficoll. 
Table 4.3 
Distribution of GM-CFU over the parameters forward light scatter and 
reactivity with the anti-Dr antibody YAML 555.6 (N=4). 
percentage GM-CFU/ recovery enrichment 
Cell fractions total nucl. cells 105 ofGM-CFU factor 
fico II 100 59± 11 100,0 ± 18,6% 1 ±0,2 
CAMPATH-1 12,8 583 ± 145 95,6 ±27,5% 10 ±2,4 
sort control 12,8 418± 63 118,0 ± 16,7% 8±1 
Cell sorting: 
FLS Dr-antigen 
low negative (Ia*) 1,2 214 ± 27 4,3± 0,6% 3±0,4 
low positive (Ib) 3,9 624± 30 14,8 ± 1,9% 10 ± 0,5 
high negative (IIa) 1,4 225 ±51 9,0± 2,6% 4±0,8 
high dull (lib) 1,4 2224±224 47,3 ± 5,9% 37 ±4,2 
high bright (lie) 2,7 1772± 145 63,5 ± 7,2% 29 ±2,5 
recovery 139,0 ± 18,2% 
abbreviations: FLS= forward light scatter; DR-FITC= fluorescence intensity of antibody 
Y AML and GARA/FITC. *: numbers as shown in Figure 4.3 Mean values of four sort 
experiments. Enrichment factor is calculated in reference to the ficoll cell suspension. 
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4.2.4 PURIFICATION BY MULTIPLE PARAMETERS 
When the experiments were started to purify haemopoietic stem cells, a cell 
sorter with three parameters namely forward light scatter, perpendicular light 
scatter and fluorescence was available. So far, the purification procedure 
consisted of density centrifugation, collection of light density cells, from a dis-
continuous albumin density gradient, elimination of lymphocytes by the antibody 
CAMPATH-1 plus complement, and sorting on basis of the light scatter 
properties (see also Figure 4.1). The cell sorter offered the opportunity to select 
cells also on their reactivity pattern with the anti-DR monoclonal antibody 
YAML 555.6 (Swirsky et al., 1983) and counterstained with GARA/ FITC. The 
labelled cells with Y AML 555.6 were first separated on basis of a low or high 
forward light scatter signal. Secondly, a further selection was possible on the 
expression of the antibody YAML 555.6. Among the cells with a low forward 
light scatter, cells were present which reacted positively or negative with the 
anti-DR antibody. Cells with a high forward light scatter could be divided in 
cells reacting negative, positive (dull fluorescence signal) and strong positive 
(bright fluorescence signal) with the antibody. So, five cell clusters could be 
distinguished according to the parameters forward light scatter and green 
fluorescence signal (Figure 4.3). Using electronic sorting windows these cell 
populations were sorted and the functional properties of these cells were 
analyzed in the GM-CFU assay. At first, the cells were divided in a population 
with a low (cell population I) and a high forward light scatter signal (cell 
population II). Secondly, cells were distinguished according to their reactivity 
pattern with the anti-DR antibody YAML 555.6. A negative cell population (Ia) 
and a positive cell population (Ib) was seen in the cell population with a low 
forward light scatter signal. Three subpopulations could be distinguished in the 
cell population with a high forward light scatter (ITa: neagtive, lib: dull 
fluorescence, lie: bright fluorescence). Table 4.3 shows the enrichment and 
distribution of GM-CFU's over these cell clusters defined by forward light 
scatter and expression of the DR antigen. The highest concentration of GM-
CFU's were found in the cell populations characterized by high forward light 
scatter and a dull ( cell population lib; see Figure 4.3) or bright ( cell population 
lie; see Figure 4.3) fluorescence signal. A mean 37 and 29-fold enrichment in 
comparison to the ficoll cell suspension was found respectively. The enrichment 
in reference to the starting material, i.e. aspiration bone marrow, can be 
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calculated by multiplying the enrichment factors with a factor 2.4. The result of 
such a calculation is that GM-CFU's were 89 and 70-fold enriched in the cell 
populations with a dull (lib) and bright (lie) fluorescence signal respectively. 
These results also indicated that labelling progenitor cells with the antibody 
Y AML 555.6 did not influence the proliferation of these cells in vitro. 
4.3 IN VIVO EXPERIMENTS WITH CONCENTRATES 
OF PLURIPOTENT HAEMOPOETIC STEM CELLS 
For assessment of enrichment of pluripotent haemopoietic stem cells, the 
regeneration assay described in chapter III was used. This autologous 
transplantation assay is based upon the determinations that the regeneration rate 
of peripheral blood cells is directly related to the size of autologous bone mar-
row grafts which reflects the number of pluripotent haemopoietic stem cells in a 
marrow graft. The purification steps were monitored for the presence of 
pluripotent haemopoietic stem cells. These experiments were performed to 
verify whether the GM-CFU's values correlated with the in vivo results. 
4.3.1 DISCONTINUOUS ALBUMIN DENSITY GRADIENT 
One monkey was transplanted with 3 x 106 cells/kg body weight of the top 
fraction of a discontinuous albumin density gradient. This fraction contained 
5.8% of total nucleated cells and 71% (normalized value) of the GM-CFU's were 
found in this fraction. The enrichment factor for GM-CFU's was calculated to be 
8.5 ± 1.4. After autologous transplantation of these cells, leukocyte counts rose 
above 109!1 at day 20 and reticulocyte counts were greater than 1% at day 19. In 
figure 4.4 it is illustrated in what way these findings were used to calculate the 
repopulating capacity of the marrow graft. Day 19 of the reticulocytes 
corresponds with a bone marrow graft of 12.1 x 106 unseparated cells /kg body 
weight. The 95% confidence limits indicate a range of 8.5 to 17.2 x 106 cells/kg 
body weight. From these figures it can be concluded that there is a significant 4-
fold (2. 7- 5. 7) enrichment of pluripotent haemopoietic stem cells. 
Leukocytes counts could not be used for the calculation of enrichment 
because of the low slope of the regression line and the broad 95% confidence 
range as has been discussed in detail in chapter III. 
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Figure 4.4 Assessment of enrichment of purified cells using the regeneration assay 
of reticulocytes. 
4.3.2 ELIMINATION OF LYMPHOCYTES 
After a discontinuous albumin density gradient cells from the two top fraction 
were collected. It was decided to collect cells from the top fraction as well as 
cells from the second layer since in this way almost all haemopoietic stem cells 
would be recovered. Lymphocytes were eliminated from this light density cell 
suspension by complement mediated lysis using the antibody CAMP ATH-1. This 
resulted in a 10-fold enrichment of GM-CFU's with 9.7% of the nucleated cells 
in comparison to the ficoll cell suspension. After autologous trans-plantation of 1 
x 107 cells/kg body weight reticulocytes reappeared at day 9, which means that 
the number of pluripotent haemopoietic stem cells in this graft was equivalent to 
the numbers present in an unmanipulated bone marrow graft of 1.3 x 108 
cells/kg body weight (range:0.74-2.37 x 108 cells/kg body weight). Since the 
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expected regeneration of reticulocytes was between day 18 and 21 on basis of the 
cell number grafted, the observed regeneration at day 9 indicates a significant 
enrichment of 13 times, which agrees with the enrichment of GM-CFU's. 
4.3.3 FORWARD LIGHT SCATTER PROPERTIES OF 
PLURIPOTENT STEM CELLS 
So far, the experiments have demonstrated that both concentration of stem cells 
by density centrifugation and depletion of lymphocytes are feasible methods to 
use without loosing the repopulating capability of a bone marrow graft. The next 
step to isolate cells was to use a light activated cell sorter. The first parameter to 
be tested was the forward light scatter in view of the results with GM-CFU. 
Since the optimal sorting speed is approximately 2500 cells per second, it is 
advisable to preconcentrate the desired cells. On basis of the former experiments 
the stem cells were concentrated by an albumin density gradient. Cells were 
collected from the top fraction of the gradient and sorted according to an high 
forward light scatter signal. After the gradient 3.6% of the cells were recovered 
and 40% of the GM-CFU's. After sorting 1.3% of the cells were recovered and 
the enrichment factor on basis of GM-CFU counts was 11.5. Transplantation of 
1.5 x 106 autologous bone marrow cells/kg body weight, which were isolated on 
basis of light density and high forward light scatter, resulted in a regeneration of 
reticulocytes (> 1 %) at day 19. This corresponds with a bone marrow graft size 
of 12.1 x 106 /kg and an enrichment factor of 8.1 (range: 5.7-11.5). Although 
the recovery of stem cells is not optimal in this experiment, the significant 
enrichment demonstrates that forward light scatter can be used as parameter for 
isolation of cells with repopulating capacity. 
4.3.4 OPSONIZATION OF LABELLED HAEMOPOIETIC 
STEM CELLS 
On basis of previous experiments described above, it would be logical to purify 
pluripotent stem cells by a combination of density centrifugation, elimination of 
lymphocytes, forward light scatter. Since elimination of Dr positive cells 
resulted in markedly delayed regeneration, positive selection of repopulating 
stem cells would be a logical step in a purification procedure. This latter step 
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includes that cells, labelled with an antibody, have to be injected into a monkey, 
which could lead to either complement mediated lysis or antigen modulation or 
phagocytosis of the labelled cells (van den Engh et al., 1978; Bauman et al., 
1985). Incubation of labelled cells with autologous complement did not result in 
a reduction of the number of GM-CFU's (data not shown). Since it is known that 
the Dr-antigen has an important function in immunological reactions, antigen 
modulation could chance the function of the labelled progenitor cells. Therefore, 
cells collected from the top fractions of a discontinuous albumin gradient were 
incubated with the antibody Y AML and GARA/FITC. 
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Figure 4.5 Influence of 370 C on the stability of binding of the antibody YAML 
555.6 and GARA/FITC at bone marrow cells. 
Thereafter these cells were resuspended in a medium containing 20% autologous 
serum and placed in an incubator at 370 C. At different time intervals the flu-
orescence intensity and the percentage positive cells were measured to investigate 
if the antigen-antibody complex with GARA/FITC was modulated. As is shown 
in Figure 4.5, the number of labelled cells as well as the fluorescence intensity 
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remained stable during a period of incubation of 24 hours. Autologous bone 
marrow graft consisting of 108 cells/kg body weight was incubated with the 
monoclonal antibodies Y AML and GARA/FITC and injected into a monkey 
which was prepared by 9.8 Gy total body irradiation (double beam). The 
regeneration pattern of leukocytes and reticulocytes were identical to that of a 
monkey which received an untreated bone marrow graft. This result demon-
strates that these incubated bone marrow cells were not eliminated, but retained 
their capacity to repopulate an irradiated recipient monkey. 
Table 4.4 
Concentration of repopulating pluripotent haemopoietic stem cells (PHSC) 
calculated from reticulocyte regeneration rate. 
cell dose cell dose PHSC 
(x 1Q6fkg Reticuloc)!e > 1% fitting to enrichment 
FLS DR body weight) expected observed regr.line 
low ++ (lb*) 0,5 32 23 4,7 
high + (lib) 0,7 31 16 24,8 
high ++ (lie) 0,5 32 17 19,5 
all 
-
(la+IIa) 0,6 31 >22 <5,9 
FLS: Forward light scatter, DR: expression of the anti DR antibody Y AML 555.6, 
regr.: regression, PHSC: pluripotent haemopoietic stem cells 
*: numbers as shown in Figure 4.3 
factor 
9,4 
35,4 
39,0 
<9,6 
4.3.5. POSITIVE SELECTION OF HAEMOPOIETIC STEM 
CELLS 
The final step in the purification procedure was isolation of bone marrow cells 
according to the parameters forward light scatter and reactivity pattern with an 
indirect labelled anti-Dr antibody, called Y AML (see also figure 4.1 and 4.3). 
Using the modified FACS II, autologous bone marrow cells were sorted and 
small numbers of cells were injected into an irradiated recipient. On basis of the 
regeneration rate of reticulocytes, the repopulating capacity of the purified cells 
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could be calculated (Table 4.4). Transplantation of Dr-negative cells gave no 
regeneration of peripheral blood cells. The monkey died after 22 days due to 
sepsis secondary to bone marrow aplasia. At autopsy total bone marrow aplasia 
was observed. 
Cells which were Dr-positive and which gave a low forward light scatter 
signal, (cell population Ib; see Figure 4.3) had some repopulating ability. 
Table 4.5. 
Recovery of cells with repopulating ability. 
forward light reactivity with %of total enrich- recovery 
scatter Dr-antibody nucl. cells ment 
low + high negative 2,7% <6 13,5% 
low positive 1,6% 9,4 15,0% 
high dull positive 1,4% 35 49,0% 
high bright positive 0,7% 39 27,3% 
Total 104,8% 
Transplantation of cells with a high forward light scatter and a dull 
fluorescence signal with the anti-Dr antibody ( cell population lib; see Figure 
4.3) resulted in a regeneration of reticulocytes at day 16, which meant a 36.3 
(range: 21-64) times enrichment. A graft consisting of cells sorted on basis of a 
high forward light scatter signal and bright fluorescence signal with the anti-Dr 
antibody (cell population lie; see Figure 4.3), showed a different regeneration 
pattern of reticulocytes. At day 9 reticulocyte counts rose above 1%, but 
dropped at day 13 and rose again at day 17. This latter day was taken for 
calculation of the enrichment, since after day 17 the regeneration of 
reticulocytes showed a normal pattern. The enrichment factor was calculated to 
be 39.7 (range: 23-70) times. On basis of the percentage of total nucleated cells 
and the enrichment factors calculated, a recovery can be estimated (Table 4.5). 
The distribution of stem cells over the different cell clusters is similar to the 
distribution of progenitor cells with 76% of stem cells characterized by high 
forward light scatter and positive reaction with the Dr-antibody. 
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Leukocyte regeneration was comparable to the regeneration rate of retic-
ulocytes in the animals, which received a bone marrow graft consisting of either 
Dr-negative cells or cells with low forward light scatter signal and Dr-positive 
signal, while in the other two monkeys, the regeneration rate of leukocytes was 
slower in comparison to reticulocyte regeneration. However, the number of 
platelet transfusions required was within normal limits, indicating clearly that 
the bone marrow graft consisted of multipotent stem cells (Figure 4.6 + 4.7). 
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Figure 4.6 Regeneration of thrombocytes after transplantation of cells selected on 
the basis of DR expression and forward light scatter. Fraction Hb; high forward 
light scatter and strong expression of the DR-antigen. 
4.4 ANALYSIS OF GM-CFU BY DOUBLE FLUORESCENCE 
ANALYSIS 
Further enrichment was possible when a new cell sorter was build in our labo-
ratory. This experimental light activated cell sorter was able to identify more 
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than three parameters and for immunofluorescence analysis a second laser beam 
was available. 
The availability of the fluorescent dye phycoerythrin (PE) allowed further 
purification since two color immunofluorescence can be obtained using a single 
wavelength excitation when PE is paired with FITC.As stated before, not only 
lymphocytes and activated T lymphocytes, but also some macrophages, mono-
cytes and committed progenitor cells have the Dr-antigen on their cell surface. 
The antibody My4 reacts in humans with monocytes and promonocytes (Griffin 
et al., 1983). These two cell types also express Dr-antigens on their cell surface. 
Both the antibody Mol and an anti-Dr antibody recognize monocytes, promono-
cytes and myeloblasts (not identical to cells which produce granulocytes and 
monocytes). Besides these cells the antibody Mol is directed against promyelo-
cytes, myelocytes and polymorphs (Griffin et al., 1983). The antibody Mol as 
well as My4 crossreact with rhesus monkey cells (Letvin et al., 1983) and does 
not react with cells which produce GM-CFU's (Table 4.2). 
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Figure 4.6 Regeneration of thrombocytes after transplantation of cells selected on 
the basis of DR expression and forward light scatter. Fraction lie; high forward 
light scatter and very strong expression of the DR-antigen. 
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A pilot experiment showed that there is a small cell population in rhesus 
bone marrow which has only the Dr-antigen on their cell surface and not the 
antibodies CAMPATH-1 and Mol. Selection of those cells which gave a high 
forward light scatter signal, had the DR-antigen on their cell surface and not the 
antibodies CAMPATH-1 and Mol lead to further enrichment of GM-CFU (Table 
4.6). 
Table 4.6 
Purification of progenitor cells using a discontinuous albumin density gradient 
and multiple parameter cell sorter. 
percent of GM-CFU/ enrichment 
cell material total nucl cells 105 factor recovery% 
Ficoll 100 15 1 100 
albumin gradient 12 110 7,3 86 
top fractions 
high fls/low pls window: 
DR!PE CAMPATH-1+Mo1/FITC 
pos neg 0,039 2540 169 66 
pos pos 0,84 300 20 17 
neg pos+neg 2,12 30 2 4 
all cells outside this window 8,7 160 10,6 38 
total nucl cells: total nucleated cells; DR!PE: anti HLA-Dr directly coupled to phycoerythrin; 
pos:positive,neg:negative 
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4.4 DISCUSSION 
These experiments were primarily carried out to conduct enrichment procedures 
to be used for human progenitor cells in a preclinical rhesus monkey model. 
Therefore, monoclonal antibodies directed against human myeloid progenitor 
cells were used with rhesus monkey bone marrow. Studies with monoclonal 
antibodies directed against human granulocytes (Letvin et al., 1983) and 
lymphocytes (Jonker, 1984, 1986; Hansen, 1984) have demonstrated that these 
antibodies react with the same antigenic structures in several primates. 
The first steps in the purification procedure consisted of density centrifu-
gation. According to the results of Dicke (1970) and Moore et al.(1972), rhesus 
monkey pluripotent haemopoietic stem cells were recovered from the light den-
sity fractions of a discontinuous albumin density gradient as has been demon-
strated in the GM-CFU assay as well as in the in vivo experiments. Depletion of 
lymphocytes had no influence on the colony growth, which is in agreement with 
results with human bone marrow (Martin et al., 1985; Granger et al., 1982; 
Berenson et al., 1984). Scatter of light by cells in flow gave a distribution of 
rhesus bone marrow cells according to their size and shape. The distribution is 
very similar to human bone marrow cells. GM-CFU's and pluripotent stem cells 
were recovered from the fractions with a high forward light scatter signal. Ex-
periments with human bone marrow cells using either cell sorters or 
counterflow elutriation centrifugation did also show that myeloid progenitor 
cells can be identified by a high forward scatter signal (Beverley t al., 1980; 
Mouchiroud et al., 1985; Bodger et al., 1983; de Witte et al., 1984). 
Since several antibodies directed against human cells crossreact with rhesus 
monkey cells, they could be used in this preclinical model. Since none of the 
tested antibodies reacted exclusively with GM-CFU's, the anti-DR antibody 
YAML 555.6 was applied to purify pluripotent haemopoietic stem cells on the 
analogy of the purification of mouse stem cells (Visser et al., 1984). Positive 
selection of haemopoietic stem cells was not accompanied by the problem of 
opsonization in contrast to the situation in mice (Van de Engh et al., 1983; 
Bauman et al., 1985). In the murine experiments an increase in antibody con-
centration was associated with a loss of stem cells. A high concentration of 
GAM/FITC protected the labelled cells from opsonization in one mouse strain. 
In the murine experiments, a 50% loss of stem cells was measured when a 
relatively high concentration of antibody was used. Since in our experiments a 
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relatively low concentration of antibody was used and a high concentration of 
conjugate was applied, this could be an explanation for the fact that opsonization 
was not observed. On the other hand our regeneration assay is not accurately 
enough to observe a significant reduction of stem cells in the order of 50% or 
less. 
These experiments have demonstrated that the highest concentration of GM-
CFU was found in the cell populations characterized by a high forward light 
scatter signal and a weak (dull fluorescence) or strong (bright fluorescence) 
expression of the DR antigen. The GM-CFU were 30-37 fold enriched in com-
parison to the cell suspension harvested from the ficoll gradient. In agreement 
with the in vitro data pluripotent stem cells were found in the same cell popula-
tions. A 40-fold enrichment of pluripotent stem cells was achieved in compari-
son to the ficoll cell suspension. In comparison to the starting material, i.e. 
aspiration bone marrow, a 90-fold enrichment was achieved. Dicke et al (1973) 
determined that the number of pluripotent stem cells in aspiration rhesus 
monkey bone marrow was approximately 0.5-0.7%. Thus, a cell suspension 
consisting of pure stem cells would require an enrichment of 143-200 fold. Since 
in our experiments an enrichment of 90-fold was found, further enrichment is 
required when a pure stem cell populations is desired. 
A pilot experiment has revealed that the antibody Mol can be used in com-
bination with the antibody CAMPATH-1 for the identification of committed 
progenitor cells which have also the DR antigen on their cell surface. More 
preferable would be antibody which identify early progenitor cells such as the 
MylO (CD34) in man. Recently, a CD34 antibody has been described which 
identify early progenitor cells in baboons (Berenson et al., 1988) and rhesus 
monkeys ( Wielenga et a1.,1989). 
The calculation of enrichment of stem cells on basis of the GM-CFU assay 
corresponded very well with the results of the in vivo experiments. The feeder 
layer of leukocytes produce apparently sufficient growth factors for stem cells to 
differentiate along the granulocyte-macrophage pathway. This observation is 
important for further experiments because these experiments have proven that 
enrichment of pluripotent stem cells can be assayed in vitro as good as in vivo. 
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CHAPTER V 
RADIATION DOSE REQUIRED FOR 
ENGRAFTMENT OF 2LOG T LYMPHOCYTE 
DEPLETED BONE MARROW GRAFTS 
5.1 INTRODUCTION 
The direct relationship between the number of donor T lymphocytes and the 
incidence of acute Graft-versus-Host Disease (GvHD) was established two 
decades ago in mice (van Bekkum et al., 1964). Several methods for selective 
elimination of lymphocytes were developed and applied. All showed that T 
lymphocyte depletion did indeed prevent acute GvHD. Prevention of acute GvHD 
could not only be achieved in species with a low proportion of T lymphocytes in 
bone marrow such as rodents (Dicke et al., 1968; Vallera et al., 1981; Rodt et 
al., 1974) and dogs (Kolb et al., 1979) but also in rhesus monkeys with a rel-
atively high proportion ofT lymphocytes in bone marrow (Wagemaker et al., 
1982). It was also established in experimental animals that T lymphocyte 
depletion of the graft may cause a high incidence of engraftment failures 
(Vriesendorp et al., 1982; Wagemaker et al., 1982). The logical conclusion of 
these observations was that donor T lymphocytes exert an immunosuppressive 
action (the Graft-versus-Host reaction) which suppresses the Host-versus-Graft 
reaction. Abrogation of the acute GvH reaction by T lymphocyte depletion will 
require additional suppression of the Host-versus-Graft reaction since the Host-
versus-Graft reaction may get stronger. After establishing the reciprocal 
interference (Vriesendorp et al., 1981) between Graft-versus-Host reaction and 
Host-versus-Graft reaction, conditioning schemes were developed for the 
promotion of engraftment of T lymphocyte depleted bone marrow grafts. In our 
dog and rhesus monkey models for bone marrow transplantation, a high dose of 
total body irradiation was effective in preventing engraftment failures of T 
lymphocyte depleted bone marrow grafts. 
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Unmodified bone marrow grafts from DLA-identical siblings engrafted in 
10/10 dogs after conditioning with 7.5 Gy total body irradiation. Transplantation 
of stem cell enriched T lymphocyte depleted marrow grafts resulted in 4/7 
engraftment failures with the same irradiation dose. When the dose of irradiation 
was increased to either 2 x 4.5 Gy (5/5 dogs) or 2 x 6.0 Gy (7/7 dogs) with a 72 
hours interval (Walma et al., 1987) engraftment was uniformly observed. In 
rhesus monkeys similar results were obtained with T lymphocyte depleted 
unrelated bone marrow grafts. A single dose of 8.5 Gy total body irradiation 
resulted in engraftment of 5 out of 18 recipient monkeys. When the conditioning 
regimen was changed to 2 x 7 Gy (72 hour interval) take failures were no longer 
observed (Wagemaker et al., 1982). 
A disadvantage of higher doses of total body irradiation is the increased 
toxicity especially to the gastrointestinal tract and the lungs. Previous experi-
ments in dogs and rhesus monkeys did not give exact information on the minimal 
dose of irradiation required to prevent graft rejection completely when T 
lymphocyte depleted bone marrow grafts were transplanted. Therefore, graded 
doses of total body irradiation were administered to rhesus monkeys which 
received T lymphocyte depleted bone marrow grafts. Since the problem of 
engraftment failure is especially encountered in mismatched donor-recipient 
combinations, unrelated, mismatched donors were used in this study. 
5.2. ENGRAFTMENT OF 2 LOG T LYMPHOCYTE 
DEPLETED BONE MARROW GRAFTS 
Donor monkeys were sacrificed for these experiments and bone marrow was 
extruded from the bones by pressure. A buffy-coat cell suspension was prepared 
by centrifugation. The cell yield from a single donor was 1-2 x 1010 cells which 
is sufficient for 3-4 recipients. Buffy coat cells were layered on top of a 
discontinuous albumin density gradient. In a discontinuous albumin density 
gradient T lymphocytes and myeloid progenitor cells are concentrated in 
different fractions (Figure 5.1). A T lymphocyte depleted, stem cell enriched 
cell suspension was collected from the two low density fractions in top of a gra-
dient. In these low density fractions the percentage T lymphocytes is still compa-
rable to the concentration of T lymphocytes in the initial cell suspension. 
However, since stem cell concentration results in an approximately 8-10 fold 
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lower number of nucleated cells required for sustained engraftment the absolute 
number of T lymphocytes grafted is correspondingly decreased C:W agemaker et 
al., 1982). Accordingly, stem cell concentration results in approximately one log 
T lymphocyte depletion (Table 5.1). 
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Figure 5.1 Distribution of GM-CFU and T lymphocytes from Rhesus monkey bone 
marrow over a discontinuous albumin gradient. 
Table 5.1 
Enrichment of GM-CFU by a discontinuous albumin density gradient and deple-
tion of T lymphocytes by E-rosette sedimentation. 
bone marrow enrichment of graft size in E-RFC E-RFC/ 
fraction GM-CFU tnc/kg b.w. 
(x 108) 
(%) kgb.w. 
(x 108) 
buffy coat 1 4 5 0,2 
low density 
fraction 8,4 0,5 5 0,02 
E-rosette 
sedimentation 10,6 0,25 0,20 0,0005 
The results of one representative experiment. E-RFC = E-rosette forming cells; 
tnc =total nucleated cells; kg b.w. =kilogram body weight 
depletion 
factor 
0 
lOx 
400x 
85 
Using the property ofT lymphocytes to form rosettes with sheep red blood 
cells, the remaining T lymphocytes were removed from the stem cell fractions 
by E-rosette sedimentation. After this step a bone marrow graft of 2.5 x 107 
nucleated cells/kg body weight could be given since the progenitor cells were 
further enriched. Such a graft contained 0.2-0.5% T lymphocytes (= E-rosette 
forming cells) corresponding to a 2-3 log depletion of T lymphocytes (Table 
5.1) as compared to unmodified bone marrow. 
Recipients of T lymphocyte depleted bone marrow grafts were prepared for 
grafting by fractionated total body irradiation with an interval of 24 hours. 
Graded doses of total body irradiation were administered in a range of 2 x 4.2 
Gy to 2 x 6.1 Gy (Figure 5.2). Up to a dose of 2 x 5.2 Gy engraftment ofT 
lymphocyte depleted bone marrow grafts was not documented. 
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Figure 5.2 Dose-effect relationship between fractionated total body irradiation (X-
rays; 2 fractions with 24 hours interval) and engraftment of 2 log T lymphocyte 
depleted bone marrow grafts in rhesus monkeys. Unrelated, mismatched donor-
recipients combinations. 
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An increment of the irradiation dose with 1-2 Gy resulted in sustained engraft-
ment of T lymphocyte depleted bone marrow grafts. These results demonstrate 
that a steep dose-effect relationship exists between the dose of fractionated total 
body irradiation (24 hours interval) and engraftment of T lymphocyte depleted 
bone marrow grafts as illustrated in Figure 5.2. 
5.3 LATE REJECTION OF MORE THAN 3 LOG L YMPHO-
CYTE DEPLETED BONE MARROW GRAFTS 
A dose of 2 x 6 Gy total body irradiation was sufficient for engraftment of 2 log 
T lymphocyte depleted bone marrow grafts. Since earlier experiments have 
shown that a 2 log T-lymphocyte depletion is not sufficient in preventing com-
pletely acute GvHD in unrelated, mismatched donor-recipient combinations, it 
was investigated whether 2 x 6 Gy total body irradiation would result in 
engraftment of more than 3 log T-lymphocyte depleted bone marrow grafts. 
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Figure 5.3 Regeneration of leukocytes after allogeneic bone marrow transplantation 
with 3 log T lymphocyte depleted bone marrow grafts. 
UMN= unique monkey number 
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Two rhesus monkeys were conditioned by 2 x 6.0 Gy total body irradiation (24 
hours interval; X-rays) and given a bone marrow graft from which T-
lymphocytes were depleted by a combination of albumin gradient, E-rosette 
sedimentation and complement lysis of T -lymphocytes using the antibody 
CAMPATH-1 plus complement. A discontinuous albumin gradient followed by 
E-rosette sedimentation deplete 2-3 log T lymphocytes (Table 5.1). Complement 
lysis ofT lymphocytes with CAMPATH-1 plus complement depletes also 2-3 log 
T lymphocytes. Therefore, it was assumed that these methods would deplete 
more than 3 log T lymphocytes. After T lymphocyte depletion by these two 
methods, T lymphocytes were not detected using the E-rosette forming method 
for enumeration ofT lymphocytes. As shown in Figure 5.3 peripheral blood cell 
counts rose around day 20. After transplantation of a 2 log T lymphocyte 
depleted bone marrow graft, leukocyte counts continued to rise to normal values. 
A gradual decrease in leukocyte counts was observed after 25 days 
posttransplantation when 3 log T lymphocyte depleted bone marrow grafts were 
administered. Leukocytes of monkey 1MM were of both recipient and donor 
type at day 25. At day 32 these cells were of recipient type indicating graft 
rejection had occurred in monkey 1MM. The leukocytes of monkey 1PW were 
of donor type at day 32, 38 and 42, but at day 45 posttransplantation the cells 
were both of donor and recipient. Monkey 1 MM was killed after 32 days when 
it was become transfusion dependent. Monkey 1PW died after 45 days from 
Cytomegaly virus pneumonitis. The phenomenon of late rejection was not 
observed when T-lymphocytes were depleted by stem cell enrichment and E-
rosette sedimentation alone. 
5.4 TOXICITY OF THE CONDITIONING REGIMENS 
Autologous bone marrow transplantations were performed to determine the 
toxicity of the conditioning regimen. The monkeys were prepared for bone 
marrow grafting by 2 x 5.6 Gy total body irradiation. This was the minimal dose 
of irradiation required for engraftment ofT lymphocyte depleted bone marrow 
grafts. Four monkeys were given either an unmodified, autologous bone marrow 
graft, consisting of 5 x 107 cells/kg body weight, or a T lymphocyte depleted, 
stem cell enriched bone marrow graft consisting of 0.9 x 107 cells/kg body 
weight. Concentration factor for GM-CFU was 7.5 and 6.1, which means that 
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approximately an equal numbers of progenitor cells were present in both 
unmodified marrow grafts and T lymphocyte depleted marrow grafts. 
Table 5.2 
Incidence of radiation induced, acute exsudative pneumonitis following total 
body irradiation and autologous bone marrow transplantation in rhesus monkeys. 
Monkeys which survived for more than 2 months after transplantation. 
UMN 
1 GA 
1 LP 
ILG 
1 NN 
lOT 
ILQ 
1 TO 
IMY 
IQT 
1 KK 
1 SN 
1 HH 
IHW 
1 HJ 
IAT 
DOSE OF IRRADIATION CQy) 
TBI LUNG DOSE 
9.35 
9.40 
9.45 
9.50 
9.50 
9.50 
9.55 
9.65 
9.65 
9.70 
9.80 
9.85 
9.85 
2 X 5.6 
2 x5.6 
10.45 
10.45 
10.50 
10.50 
10.50 
10.55 
10.55 
10.55 
10.55 
10.60 
10.60 
10.60 
10.70 
2 X 6.1 
2 X 6.1 
SURVIVAL TIME RADIATION 
(Days) PNEUMONITIS 
80 
> 100 
87 
> 100 
> 100 
87 
> 100 
67 
87 
60 
93 
> 100 
61 
59 
87 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
TBI: total body irradiation, UMN; unique monkey number 
The monkeys survived for 40, 53, 59 and 87 days. At the time of death normal 
peripheral blood cell counts were documented. At the autopsy whitish nodules 
were predominantly seen in liver and spleen of monkey lAT and bacterial 
cultures revealed that these organs were infiltrated with Yersinia pseudotuber-
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culosis. Monkey 2A W suffered from dyspnea and at autopsy pneumocystis 
carinii were observed in the lungs. The other two monkeys (lFB and lHJ) lived 
longer and died from interstitial pneumonitis without positive viral or bacterial 
cultures. 
Since irradiation had most probably induced these lesions in the lungs, it 
was decided to review all recipients, which were given autologous bone marrow 
grafts and which survived for more than 60 days, for signs of radiation pneu-
monitis at autopsy. The results of this survey is shown in Table 5.3. After 
preparation of recipients with a single beam X-ray signs of exsudative radiation 
pneumonitis was observed in 5 out of 13 monkeys. The frequency of pneumoni-
tis was 1 out of 9 when monkeys received a total lung dose of 10.45 - 10.55 Gy. 
When a total lung dose was 10.60 Gy or higher the frequency of pneumonitis 
was 4 out of 4 monkeys suggesting a steep dose-effect relation between irradia-
tion dose and the induction of radiation induced pneumonitis. 
Table 5.4 
Engraftment, severity of Graft-versus-Host Disease and survival of monkeys 
which received a T lymphocyte depleted bone marrow graft from unrelated, 
mismatched donors. 
UMN Irradiation Engraftment survival cause of GvHD 
dose (Gy) (days) death grading 
1 EP 2x5.6 + 34 CMV 0 
1 cc 2 X 6.1 + 24 sepsis I 
lEG 2 X 6.1 + 34 CMV II 
UMN: unique monkey number, GvHD: Graft-versus-Host Disease, CMV: Cytomegaly virus 
5.5 ENGRAFTMENT AND ACUTE GVHD 
Three monkeys were . conditioned with either 2 x 5.6 Gy or 2 x 6.1 Gy 
(unilateral total body irradiation) and received T lymphocyte depleted bone 
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marrow grafts from unrelated, mismatched donors. They survived for 34, 24 
and 34 days respectively. Survival was significantly prolonged in comparison 
with historical controls. In this donor-recipient combination (unrelated and 
totally mismatched for the MHC-antigens) survival ranged from 8-17 days (N=7: 
Wagemaker, 1982). Historical control monkeys, which were given unmodified 
bone marrow grafts, all died from severe GvHD (grade Ill), while the recipients 
ofT lymphocyte depleted grafts died from complications secondary to the trans-
plantation procedure such as Cytomegaly virus (CMV) infection and bacterial 
infections (Table 5.4). Only mild signs of acute GvHD were seen (Table 5.4). 
5.6 DISCUSSION 
It is estimated that approximately 60-70% of patients who might benefit from a 
bone marrow transplant will not have an HLA-identical sibling as donor. 
Therefore it was attempted to use HLA-nonidentical siblings as donors. In 
humans (Hansen et al., 1986; Powles et al., 1983), dogs (Vriesendorp, 1985) as 
well as rhesus monkeys (Wagemaker et al., 1982) similar obstacles were 
observed when HLA-nonidentical siblings were used as donors; HLA incompati-
bility creates a higher immunological barrier which results in an higher inci-
dence of engraftrnent failures and an higher incidence of acute GvHD. T lym-
phocyte depletion as a method to prevent GvHD has dramatically decreased the 
incidence of acute GvHD to less than 10% in HLA-identical, related donor-
recipient combinations (see Table 1.4). On basis of these encouraging results, 
several transplantation centers have started to apply this method for prevention 
of GvHD in HLA-nonidentical, related donor-recipients combinations. Engraft-
ment failures occurred in 25-50% of the patients (see Table 1.5). 
The aim of the present study was to investigate which additional dose of ir-
radiation is required for sustained engraftment of T lymphocyte depleted bone 
marrow grafts in unrelated, mismatched donor-recipient combinations. Rhesus 
monkeys were chosen for these experiments since their bone marrow composi-
tion and immunological reactions are very similar to man (van Bekkum, 1978). 
Using a combination of discontinuous gradient and E-rosette sedimentation, 
depletion ofT lymphocytes was in the order of 2-3 log depletion. In accordance 
to calculations by Wagemaker (1986) which predicted that a reduction of 3 log T 
lymphocyte depletion is required to prevent lethal GvHD in unrelated, MHC-
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mismatched donor-recipient combinations, mild symptoms of acute GvHD were 
observed in two monkeys and severe Gv HD was seen in one monkey. 
The steep dose-effect curve between dose of fractionated irradiation and 
engraftment indicates that a difference of 1-2 Gray fractionated total body irra-
diation determines a successful engraftment of T lymphocyte depleted bone 
marrow grafts. A radiation dose of 2 x 6.0 Gy offered sufficient immunosup-
pression to permit engraftment of 2 log T lymphocyte depleted bone marrow 
grafts. In accordance with the concept of reciprocal interference, this radiation 
dose was insufficient when 3 log T lymphocytes were removed from a bone 
marrow graft. These results will have important implications for clinical centers. 
In the first place it provides support to do bone marrow transplantations with 
HLA-nonidentical siblings since T lymphocyte depleted grafts did engraft and the 
incidence of acute GvHD was low in these unrelated, mismatched donor-recipient 
combinations. Secondly, this study strongly indicates that the problem of en-
graftment failures of T lymphocyte depleted marrow grafts may be solved by a 
relatively small increment in immunosuppression. 
In our study total body irradiation was used for this purpose. A disad-
vantage of increasing the dose of irradiation is toxicity particularly to the lungs. 
In our study two out of two evaluable monkeys, transplanted with autologous 
bone marrow grafts, died due to interstitial pneumonia. From human studies it is 
known that there exists a marked increase in the incidence of this complication 
when irradiation doses above 10.5 Gy are administered (Barrett, 1982). Almost 
all conditioning regimens for human patients lung shielding is applied when the 
irradiation dose exceeds 8-8.5 Gy. After these experiments a new conditioning 
protocol with lung shielding was developed for rhesus monkeys. 
An alternative approach is the use of immunosuppressive agents in 
combination with total body irradiation such as ARA-C and cyclosporine A 
(Bozdech, 1985). This combination promoted the engraftment ofT lymphocyte 
depleted marrow grafts from HLA-nonidentical siblings. Another approach is 
the use of more selective agents specially cytotoxic for T lymphocytes. In rhesus 
monkeys (Reisner, 1986) as in humans (Kernan, 1987) residual alloreactive T 
lymphocytes can be detected after a conditioning regimen consisting of 
cyclophosphamide and hyperfractionated total body irradiation. Injection of anti-
T lymphocyte monoclonal antibodies in recipients pr!or to a sublethal dose of 
total body irradiation (6 Gy) prevented rejection of T lymphocyte depleted 
marrow grafts in 7/7 mice (Cobbold, 1986), while normal recipients all rejected 
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their bone marrow graft. In human patients similar results were obtained with an 
antibody against against human leucocyte functional antigen (HLFA-1), which is 
expressed on T lymphocytes, natural killer cells, leukocytes and macrophages. 
In 7/7 patients with immunodeficiencies engraftment of T lymphocyte depleted 
bone marrow grafts from HLA-haploidentical siblings was facilitated by injec-
tions of the antibody HLFA-1. In a historical control group engraftment was 
only documented in 1/7 patients using the same condition regimen containing 
busulphan without injection of this antibody (Fisher, 1986). 
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CHAPTER VI 
PREVENTION OF ACUTE GRAFT VERSUS-
HOST DISEASE BY DEPLETION OF 
T LYMPHOCYTE SUBPOPULA TIONS 
6.1 INTRODUCTION 
In several species, T lymphocyte depletion is successfully applied for the pre-
vention of acute GvHD. The mature T lymphocyte population can be divided 
into two subpopulations with distinct functions; suppressor/cytotoxic T lympho-
cytes, characterized by the CDS antigen, and helper/inducer T lymphocytes, 
characterized by the CD4 antigen. The role of these T lymphocyte subpopula-
tions in the induction of acute GvHD has been investigated in rodents. These 
murine experiments have demonstrated that depletion of helper T lymphocytes 
could mitigate the severity of GvHD after bone marrow transplantation across 
major histocompatibility barriers (Mason, 1981; Vallera et al., 1982; Komgold 
and Sprent, 1985; Sprent et al., 1986; Pietryga et al., 1987). It was decided to 
deplete either helper/inducer T lymphocytes or cytotoxic/suppressor T lympho-
cytes or all T lymphocytes from bone marrow grafts and to observe the 
resulting effect on acute GvHD in monkeys. 
Monoclonal antibodies directed against human subpopulations of T lym-
phocytes were analyzed for their reactivity with rhesus monkey T lymphocytes. 
Subsequently, the function of the T lymphocyte subpopulations, recognized by 
the selected antibodies, was studied in vitro. When it was demonstrated that the 
selected antibodies reacted with only one of the two distinct T lymphocyte sub-
populations, these monoclonal antibodies were used to investigate whether 
depletion of subpopulations ofT lymphocytes prevented acute GvHD in mis-
matched donor-recipient combinations. 
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Figure 6.1 Double fluorescence analysis of rhesus monkey T lymphocytes. 
(A): CAMPATH-1, (B): WT-1, (C): T lymphocytes 
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In chapter V it was demonstrated that 2 x 6 Gy total body irradiation (X-
ray; unilateral irradiation; 24 hours interval) would be sufficient to allow 
engraftment ofT lymphocyte depleted bone marrow grafts. For a more homo-
geneous dose distribution of radiation bilateral irradiation was applied for the 
experiments in this chapter. Experiments in chapter V have shown that a dose of 
2 x 6 Gy is accompanied by lung toxicity. At the time of these experiments, a 
new total body irradiation setting for total body irradiation including lung 
shielding would not yet been available for at least half a year. Symptoms of acute 
GvHD are observed before day 40 in unrelated, mismatched donor-recipient 
combinations. Dyspnea from lung toxicity is observed after day 40. Therefore, it 
was anticipated that the effect of depletion of T lymphocyte subpopulations on 
acute GvHD could be measured when total body irradiation was applied without 
lung shielding. 
6.2 CHARACTERIZATION OF ANTI T LYMPHOCYTE 
ANTIBODIES IN VITRO 
6.2.1 FLUORESCENCE ANALYSIS 
The reactivity pattern of rhesus monkey lymphocytes with the antihuman T 
lymphocyte monoclonal antibodies was determined by use of immunofluores-
cence with 2 fluorchromes. Leu 2a/PE (CD8) and Leu 3a/PE (CD4) were used as 
reference antibodies. 
Pure T lymphocytes were obtained byE-rosette sedimentation with rhesus 
monkey peripheral blood cells; a combination of Leu 2a and Leu3a stained 99% 
of all the T lymphocytes. Incubation of mononuclear peripheral blood cells with 
Leu2a/FITC and Leu3a/PE resulted in 2 separate subpopulations of approxi-
mately equal size with only 1-3% of the cells sharing the markers (Figure 6.lc), 
demonstrating great similarity between humans (Clark et al., 1986) and rhesus 
monkeys with respect to the major T lymphocyte subsets. Figure 6.1a demon-
strates that CAMPATH-1 reacts with all bone marrow cells positive for Leu2a 
and/or Leu3a, which represented 68% of the cell populations reacting with 
CAMPATH-1 (Hale et al.,1983) cells; the remaining 32% were most probably, 
analogous to human bone marrow, B-lymphocytes and monocytes. Figure 6.1b 
shows that all bone marrow cells that react with the WT 1 (CD7) antibody 
shared the T lymphocyte markers Leu2a and/or Leu3a. A small subpopulation of 
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Leu 2a/Leu3a positive cells was observed that lacked the the WT 1 antigen. Also, 
these findings are similar to the reactivity pattern of WT 1 with human 
lymphocytes (Tax et aL, 1984). Double fluorescence analysis demonstrated that 
the B9 monoclonal antibodies and Leu2a recognize the same T lymphocyte 
subpopulation and that the antibodies OKT4+4a and Leu3a also shared the same 
subpopulation ofT lymphocytes. 
6.2.2 FUNCTIONAL CAPACITY OF LYMPHOCYTES IN 
VITRO AFTER DEPLETION. 
The functional capacity of residual T lymphocytes after depletion was studied in 
vitro. Peripheral blood cells (PBL) was stimulated to proliferate by the mitogen 
phytoagglutinin (PHA). Since some anti-T lymphocyte antibodies such as OKT3 
induce and enhance proliferation of PBL's, it was investigated whether a 
proliferative response could be attributable to labelling lymphocytes with either 
B9-pool ( a combination of four antibodies directed against cytotoxic/suppressor 
T lymphocytes) or OKT4+4a (helper/inducer T lymphocytes) or CAMPATH-1 
(anti T and B-lymphocytes). The proliferative capacity was compared to 
proliferation of unlabeled cells. Labelling of PBL's with antibodies, directed 
against T lymphocyte subpopulations, did not influence their proliferative 
capacity. The proliferation of lymphocytes with CAMPATH-1, an antibody 
directed against all lymphocytes, on their cell surface was reduced to 34 ± 4% in 
comparison to untreated PBL's. 
Depletion of either B9-pool positive lymphocytes or OKT4+4a positive 
lymphocytes, prior to stimulation with PHA, provides insight in the function of 
these subpopulations in rhesus monkeys. After complement lysis of labelled cells, 
residual cells were counted and the same number of viable cells were used as in 
the control experiments. Complement lysis with the antibody CAMPATH-1 
eliminated the proliferative response completely as could be expected. After 
elimination of B9-positive cells by complement lysis, the residual cells had a 
similar proliferative response to PHA stimulation as the untreated cells. Deple-
tion of OKT4+4a positive cells did reduce significantly the proliferative capacity 
of PBL's. These latter results suggest that OKT4+4a positive cells have an 
helper/inducer function in rhesus monkeys similar to that in humans. A func-
tional assay to investigate the cytotoxic capacity of lymphocytes is not yet 
available for rhesus monkeys. 
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Fluorescence analysis of the OKT4 and B9-pool positive cells has shown that 
these antibodies recognize complementary T lymphocyte subpopulation in rhesus 
monkeys. The results of fluorescence analysis together with the experiments 
described above provide sufficient evidence that the antibodies OKT4 and B9-
pool recognize the same T lymphocyte subpopulations in man as in the rhesus 
monkey. Therefore, we used these antibodies to investigate the influence of 
depletion ofT lymphocyte subpopulations on the induction of acute GvHD in 
rhesus monkeys. 
6.3 PREVENTION OF ACUTE GVHD. 
Recipients of unrelated, mismatched bone marrow grafts were prepared with 2 x 
6.7 Gy total body irradiation (X-ray; bilateral irradiation; 24 hours interval). 
Bone marrow cells were obtained by aspiration. A mononuclear cell suspension 
was prepared by ficoll density centrifugation. One monkey received 4 x 1 o8 
unmodified bone marrow cells/kg body weight. This animal died after 12 days 
from severe GvHD. This result was in accordance with survival and cause of 
death of historical controls. These latter animals were prepared with a single 
dose of 8.5 Gy TBI and all died due to severe GvHD within 17 days after trans-
plantation (median: 12 days; N=7). 
Before the in vitro treatment with antibody and complement, the cell 
number given was 4 x 108 bone marrow cells/kg body weight. Cells left after 
incubation were directly infused into recipients. 
Depletion of suppressor/cytotoxic T lymphocytes from a bone marrow graft 
by the antibodies B9-pool did not eliminate the cells responsible for induction of 
acute GvHD. Two rhesus monkeys died after 14 and 15 days from severe GvHD 
(Table 6.1). Elimination of helper/inducer T lymphocytes (OKT4+4a) neither 
prevented GvHD and both monkeys died due to severe GvHD (Table 6.1). WT 1 
is present on most mature T lymphocytes and thymocytes. 
After elimination of WT 1 positive cells the residual cells could induce 
GvHD. Both monkeys died due to kidney failure secondary to shock induced by 
severe GvHD (Table 6.1). Incubation of a bone marrow graft with CAMPATH-1 
plus autologous monkey serum as complement source reduced the number of T 
lymphocytes from 5-16% E-rosette forming (E-RF) cells prior to treatment to 
0.1-0.5% E-RF cells after complement lysis. Using immunofluorescence analysis 
as shown in figure 6.2 did not detect any T lymphocytes after complement lysis 
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with CAMPATH-1. The same holds for the antibodies B9-pool, OKT4+4a and 
WT 1 where after complement lysis no target cells could be detected by 
immunofluorescence analysis (Figure 6.2). 
Table 6.1 
Effect of depletion of T lymphocyte subpopulations on the occurrence of acute 
GvHD in unrelated, mismatched donor-recipient combinations. 
number of survival 
pretreatment animals (range in 
days) 
none 7 7-18 (median: 12) 
OKT4+4a 2 10,13 
B9-pool 2 14, 16 
WT1 2 13, 18 
histopathological 
GvHD grading 
(0-III) 
II-III 
II-III 
II-III 
II 
cause of 
death 
GvHD 
GvHD 
GvHD 
GvHD, shock 
A total of six monkeys received a bone marrow graft depleted of lymphocytes by 
CAMPATH-1 and complement (Table 6.2).The monkeys were prepared for 
grafting by 2 x 6.7 Gy total body irradiation Monkey 1EC died after 19 days due 
to intussusception of jejunum. This monkey showed no signs of engraftment. In 
comparison to the other monkeys with documented engraftment the initial cell 
dose was 2.7 x 108 bone marrow cells/kg body weight instead of 4 x 108 bone 
marrow cells/kg body weight. In all the monkeys within 14 days after 
transplantation the leukocyte counts normalized and engraftment was docu-
mented by taken blood samples 3 weeks after transplantation and using serologi-
cally defined determinants (Bainer et al., 1981). At autopsy of monkey 1 JR a 
massive infiltration of the gastro-intestinal tract of protozoa, resembling lam-
bliasis, was observed and only mild signs of GvHD. 
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BEFORE TREATMENT WITH CAMPATH-1 PLUS COMPLEMENT 
Gara/FITC 
89- pool 
AFTER TREATMENT WITH CAMPATH-1 PLUS COMPLEMENT 
Gara/FITC OKT4a 
89- pool 
fluorescence intensity 
Figure 6.2 Effectiveness of elimination of T lymphocytes using CAMPATH-1 plus 
complement. Fluorescence analysis before and after treatment of bone marrow 
cells. 
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Table 6.2 
Incidence of acute GvHD in recipients of bone marrow grafts depleted of 
CAMPATH-1 positive cells. 
GvHD grading 
UMN survival skin liver GI-tract cause of death 
lEC 19 I 0 0 intussusception jejunum, 
graft failure 
1JR 18 I 0 I extensive lambliasis in GI-tract 
1CI 22 II I II GvHD and sepsis 
1FN 27 * I I euthanasia 
1LJ 40 0 0 0 radiation pneumonitis 
lHC 45 0 0 0 radiation pneumonitis 
* extensive necrosis of skin with massive in!Jltration of granulocytes (see also text) 
Monkey lCI showed grade II GvHD in skin and gastro-intestinal tract and this 
animal died due to a combination of acute GvHD and sepsis. In the skin of 
monkey lFN extensive necrosis with massive infiltration of granulocytes was 
seen. The latter lesions are not typical for acute GvHD and no signs of GvHD 
could be observed in other epithelial tissues such as tongue and lip, and neither 
in liver and gastro-intestinal tract. Therefore, it was concluded that these lesions 
were not attributable to GvHD. Monkeys lU and lHC had no signs of GvHD but 
died after 40 and 45 days due to radiation induced pneumonitis. This diagnosis 
was made after exclusion of viral infections. Depletion of CAMP A TH -1 positive 
cells result in a very substantial mitigation of the incidence and severity of acute 
GvHD. 
6.4 DISCUSSION 
In humans as well as in rodents two distinct T lymphocyte subpopulations, 
namely helper/inducer T lymphocytes (murine markers: Lyt l,L3T4; human 
markers: ea Leu 3, OKT4) and cytotoxic/suppressor T lymphocytes (murine 
markers: Lyt 2; human markers: ea Leu 2, OKT8, B9-pool) can be dis-
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tinguished. After establishing that T lymphocyte depletion by the use of anti-
serum or monoclonal antibody against Thy 1.2 plus complement successfully 
prevented GvHD (Ledney and van Bekkum, 1968; Tyan, 1973; Rodt et aL, 1974; 
Miiller-Ruchholtz et aL, 1979; Komgold and Sprent, 1978 Vallera et aL, 1981), 
the possible role ofT lymphocyte subpopulations in induction of GvHD has been 
investigated. The first study was performed in rats (Mason, 1981). Depletion of 
OX8 (cytotoxic/suppressor T lymphocytes) donor cells failed to prevent GvHD 
in a P --> F1 combination. Removal of helper/inducer T lymphocytes mitigated 
the incidence of GvHD; the induction of GvHD was not prevented, but survival 
was prolonged. Successful prevention was obtained after depletion of both 
subpopulations ofT lymphocytes. Similarly, lethal GvHD was observed after 
depletion of Lyt 2+ donor cells and transplantations across full H-2 differences 
in mice (Vallera et aL, 1982; Komgold and Sprent, 1985). Results of depletion 
of Lyt 1 + donor cells differed in that Vallera et al (1982) reported complete 
prevention of GvHD while Komgold and Sprent (1985) observed only prolon-
gation of survivaL Using a more specific antibody against helper/inducer T 
lymphocytes (L3T4) for depletion of this subpopulation a prolongation of 
survival time was observed by both groups of investigators, indicating that 
helper/inducer cells mediate lethal GVHD (Komgold and Sprent, 1987; Pietryga 
et aL, 1987) when donor and recipient are fully H2-mismatched. Recently, more 
different donor-recipient combinations were tested and it was found that GvHD 
could be caused by helper/inducer T lymphocytes as well as suppressor/cytotoxic 
T lymphocytes (Komgold and Sprent, 1987). 
In our rhesus monkey model acute GvHD could not be prevented by deple-
tion of OKT4+4a (CD4; helper/inducer T lymphocytes) positive ce~ls in an 
unrelated, mismatched donor-recipient combination. Severe GvHD was observed 
and survival was not prolonged in comparison to untreated historical controls. 
Depletion of either WT 1 (CD7; majority of mature T lymphocytes) or B9-pool 
(CD8; suppressor/cytotoxic T lymphocytes) positive cells could neither mitigate 
the incidence of acute acute GvHD. Only depletion of all lymphocytes by com-
plement lysis of CAMPATH-1 positive cells mitigated the incidence and severity 
of acute GvHD. The results of CAMPATH-1 were comparable to results with 
stem cell enrichment by density centrifugation followed by further T lympho-
cyte depletion using E-rosette sedimentation. In the latter group, the survival of 
the monkeys ranged from 24 to 86 days (median: 36 days) and acute GvHD > 
grade II was observed in 2 out of 7 monkeys. Causes of death were viral 
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(Cytomegaly virus) and bacterial infections (Wagemaker et al., 1982; Wage-
maker, 1986). These data are conclusive in that acute GvHD can only be 
prevented in unrelated, mismatched donor-recipient combinations when both 
subsets of T lymphocytes are sufficiently eliminated. The results do not confirm 
the results obtained in some rodent combinations where depletion of T lympho-
cyte subpopulations could prevent Gv HD. The discrepancy can be explained by 
the patterns of mortality due to GvHD in rhesus monkeys and rodents. Severe 
GvHD is observed with early mortality (survival< 18 days) in rhesus monkeys 
when unrelated, mismatched donor-recipients were used. It is possible that in 
other donor-recipient combinations such as RhLA-identical siblings a mitigation 
of the incidence of acute GvHD can be observed after depletion of subsets ofT 
lymphocytes. Until more information is available about this subject, our data 
argue that elimination of all T lymphocytes is necessary for prevention of GvHD 
prophylaxis, especially when mismatched donor-recipient combinations are used. 
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CHAPTER VII 
GENERAL DISCUSSION 
The outcome of a bone marrow transplantation is determined by the functioning 
of pluripotent haemopoietic stem cells, which sustain engraftment by their 
capacity of self-replication and differentiation, and T lymphocytes, which are 
responsible for the induction of the acute Graft-versus-Host reaction. T lym-
phocytes promote engraftment of an allogeneic bone marrow graft by inducing 
an antihost immune reactivity, i.e. Graft-versus-Host reaction. These two cell 
population were the main subject of this thesis (Figure 7.1). 
7.1 HAEMOPOIETIC STEM CELLS 
7.1.1 HAEMOPOIETIC STEM CELLS AND THE TROPHIC 
FUNCTION OF T LYMPHOCYTES 
The process of proliferation and differentiation to functional end cells, such as 
leukocytes, thrombocytes and erythrocytes, is controlled by haemopoietic growth 
factors (Metcalf, 1986; Clark et al., 1987). The growth factors were discovered 
and defined by their virtue to support haemopoietic colony formation in vitro. 
Several factors have been purified and produced by recombinant DNA tech-
niques such as the granulocyte-macrophage colony stimulating factor (GM-CSF; 
Wong et al., 1985), the granulocyte-CSF (G-CSF; Souza et al., 1986), the 
macrophage-CSF (M-CSF; Kawasaki et al., 1985), the interleukins-1,3,4, and 6 
(IL-l; Moore et al., 1987: IL-3; Yang et al., 1986; Dorssers et al., 1987: IL-4; 
Yokata et al., 1986: IL-6; Ikebuchi et al., 1987) and erythropoietin (Jacobs et al., 
1985). Most growth factors are produced by T lymphocytes (Metcalf, 1986; 
Clark et al., 1987). 
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I PLURIPOTENT STEM CELLS I 
BONE MARROW CELLS 
T LYMPHOCYTES 
Figure 7.1 The most essential cells in a bone marrow graft 
Therefore it was suggested that removal of T lymphocytes would deprive a bone 
marrow graft of the trophic function of lymphocytes and T lymphocyte depletion 
would result in delayed engraftment (Sieff et aL, 1985; Soderling et aL, 1985). 
In chapter Ill an in vivo assay was developed to assess quantitatively the 
influence of in vitro manipulation of bone marrow on the repopulating ability of 
a bone marrow graft. Indirectly this provided information on the influence on 
haemopoietic stem cells. Murine experiments have proven that these cells are 
primarily responsible for the repopulation of an haemopoietic system of a 
lethally irradiated recipient (Trentin, 1963; Visser et al., 1984; Bauman et al., 
1986; Spangrude et aL, 1988). Early autologous repopulation was used to mea-
sure stem cell toxicity. Autologous transplantation avoided the complicating and 
unpredictable (i.e. multifactorial) host-versus-graft reactions that occur in an 
allogeneic setting. 
This semiquantitative assay provided information with regard to the influ-
ence of T lymphocyte depletion on the regeneration of leukocytes and reticulo-
cytes. T lymphocyte depletion did not significantly reduce the repopulating 
capacity of an autologous bone marrow graft. This finding means that in rhesus 
monkey no direct evidence is found for a trophic function of T lymphocytes 
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during the phase of early repopulation after total body irradiation. This obser-
vation is in accordance with the experiments with purified stem cells, which 
could repopulate a lethally irradiated recipient without help from other cell 
populations. 
7.1.2 ENRICHMENT OF PLURIPOTENT HAEMOPOIETIC 
STEM CELLS 
Depletion of DR-positive cells from an autologous bone marrow graft ablated the 
repopulating capacity of such a graft resulting in a severely delayed regeneration 
of peripheral blood cells. Several monoclonal antibodies were tested for their 
reactivity with rhesus monkey GM-CFU's, but none of the tested antibodies 
reacted primarily with GM-CFU's. Therefore, analogous to the results of murine 
experiments with an antibody against a class I antigen (Visser et al., 1984) it was 
attempted to enrich haemopoietic stem cells by using an anti-DR antibody (class 
II) for positive selection of stem cells. The experiments described in chapter IV 
have revealed that stem cells of rhesus monkeys can be characterized by low 
density, by a negative reaction with the anti-lymphocyte antibody CAMPATH-1, 
high forward light scatter and positive reaction with the DR-antigen. An enrich-
ment of approximately 40 times was observed in vivo in comparison to ficoll 
bone marrow cell suspension and 94 times when compared to the original cell 
suspension obtained directly after aspiration. Dicke et al (1973) have described 
the morphological characteristics of the haemopoietic stem cells in rhesus 
monkeys and estimated that aspiration bone marrow contains approximately 
0.7% stem cells. On basis of this value an enrichment of at least 150 times is 
required to obtained a pure stem cell suspension. Since these experiments were 
performed in 1985/1986, new monoclonal antibodies have become available. 
Very promising are the results with the CD34 antibody ICH3 (Watt et al, 1987), 
which reacts with 5 % of the cells in human as well as rhesus monkey bone 
marrow. Transplantation of ICH3-positive cells has demonstrated in rhesus 
monkeys that positive selection of these cells result in a 75 fold (95% confidence 
limits: 40-120 fold) enrichment (Wielenga et al., 1989). At present no stem cell 
specific antigens are available and thus further enrichment of rhesus monkey 
stem cells can be achieved by multiparameter cell separation similar to the 
purification of mouse haemopoietic stem cells (Visser et al., 1984; Bauman et al., 
1986; De Vries et al., 1988; Spangrude et al., 1988). 
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The availability of highly purified stem cell populations could have impor-
tant consequences for experimental and clinical bone marrow transplantations. 
Haemopoietic growth factors, especially GM-CSF and G-CSF, are widely applied 
to stimulate early regeneration of peripheral blood cells after either bone 
marrow transplantation (Donahue et al., 1986; Donahue et al., 1988; Mayer et 
al., 1987; Monroy et al., 1987; Gillio et al., 1987; Nemunaitis et al., 1988) or 
myeloablative, high dose chemotherapy (Brandt et al., 1988; Morstyn et al., 
1988; Socinski et al., 1988, Gabrilove et al., 1988). At present it can not be 
distinguished whether the more rapid recovery of peripheral blood cells after 
myeloablative treatment and administration of GM-CSF or G-CSF is due to 
stimulation of pathway restricted progenitor cells or to direct stimulation of the 
proliferation and differentiation of haemopoietic stem cells. Purified haemopoi-
etic stem cells can be used to elucidate which growth factors have receptors on 
stem cells and what the consequence is of stimulation of stem cells with a specific 
growth factor. 
An other application of purified stem cells is the eradication of malignant 
cells from autologous bone marrow grafts for hematological malignancies and 
solid tumors. At the moment several methods have been developed to remove 
tumor cells from bone marrow graft. A disadvantage of this approach is that 
specific methods are required for each specific tumor. A generally applicable 
method would be the positive selection of haemopoietic stem cells from tumor 
cells, contaminating bone marrow as was recommended by van Bekkum in 
1986). 
7.2 T LYMPHOCYTES 
Donor T lymphocytes play an important role in the outcome of allogeneic bone 
marrow transplantation. They induce the acute Graft-versus-Host reaction. A 
strong Graft-versus-Host reaction will inhibit the Host-versus-Graft reaction and 
prevent rejection. 
7.2.1 T LYMPHOCYTES AND ENGRAFTMENT 
As early as 1957 Van Bekkum et al noticed that host lymphoid cells could reject 
rat bone marrow cells transplanted into lethally irradiated mice. At that time 
their interpretation was that rejection was mediated via the production of anti-
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bodies against the graft. Later, more evidence for the role of T lymphocytes in 
the Host-versus-Graft reaction was brought in by the observations that stable 
mouse-to-rat chimaeras could be obtained when the recipients were conditioned 
with supralethal TBI and a high dose of anti-rat lymphocyte serum (Bau, 1973). 
Donor T lymphocytes induce the Graft-versus-Host reaction and host T 
lymphocytes are among the cells which are subject of the GvH reaction. 
Therefore, one of the solutions to reduce the immunological activity of host 
lymphocytes against an allogeneic bone marrow is to knock out the host T lym-
phocytes by a GvH reaction induced with donor T lymphocytes. Studies with 
dogs, where transfusion of donor leukocytes or lymphocytes promoted the 
engraftment of histoincompatible bone marrow, supported this concept (Deeg et 
al., 1979). In agreement with the concept of reciprocal interference the success 
of engraftment was counterbalanced by an increase in lethal GvHD. Irradiated 
donor leukocytes were not effective (Deeg et al., 1979). So, the outcome of a 
bone marrow transplantation is the result of competing Host-versus-Graft and 
Graft-versus-Host Reactions. Depletion of donor T lymphocytes will reduce the 
incidence of acute GvHD and subsequently a stronger HvG reaction will arise 
resulting in more rejections in comparison to unmanipulated bone marrow 
grafts. Additional immunosuppression will be required to suppress the stronger 
HvG following T lymphocyte depletion. 
In chapter V the minimal dose of fractionated total body irradiation was 
determined for engraftment ofT lymphocyte depleted bone marrow grafts. A 
rather steep dose-effect curve established the relation between graded doses of 
fractionated TBI (24 hours interval) and engraftment. The difference between 
sustained engraftment and engraftment failure appeared to be l-2 Gy fractionated 
total body irradiation (X-rays). 
These data seem to agree very well with observations in mice where titrated 
doses of spleen cells, syngeneic with host cells, were added to 107 allogeneic bone 
marrow cells and injected into lethally irradiated recipients (van Bekkum, 1988). 
In this experimental setting mortality is due to graft failure. When no recipient-
type spleen cells were added, 90% of the recipients survived. The addition of 104 
recipient-type spleen cells gave 100% survival, while the addition of 105 host 
spleen cells reduced survival to 25% due to more graft failures. Addition of 106 
host spleen cells resulted in a poor survival of 10%. These results indicate that 
the difference between 100% engraftment and 50% engraftment is less than one 
log immunocompetent cells in mice. Since one log cell kill of lymphocytes 
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corresponds with 2-3 fold Do in mice (Smith, 1963), this would imply that 1.5-2 
Gy is sufficient to overcome engraftment failures assuming a Do of 70 cGy. 
Several groups have confirmed this concept in their murine models for engraft-
ment of T lymphocyte depleted bone marrow grafts (Soderling et al., 1985; 
Schwartz et al., 1987; Ferrara et al., 1988; Gassmann et al., 1988). Additional 
support for our results in rhesus monkeys has come from clinical studies. Several 
transplant centers have reported that increasing the dose of fractionated total 
body irradiation with 2 Gy prevented engraftment failures (Martin et al., 1985; 
Burnett et al., 1988; O'Reilly et al.,1986; Champlin et al., 1987). 
Alternative approaches, which have been investigated in animal models, are 
the addition of total lymph node irradiation (Blazar et al., 1988), monoclonal 
antibodies directed against either T lymphocytes (Cobbold et al., 1986) or class II 
antigens (Deeg et al., 1987), and immunosuppressive 'drugs (Gassmann et al., 
1988). Fractionated total lymph node irradiation (2 x 3.3 Gy) in addition to 7.5 
Gy total body irradiation resulted in improved survival in mice grafted with 
allogeneic bone marrow and none of the mice rejected their T lymphocyte 
depleted grafts in contrast to a 50% rejection rate in recipient mice which were 
prepared by 7.5 Gy total body irradiation (Blazar, 1988). Cobbold et al (1986) 
demonstrated the usefulness of monoclonal antibodies against T lymphocytes for 
the promotion of engraftment of T lymphocyte depleted grafts. A sublethal dose 
of 6 Gy total body irradiation was not sufficient to prevent rejection in mice. 
Addition of a monoclonal antibody against T lymphocyte to 6 Gy total body 
irradiation resulted in 90% chimaerism. Injection of monoclonal antibodies 
directed against subpopulations of T lymphocytes had no effect on engraftment. 
Recipient dogs reject bone marrow grafts from unrelated, DLA-nonidentical 
donors when they are conditioned with 9.2 Gy total body irradiation. 
Administration of anti-class II monoclonal antibody pregrafting and methotrexate 
postgrafting proved to result in engraftment in 9/10 dogs. Methotrexate 
postgrafting alone resulted in engraftment in 6 out 10 recipient dogs. The results 
of these two groups did not differ significantly (Deeg et al., 1987). Depletion of 
DR-positive cells ablated the repopulation capacity of bone marrow grafts in 
dogs (Szer et al., 1986) and rhesus monkeys (this thesis). The use of anti-DR 
antibodies for conditioning can not be recommended since the risk of 
jeopardizing haemopoietic reconstitution is great. The immunosuppressive 
potential of cyclophosphamide, etoposide and cytarabin (ARA-C) was compared 
in addition of a standard conditioning regimen of 35 mg/kg busulphan in mice. 
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Cytarabin (dose range 600-1200 mg/kg) and etoposide (dose range 30-60 mg/kg) 
were significantly inferior to cyclophosphamide (dose range 30-360 mg!kg) in 
their potential to promote engraftment (Gassmann et al., 1988). 
fu case of leukemia, a conditioning regimen for T lymphocyte depleted bone 
marrow grafts has to fulfill two criteria; it has to give extra immunosuppression 
and it should eliminate residual leukemia cells to prevent the higher increased 
risk of relapse after T lymphocyte depleted grafts. Assuming that the anti-
leukemic effect of GvHD is due to alloreactivity, T lymphocyte depletion will 
require additional anti-leukemic treatment as part of the conditioning regimen. 
Schultz et al (1989) calculated that the difference between 90% cure and 40% 
cure corresponds with a difference of one log leukemic cell kill, which is in turn 
equivalent to 2-3 Do. Although exact values for the DO are not available, one can 
assume that it is in the order of the same magnitude for lymphocytes and this will 
mean that an additional dose of 1-2 Gy total body irradiation will provide the 
additional one log kill of leukemia cells. 
This means that when additional immunosuppression is given in the form 
of anti-lymphocyte antibodies or total lymph node irradiation, an additional 
anti-leukemia treatment is required. fu view of the experiments of Gassmann 
(1988) with ARA-C and Etoposide, extra addition of these agents to eliminate 
more leukemic cells, will require additional immunosuppression in case of T 
lymphocyte depleted bone marrow grafts. At this moment an increment of 1-2 
Gy (single fraction) of total body irradiation is the best option since this 
approach fulfils both criteria. 
7 .2.2 T LYMPHOCYTES AND GRAFT- VERSUS-HOST 
DISEASE 
The relation between donor T lymphocytes and acute GvHD has been welles-
tablished in several species. In chapter VI it was investigated whether anti T 
lymphocyte monoclonal antibodies plus complement eliminated sufficient T 
lymphocytes to prevent acute GvHD in a unrelated, mismatched donor-recipient 
combination. As expected, removal of all detectable T lymphocytes successfully 
prevented acute GvHD. Depletion of subpopulation ofT lymphocytes did not 
prevented the induction of lethal GvHD in this donor-recipient combination. 
These data prove that it is hazardous to extrapolate results of murine bone 
marrow transplantation to outbred species. The morbidity and mortality in man 
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and monkeys is much higher than in mice due to a higher proportion of lym-
phocytes in bone marrow. In an unrelated, mismatched donor-recipient combi-
nation the severity of acute GvHD is higher than in related, HLA-matched donor-
recipient combinations. Subsequently, more efficient T lymphocyte depletion is 
required to prevent acute GvHD (Wagemaker, 1986). It is therefore not excluded 
that depletion of subpopulation of T lymphocytes would not result in prevention 
of GvHD in related, HLA-identical donor-recipient combinations. 
Successful prevention of acute GvHD by either albumin density centrifu-
gation followed by £-rosette sedimentation or by CAMPATH-1 plus complement 
did not result in long term survival due to viral and bacterial infections and late 
toxicity of irradiation. Late toxicity of irradiation manifested in interstitial 
pneumonia with evidence of a viral or bacterial infection. After these experi-
ments a new conditioning regimen was prepared where the monkeys were irra-
diated with 2 x 6 Gy (24 hour interval), but the lungs were shielded after 8.5 Gy. 
With this new conditioning regimen radiation pneumonitis was no longer 
observed and recipients of autologous bone marrow grafts became long term 
survivors (Wielenga: personal communication). 
With regard to the influence ofT lymphocyte depletion on engraftment and 
acute GvHD, Vriesendorp et al (1985) draw the attention to the consequences of 
higher irradiation doses for the incidence of acute GvHD. The incidence of 
mortality due to either Graft-versus-Host or to Host-versus-Graft reaction has 
been investigated in dogs. A single dose of 4.25 Gy TBI (300 kV X-ray) resulted 
in 100% graft rejections in 8 dogs. Graft rejections were not observed after 5 Gy 
TBI, but 20% of the dogs (N=5) showed signs of GvHD. The incidence of GvHD 
increased to 40% (N=40) when recipients were prepared for grafting by 7.5 Gy 
TBI. According to the concept of reciprocal interference between Host-versus-
Graft and Graft-versus-Host reactions an optimal conditioning regimen has to be 
carefully developed. 
7.3 THE RHESUS MONKEY AS A PRECLINICAL MODEL 
FOR BONE MARROW TRANSPLANTATION 
For nearly 25 years the rhesus monkey has been employed for investigations on 
bone marrow transplantations. Since it is felt that the gap between mouse models 
and clinical bone marrow transplantations is too big, experimental bone marrow 
transplantations in rhesus monkeys have been initiated. Bone marrow c9mposi-
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tion, especially the proportion of lymphocytes, are very similar to humans. Their 
immunological reactivity has proven to be very similar in various transplanta-
tions models such as bone marrow transplantation (see chapter I and chapter V), 
kidney transplantation (Borleffs, 1983; Jonker et al., 1985; 1984) and liver 
transplantation (Neuhaus et al., 1985). 
The crossreactivity of several monoclonal antibodies, directed against 
human antigens present on human cells(Jonker, 1984; this thesis), with rhesus 
monkey cells provide that preclinical experiments can be performed to 
investigate the usefulness of antihuman monoclonal antibodies in bone marrow 
transplantation. At present the role of monoclonal antibodies in conditioning of 
the recipient is subject of study. The human haemopoietic growth factors G-CSF 
and GM-CSF has shown an enhancement of peripheral blood recovery following 
bone marrow transplantations in rhesus monkeys (Donahue, 1986; Donahue, 
1988; Mayer, 1987; Monroy, 1987; Gillio, 1987). From all the experiments with 
monkeys it can be concluded that the rhesus monkey provides a near optimal 
model for preclinical investigations of bone marrow transplantation. 
Disadvantages of the monkey model are the susceptibility for bacterial and 
viral infections, the scarcity of monkeys and the high costs of housing and 
handling of monkeys. The small family size of rhesus monkeys and slow 
breeding is a biological limitation for studies with realted donor-recipient 
combinations. The scarcity of the monkeys is the reason that experiments had to 
performed with a low number of monkeys. Nevertheless, experiments in a low 
number of rhesus monkeys has provided crucial information for clinical bone 
marrow transplantations. 
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SUMMARY 
Bone marrow transplantation is a successful treatment for many lethal diseases of 
the haematopoietic system such as severe aplastic anemia and leukemia. Patients 
with inborn errors of the immune system such as severe combined im-
munodeficiency can be cured by bone marrow transplantation. In a bone mar-
row graft many different haemopoietic cells are present. Among these cells 
pluripotent haemopoietic stem cells and T lymphocytes mainly determine the 
outcome of a transplantation. Haemopoietic stem cells have the ability of self-
replication and they can differentiate into one of the cell lineages. Because of 
their ability of self-replication haemopoietic stem cells are responsible for 
sustained engraftment. The function ofT lymphocytes is to react against foreign 
antigens. When there is a discrepancy between donor and recipient with regard 
to the minor or major histocompatibility antigens, mature T lymphocytes of the 
donor will mount an immunological attack against foreign antigens in the 
recipient resulting in a graft-versus-host reaction. Depletion of donor T 
lymphocytes will eliminate those immunocompetent cells which are responsible 
for the graft-versus-host reaction. A disadvantage of this method for prevention 
of acute graft-versus-host disease is that it is associated with more engraftment 
failures. 
The main subjects of this thesis was the investigation of the influence of T 
lymphocyte depletion on engraftment of autologous and allogeneic bone marrow 
grafts, the influence of depletion of subpopulations of T lymphocytes on the 
severity of acute GvHD and the enrichment of pluripotent haemopoietic stem 
cells. The rhesus monkey was used as a preclinical model since its bone marrow 
composition and their immunological reactions are very similar to those of 
humans. 
The principles of bone marrow transplantation and the role of pluripotent 
haemopoietic stem cells are described in the first part of chapter I. Most part of 
chapter I is dealing with engraftment, the nature of graft-versus-host disease and 
the methods to prevent graft-versus-host disease. 
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In chapter II is a summary of the materials and methods which are relevant 
for the studies discussed in the chapters III to VI. 
T lymphocytes produce several haemopoietic growth factors. A hypothesis 
is that depletion of T lymphocyte will result in a deprivation of haemopoietic 
growth factors essential for the proliferation and differentiation of haemopoietic 
stem cells. This hypothesis was tested in chapter III. After transplantation of 
graded number of autologous bone marrow cells, relationship between between 
the number of cells transplanted and the regeneration rate of leukocytes and 
reticulocytes was observed. This allows to asssay for stem cells in bone marrow. 
This in vivo assay enabled the investigation of the influence of depletion of T 
lymphocytes and DR-positive cells on the regneration of peripheral blood cells. 
Monoclonal antibodies and complement were used for complement lysis. Deple-
tion of subpopulation of T lymphocytes from an autologous bone marrow graft 
by the antibodies OKT4+4a (helper/inducer T lymphocytes) and B9-pool 
(cytotoxic/suppressor T lymphocytes) did not affect the regeneration rate of 
leukocytes and reticulocytes. Depletion of all lymphocytes, using CAMPATH-1, 
did neither influence the regeneration of peripheral blood cells. A strong delay 
in regeneration occurred when all DR-positive cells were removed from a bone 
marrow graft illustrating that toxicity to stem cells could be assessed with this 
autologous assay. 
Depletion of DR-positive cells eliminated the capacity of a bone marrow 
graft to repopulate a sublethally irradiated recipient. This result suggested that 
pluripotent haemopoietic stem cells carry the DR-antigen on their cell surface. In 
chapter IV, pluripotent stem cells were enriched using a combination of density 
centrifugation, depletion of T lymphocytes and cell sorting with a fluorescence 
activated cell sorter. Progenitor cells, measured in the GM-CFU assay, were 
characterized by light density cells in a discontinuous albumin density gradient, 
negative for the anti-lymphocyte antibody CAMPATH-1 and they gave a high 
forward light scatter during the flow through a laser beam of the cell sorter. 
After labelling bone marrow cells with an anti-DR antibody Y AML 555.6, 
several cell clusters could be distinguished. The highest concentration of OM-
CPU's (37 x) were found in the cell populations characterized by a high forward 
light scatter and positive for the DR-antigen. Autologous transplantation 
experiments with the enriched fractions did show similar results. Transplantation 
of cells, selected on basis of high forward light scatter and presence of the DR-
antigen on the cell surface, were able to repopulate an irradiated recipient. In 
116 
comparison to unseparated bone marrow cells, pluripotent haemopoietic stem 
cells were 40 x times enriched. 
After T lymphocyte depletion a higher incidence of engraftment failures is 
observed than with T lymphocyte containing bone marrow. Since the 
experiments in chapter III have demonstrated that T lymphocyte do not have a 
significant trophic function, the engraftment failures are attributable to the 
elimination of the immunosuppressive action of donor T lymphocytes on the im-
munological reactivity of the recipient. Donor T lymphocytes exert an 
immunosuppressive action since the lymphocytes of the recipient (inducing the 
host-versus-graft-reaction) are among the targets of the graft-versus-host 
reaction. Hence, depletion of donor T lymphocytes will require more 
immunosuppression of the recipient. In chapter V, the minimal dose of 
fractionated total body irradiation was determined for 2 log T lymphocyte 
depleted bone marrow grafts. A steep dose-effect relationship appeared to exist 
between engraftment and total body irradiation. A difference of 1-2 Gy 
fractionated total body irradiation determines the outcome of a transplantation 
with 2 log T lymphocyte depleted bone marrow. 
In view of the problems with T lymphocyte depleted bone marrow grafts, it 
was investigated whether depletion of subpopulations of T lymphocytes was 
sufficient to prevent acute graft-versus-host disease. Murine experiments had 
suggested that depletion of subpopulations of T lymphocytes successfully 
prevented graft-versus-host disease. Depletion of subpopulations did not prevent 
acute graft-versus-host disease in our rhesus monkey model for mismatched bone 
marrow transplantations (chapter VI). Depletion of all lymphocytes resulted in a 
successful mitigation of the severity of graft-versus-host disease. 
Finally, in chapter VII (General Discussion) the most important results and 
their possible implications for clinical transplantations has been discussed. 
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SAMENV A TTING 
Voor vele dodelijke aandoeningen van het haemopoietische systeem, zoals 
emstige aplastische anemie en leukemie, is beenmergtransplantatie een suc-
cesvolle behandeling. Patienten met aangeboren afwijkingen van het immuun 
systeem zoals 'severe combined immunodeficiency' kunnen genezen worden door 
een beenmergtransplantatie. 
In een beenmergtransplantaat zijn verschillende beenmergcellen aanwezig. 
Van deze cellen bepalen vooral de T lymfocyten en de haemopoietische stam-
cellen hoe een beenmergtransplantatie zal verlopen. Haemopoietische stamcellen 
hebben de mogelijkheid tot zelf-replicatie en de stamcellen kunnen gaan 
differentieren tot perifere bloedcellen. Vanwege hun mogelijkheid tot zelf-repli-
catie zorgen de haemopoietische stamcellen ervoor dat een transplantaat niet 
uitsterft, maar dat er steeds weer opnieuw cellen aangemaakt kunnen worden. De 
functie van T lymfocyten is om te reageren op vreemde antigenen. Wanneer er 
een verschil bestaat tussen donor en gastheer met betrekking tot de 
transplantatieantigenen, zullen rijpe donor T lymfocyten de gastheer als vreemd 
herkennen en een immunologische reactie ontketenen tegen de gastheer. Deze 
reactie wordt de 'Graft-versus-Host' reactie genoemd. Verwijdering van de 
donor T lymfocyten uit een beenmergtransplantaat betekent dat de cellen 
verantwoordelijk voor de 'Graft-versus-Host' reactie verwijderd zijn. Een nadeel 
van methode om 'Graft-versus-Host' reactie te voorkomen is dat het gepaard gaat 
met een toename in het aantal afstotingsreacties. 
De belangrijkste onderwerpen van dit proefschrift zijn het onderzoeken van 
de invloed van het verwijderen van T lymfocyten op het aanslaan van autoloog 
of allogeen beenmerg, het onderzoeken van de invloed van het verwijderen van 
subpopulaties van T lymfocyten op de ernst van de acute 'Graft-versus-Host' 
reactie en de verrijking van pluripotente haemopoietische stamcellen. De 
rhesusaap werd gebruikt als preklinisch model omdat rhesusapen wat betreft 
hun beenmerg samenstelling en hun immunologische reacties heel veel op de 
mens lijken. 
De principes van een beenmergtransplantatie en de rol van de pluripotente 
stamcellen worden beschreven in het eerste gedeelte van hoofdstuk I. Het 
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grootste gedeelte van hoofdstuk I gaat over het aanslaan van beenmerg, de oor-
sprong van de 'Graft-versus-Host' reactie en de methoden die toegepast werden 
en worden om de 'Graft-versus-Host' reactie te voorkomen. 
In hoodstuk II worden de belangrijkste materialen en methoden beschreven 
die gebruikt zijn voor de experimenten welke beschreven staan in de hoofd-
stukken III tot en met VI. 
T lymfocyten produceren verscheidene haemopoietische groeifactoren. Er 
is een hypothese dat verwijdering van T lymfocyten tot gevolg zal hebben dater 
een tekort aan groeifactoren ontstaat. Groeifactoren zijn essentieel voor de 
proliferatie en differentiatie van haemopoietische stamcellen en een tekort aan 
groeifactoren zal daarom leiden tot het niet aanslaan van een been-
mergtransplantaat. Deze hypothese werd onderzocht in hoofdstuk III. Na trans-
plantatie van verschillende aantallen autologe beenmergcellen bleek er een 
directe relatie te bestaan tussen het aantal beenmergcellen wat getransplanteerd 
was en de regeneratiesnelheid van leukocyten en reticulocyten. Met behulp van 
dit in vivo assay kon de invloed onderzocht worden van het verwijderen van T 
lymfocyten en DR positieve cellen op de regeneratiesnelheid van perifere bloed 
cellen. Monoclonale antistoffen en complement werden gebruikt om cellen te 
lyseren. Verwijdering van subpopulaties van T lymfocyten door de antistoffen 
OKT4+4a (helper/inducer T lymfocyten) en B9-pool (cytotoxische/suppressor T 
lymfocyten) had geen invloed op de regeneratiesnelheid van perifere bloedcellen. 
Ook verwijdering van aile lymfocyten door het antilichaam CAMPATH-1 liet 
geen verandering zien in de regeneratie van perifere bloedcellen. Een emstige 
vertraging in de regeneratie werd gezien na het verwijderen van aile DR 
positieve cellen. Dit laatste toonde aan dat met behulp van dit assay toxiciteit 
gemeten kan worden. 
Verwijdering van DR positieve cellen uit een beenmergtransplantaat heeft 
tot gevolg dat een dergelijk transplantaat niet in staat is om een bestraalde 
gastheer een nieuw haemopoietisch systeem te geven. Dit doet vermoeden dat 
pluripotente haemopoietische stamcellen het DR antigeen op hun celoppervlak 
hebben. In hoofdstuk IV worden haemopoietische stamcellen verrijkt door een 
combinatie te gebruiken van een dichtheidsgradient, verwijdering van T 
lymfocyten en een celsorteermachine, een zogenaamde 'fluorescence activated 
cell sorter'. Voorlopercellen werden gemeten in het GM-CFU assay en bleken 
gekarakteriseerd te worden door een lage densititeit, ze reageerden niet met het 
antilichaam CAMPATH-1, en ze gaven een hoog 'forward light scatter' signaal. 
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Nadat de cellen gelabeld waren met een anti-DR antilichaam, genaamd YAML 
555.6, konden verscheidene celclusters onderscheiden worden op de cell sorter. 
De hoogste concentratie GM-CFU's (37 x) werd gevonden in de celclusters die 
een hoog 'forward light scatter' signaal gaven en het DR antigeen op hun 
celoppervlak hadden. Autologe beenmergtransplantaties met cellen, die op deze 
wijze gezuiverd waren, lieten dezelfde resultaten zien. De cellen die een hoog 
'forward light scatter' signaal gaven en positief reageerden met het anti-DR 
antilichaam, konden een bestraalde ontvanger beschermen. In vergelijking met 
normaal beenmerg bleken de stamcellen 40 x verrijkt te zijn. 
Na het verwijderen van T lymfocyten wordt een hoger aantal 
afstotingsreacties gezien. Aangezien de experimenten in hoofdstuk III hebben 
aangetoond dat T lymfocyten geen trofische functie hebben, moeten de 
afstotingsreacties een gevolg zijn van de verminderde immunosuppressieve 
werking van donor T lymfocyten. Donor T lymfocyten richten hun immu-
nologische aanval ook op de T lymfocyten van de gastheer. Aangezien de T 
lymfocyten van de gastheer verantwoordelijk zijn voor de afstotingsreactie zal 
verwijdering van de donor T lymfocyten tot gevolg hebben dat de gastheer T 
lymfocyten de overhand krijgen met als gevolg een toename van het aantal 
afstotingsreacties. Daarom zal meer immunosuppressie voor de gastheer nodig 
zijn wanneer donor T lymfocyten verwijderd worden. In hoofdstuk V, werd 
onderzocht hoeveel meer bestraling er nodig was voor het aanslaan van een 
beenmergtransplantaat waaruit de T lymfocyten 2 log gedepleteerd zijn. Er bleek 
een stijle dosis-effect relatie te bestaan tussen het aanslaan van beenmerg en de 
dosis bestraling. Een verschil van 1-2 Gray gefractioneerde lichaamsbestraling 
bepaalde het verschil tussen het aanslaan of afstoting van beenmerg. 
Met het oog op het probleem van het aanslaan van beenmerg waaruit T 
lymfocyten verwijderd zijn, werd onderzocht of het wellicht voldoende was om 
een subpopulatie T lymfocyten te verwijderen om de 'Graft-versus-Host' reactie 
te voorkomen. Experimenten met muizen hadden gesuggereerd dat de 'Graft-
versus-Host' reactie voorkomen kon worden op deze marrier. Na verwijdering 
van subpopulaties van T lymfocyten werd nog steeds emstige 'Graft-versus-Host' 
ziekte gezien in niet verwante donor-ontvanger combinaties (Hoofdstuk VI). 
Verwijdering van alle lymfocyten met behulp van het antilichaam CAMPATH-1 
verminderde de ernst van de 'Graft-versus-Host' reactie zeer duidelijk. 
In hoofdstuk VII (algemene discussie) worden de belangrijkste resultaten en 
hun betekenis voor de klinische beenmergtransplantaties besproken. 
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AET 
BMT 
CD 
CFU-S 
CFU-GEMM 
DNAse 
E-RFC 
FACS 
FCS 
FITC 
FLS 
GAM 
GARA 
GID 
GM-CFU 
GVHD 
GVL 
Gy 
LSM 
MCA 
MHC 
MTX 
PBL 
PBS 
PE 
PHA 
PLS 
RELACS 
SPF 
SRBC 
TBI 
ABBREVIATIONS 
= 2-aminoethylisothiouronium 
= Bone Marrow Transplantation 
= Cluster Defined 
= Colony Forming Unit/Spleen 
= Colony Forming Unit - Granulocyte, Erythrocyte, 
Macrophage and Megakaryocyte 
= Deoxyribonuclease 
= E-rosette Forming Cells 
= Fluorescence Activated Cell Sorter 
= Fetal Calf Serum 
= Fluorescein Isothiocyanate 
= Forward Light Scatter 
=Goat-anti-Mouse 
=Goat-anti-Rat 
=Gastro-Intestinal Decontamination 
=Granulocyte-Macrophage Colony Forming Unit 
=Graft-versus-Host Disease 
=Graft-versus-Leukemia 
=Gray 
=Lymphocyte Separation Medium 
= Monoclonal Antibody 
=Major Histocompatibility Complex 
= Methotrexate 
=Peripheral Blood Lymphocytes 
= Phosphate Buffered Salt 
= Phycoerythrin 
= Phytohaemagglutinin 
= Perpendicular Light Scatter 
= Rijswijk Experimental Light Activated Cell Sorter 
=Specific Pathogen Free 
=Sheep Red Blood Cells 
= Total Body Irradiation 
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